Tau recognition antibody
Isolated monoclonal antibodies, particularly humanized versions of 5G8, 6A10, 8A4, and 7G6, address the challenge of tau aggregation in neurodegenerative diseases by specifically binding to tau and inhibiting its deposition, offering therapeutic potential for conditions like Alzheimer's.
Patent Information
- Application Number
- JP2023093577
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2017-11-01
- Filing Date
- 2023-06-07
- Publication Date
- 2024-11-20
- Estimated Expiration
- 2038-05-02
AI Technical Summary
Current technologies lack effective monoclonal antibodies that specifically target tau protein, which is a hallmark of neurodegenerative diseases such as Alzheimer's, and are unable to inhibit tau aggregation and deposition effectively.
Development of isolated monoclonal antibodies that bind specifically to tau, including humanized versions of antibodies 5G8, 6A10, 8A4, and 7G6, which compete with antibody 5G8 for binding and can inhibit tau aggregation and deposition.
The antibodies effectively inhibit tau aggregation and deposition, providing potential therapeutic benefits for tau-related diseases by reducing tau protein levels and preventing neurofibrillary tangle formation.
Smart Images

Figure 0007587304000083 
Figure 0007587304000084 
Figure 0007587304000085
Abstract
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit under 35 USC 119(e) of U.S. Provisional Application No. 62 / 500,427, filed May 2, 2017, and U.S. Provisional Application No. 62 / 580,408, filed November 1, 2017, which are incorporated by reference in their entireties for all purposes. REFERENCE TO SEQUENCE LISTING
[0002] The sequence listing described in the file 508111SEQLST.txt is 107 kilobytes, was created on May 2, 2018, and is incorporated herein by reference. [Background technology]
[0003] Tau is a well-known human protein that can exist in phosphorylated forms (see, e.g., Goedert, Proc. Natl. Acad. Sci. USA 85:4051-4055 (1988); Goedert, EMBO J. 8:393-399 (1989); Lee, Neuron 2:1615-1624 (1989); Goedert, Neuron 3:519-526 (1989); Andreadis, Biochemistry 31:10626-10633 (1992)). Tau has been reported to play a role in stabilizing microtubules, particularly in the central nervous system. Total tau (t-tau, i.e., phosphorylated and non-phosphorylated forms) and phosphorylated tau (p-tau, i.e., phosphorylated tau) are released from the brain in response to neuronal injury and neurodegeneration and have been reported to occur at increased levels in the CSF of Alzheimer's disease patients compared to the general population (Jack et al., Lancet Neurol 9:119-28 (2010)).
[0004] Tau is the main component of neurofibrillary tangles, which, together with plaques, are a hallmark of Alzheimer's disease. Tangles constitute abnormal fibrils with a diameter of 10 nm that occur in helically wound pairs with a regular period of 80 nm. Tau within neurofibrillary tangles is abnormally phosphorylated (hyperphosphorylated) with phosphate groups attached to specific sites on the molecule. Severe involvement of neurofibrillary tangles is found in layer II neurons of the entorhinal cortex in Alzheimer's disease, the CA1 and subiculum regions of the hippocampus, the amygdala, and in deeper layers of the neocortex (layers III, V, and superficial VI). Hyperphosphorylated tau has also been reported to disrupt microtubule assembly, which may promote the destruction of neuronal networks.
[0005] Tau inclusions are part of the neuropathology that characterizes several neurodegenerative diseases, including Alzheimer's disease, frontotemporal lobar degeneration, progressive supranuclear palsy, and Pick's disease. Summary of the Invention
[0006] In one aspect, the present invention provides isolated monoclonal antibodies that specifically bind to tau. Some such antibodies compete with antibody 5G8 for binding to human tau. Some such antibodies bind to the same epitope on human tau as 5G8.
[0007] Some antibodies comprise the three light chain CDRs and three heavy chain CDRs of monoclonal antibody 5G8, which is a murine antibody characterized by a heavy chain variable region having an amino acid sequence comprising SEQ ID NO: 7 and a light chain variable region having an amino acid sequence comprising SEQ ID NO: 8. In some antibodies, the three heavy chain CDRs are defined by the Kabat / Chothia combination (SEQ ID NOs: 11, 12, and 13) and the three light chain CDRs are defined by the Kabat / Chothia combination (SEQ ID NOs: 14, 15, and 16).
[0008] For example, the antibody may be 5G8, or a chimeric, veneered, or humanized version thereof. In some such antibodies, the variable heavy chain has 85% or more identity to a human sequence. In some such antibodies, the variable light chain has 85% or more identity to a human sequence. In some such antibodies, the variable heavy and variable light chains each have 85% or more identity to a human germline sequence.
[0009] Some antibodies are humanized antibodies. Some antibodies are humanized or chimeric 5G8 antibodies that specifically bind to human tau, where 5G8 is a murine antibody characterized by a mature heavy chain variable region of SEQ ID NO: 7 and a mature light chain variable region of SEQ ID NO: 8. Some antibodies comprise a humanized mature heavy chain variable region that includes the three heavy chain CDRs of 5G8 and a humanized mature light chain variable region that includes the three light chain CDRs of 5G8.
[0010] In some antibodies, the CDRs are by a definition selected from the group of Kabat, Chothia, Kabat / Chothia combination, AbM, and Contact. In some antibodies, the humanized mature heavy chain variable region comprises the three Kabat / Chothia combination heavy chain CDRs of 5G8 (SEQ ID NOs: 11-13) and the humanized mature light chain variable region comprises the three Kabat / Chothia combination light chain CDRs of 5G8 (SEQ ID NOs: 14-16). In some antibodies, the humanized mature heavy chain variable region comprises the three Kabat heavy chain CDRs of 5G8 (SEQ ID NOs: 17, 12, and 13) and the humanized mature light chain variable region comprises the three Kabat light chain CDRs of 5G8 (SEQ ID NOs: 14-16). In some antibodies, the humanized mature heavy chain variable region comprises the three Chothia heavy chain CDRs of 5G8 (SEQ ID NO: 18, SEQ ID NO: 20, and SEQ ID NO: 13), and the humanized mature light chain variable region comprises the three Chothia light chain CDRs of 5G8 (SEQ ID NO: 14-16). In some antibodies, the humanized mature heavy chain variable region comprises the three AbM heavy chain CDRs of 5G8 (SEQ ID NO: 11, SEQ ID NO: 21, and SEQ ID NO: 13), and the humanized mature light chain variable region comprises the three AbM light chain CDRs of 5G8 (SEQ ID NO: 14-16). In some antibodies, the humanized mature heavy chain variable region comprises the three Contact heavy chain CDRs of 5G8 (SEQ ID NO: 19, SEQ ID NO: 22, and SEQ ID NO: 23), and the humanized mature light chain variable region comprises the three Contact light chain CDRs of 5G8 (SEQ ID NO: 24-26).
[0011] Some antibodies comprise a humanized mature heavy chain variable region having an amino acid sequence at least 90% identical to any one of SEQ ID NOs: 33-40, and a humanized mature light chain variable region having an amino acid sequence at least 90% identical to any one of SEQ ID NOs: 41-46.
[0012] In some antibodies, at least one of the following positions is substituted with the amino acid specified below: H48 is substituted with I, H71 is substituted with S, H93 is substituted with S, and H94 is substituted with P. In some antibodies, VH region positions H48, H71, H93, and H94 are substituted with I, S, S, and P, respectively. In some antibodies, at least one of the following positions is substituted with the amino acid specified below: H1 is substituted with E, H48 is substituted with I, H71 is substituted with S, H93 is substituted with S, and H94 is substituted with P. In some antibodies, VH region positions H1, H48, H71, H93, and H94 are substituted with E, I, S, S, and P, respectively.
[0013] In some antibodies, at least one of the following positions is filled with the amino acid specified below: H1 is filled with E, H46 is filled with D, H48 is filled with I, H71 is filled with S, H93 is filled with S, and H94 is filled with P. In some antibodies, VH region positions H1, H46, H48, H71, H93, and H94 are filled with E, D, I, S, S, and P, respectively. In some antibodies, at least one of the following positions is filled with the amino acid specified below: H1 is filled with E, H11 is filled with L, H12 is filled with V, H19 is filled with R, H20 is filled with L, H46 is filled with D, H48 is filled with I, H71 is filled with S, H76 is filled with N, H80 is filled with L, H93 is filled with S, and H94 is filled with P. In some antibodies, positions H1, H11, H12, H19, H20, H46, H48, H71, H76, H80, H93, and H94 of the VH region are arranged as E, L, V, R, L, D, I, S, N, L, S, and P, respectively.
[0014] In some antibodies, at least one of the following positions is substituted with the amino acid specified below: H66 is substituted with R, H67 is substituted with V, and H78 is substituted with V. In some antibodies, positions H66, H67, and H78 in the VH region are substituted with R, V, and V, respectively.
[0015] In some antibodies, at least one of the following positions is filled with an amino acid as specified below: H1 is filled with Q or E, H11 is filled with V or L, H12 is filled with K or V, H19 is filled with K or R, H20 is filled with V or L, H23 is filled with K or A, H46 is filled with E or D, H48 is filled with M or I, H66 is filled with K or R, H67 is filled with A or V, H71 is filled with R or S, H76 is filled with S or N, H78 is filled with A or V, H80 is filled with M or L, H93 is filled with T, S, or A, and H94 is filled with I, P, or R.
[0016] In some antibodies, the positions H48, H71, H93, and H94 of the VH region are arranged as I, S, S, and P, respectively. In some antibodies, the positions H1, H48, H71, H93, and H94 of the VH region are arranged as E, I, S, S, and P, respectively. In some antibodies, the positions H1, H46, H48, H71, H93, and H94 of the VH region are arranged as E, D, I, S, S, and P, respectively. In some antibodies, the positions H1, H11, H12, H19, H20, H46, H48, H71, H76, H80, H93, and H94 of the VH region are arranged as E, L, V, R, L, D, I, S, N, L, S, and P, respectively. In some antibodies, positions H1, H11, H12, H19, H20, H23, H46, H48, H71, H76, H80, H93, and H94 of the VH region are arranged as follows: E, L, V, R, L, A, D, I, S, N, L, S, and P, respectively. In some antibodies, positions H66, H67, H78, H93, and H94 of the VH region are arranged as follows: R, V, V, A, and R, respectively. In some antibodies, positions H1, H46, H48, H66, H67, H71, H78, H93, and H94 of the VH region are arranged as follows: E, D, I, R, V, S, V, S, and P, respectively.
[0017] In some antibodies, at least one of the following positions is filled with the amino acid specified below: L2 is filled with V, L7 is filled with S, L17 is filled with E, L36 is filled with L, L45 is filled with Q, L46 is filled with R, and L70 is filled with D.
[0018] In some antibodies, at least one of the following positions is filled with an amino acid as specified below: L2 is filled with V, L36 is filled with L, and L46 is filled with R. In some antibodies, the L2, L36, and L46 positions of the VL region are filled with V, L, and R, respectively. In some antibodies, at least one of the following positions is filled with an amino acid as specified below: L2 is filled with V, L36 is filled with L, L46 is filled with R, and L70 is filled with D. In some antibodies, the L2, L36, L46, and L70 positions of the VL region are filled with V, L, R, and D, respectively. In some antibodies, at least one of the following positions is filled with an amino acid as specified below: L45 is filled with Q, and L70 is filled with D. In some antibodies, the L45 and L70 positions of the VL region are filled with Q and D, respectively.
[0019] In some antibodies, at least one of the following positions is filled with an amino acid as specified below: L2 is filled with I or V, L7 is filled with T or S, L17 is filled with Q or E, L36 is filled with Y or L, L45 is filled with K or Q, L46 is filled with L or R, and L70 is filled with G or D.
[0020] In some antibodies, the positions L2, L36, and L46 of the VL region are arranged as V, L, and R, respectively. In some antibodies, the positions L2, L36, L46, and L70 of the VL region are arranged as V, L, R, and D, respectively. In some antibodies, the positions L2, L7, L17, L36, L46, and L70 of the VL region are arranged as V, S, E, L, R, and D, respectively. In some antibodies, the positions L45 and L70 of the VL region are arranged as Q and D, respectively. In some antibodies, the positions L2, L36, L45, L46, and L70 of the VL region are arranged as V, L, Q, R, and D, respectively.
[0021] Some antibodies comprise a mature heavy chain variable region having an amino acid sequence at least 95% identical to any one of SEQ ID NOs: 33 to 40, and a mature light chain variable region having an amino acid sequence at least 95% identical to any one of SEQ ID NOs: 41 to 46. Some antibodies comprise a mature heavy chain variable region having an amino acid sequence at least 98% identical to any one of SEQ ID NOs: 33 to 40, and a mature light chain variable region having an amino acid sequence at least 98% identical to any one of SEQ ID NOs: 41 to 46.
[0022] In some antibodies, the mature heavy chain variable region has the amino acid sequence of any one of SEQ ID NOs: 33-40, and the mature light chain variable region has the amino acid sequence of any one of SEQ ID NOs: 41-46.
[0023] In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO:33 and the mature light chain variable region has the amino acid sequence of SEQ ID NO:41. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO:33 and the mature light chain variable region has the amino acid sequence of SEQ ID NO:42. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO:33 and the mature light chain variable region has the amino acid sequence of SEQ ID NO:43. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO:33 and the mature light chain variable region has the amino acid sequence of SEQ ID NO:44. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO:33 and the mature light chain variable region has the amino acid sequence of SEQ ID NO:45. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO:33 and the mature light chain variable region has the amino acid sequence of SEQ ID NO:46.
[0024] In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO:34 and the mature light chain variable region has the amino acid sequence of SEQ ID NO:41. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO:34 and the mature light chain variable region has the amino acid sequence of SEQ ID NO:42. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO:34 and the mature light chain variable region has the amino acid sequence of SEQ ID NO:43. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO:34 and the mature light chain variable region has the amino acid sequence of SEQ ID NO:44. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO:34 and the mature light chain variable region has the amino acid sequence of SEQ ID NO:45. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO:34 and the mature light chain variable region has the amino acid sequence of SEQ ID NO:46.
[0025] In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO:35 and the mature light chain variable region has the amino acid sequence of SEQ ID NO:41. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO:35 and the mature light chain variable region has the amino acid sequence of SEQ ID NO:42. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO:35 and the mature light chain variable region has the amino acid sequence of SEQ ID NO:43. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO:35 and the mature light chain variable region has the amino acid sequence of SEQ ID NO:44. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO:35 and the mature light chain variable region has the amino acid sequence of SEQ ID NO:45. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO:35 and the mature light chain variable region has the amino acid sequence of SEQ ID NO:46.
[0026] In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO:36 and the mature light chain variable region has the amino acid sequence of SEQ ID NO:41. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO:36 and the mature light chain variable region has the amino acid sequence of SEQ ID NO:42. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO:36 and the mature light chain variable region has the amino acid sequence of SEQ ID NO:43. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO:36 and the mature light chain variable region has the amino acid sequence of SEQ ID NO:44. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO:36 and the mature light chain variable region has the amino acid sequence of SEQ ID NO:45. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO:36 and the mature light chain variable region has the amino acid sequence of SEQ ID NO:46.
[0027] In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO:37 and the mature light chain variable region has the amino acid sequence of SEQ ID NO:41. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO:37 and the mature light chain variable region has the amino acid sequence of SEQ ID NO:42. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO:37 and the mature light chain variable region has the amino acid sequence of SEQ ID NO:43. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO:37 and the mature light chain variable region has the amino acid sequence of SEQ ID NO:44. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO:37 and the mature light chain variable region has the amino acid sequence of SEQ ID NO:45. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO:37 and the mature light chain variable region has the amino acid sequence of SEQ ID NO:46.
[0028] In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO:38 and the mature light chain variable region has the amino acid sequence of SEQ ID NO:41. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO:38 and the mature light chain variable region has the amino acid sequence of SEQ ID NO:42. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO:38 and the mature light chain variable region has the amino acid sequence of SEQ ID NO:43. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO:38 and the mature light chain variable region has the amino acid sequence of SEQ ID NO:44. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO:38 and the mature light chain variable region has the amino acid sequence of SEQ ID NO:45. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO:38 and the mature light chain variable region has the amino acid sequence of SEQ ID NO:46.
[0029] In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO:39 and the mature light chain variable region has the amino acid sequence of SEQ ID NO:41. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO:39 and the mature light chain variable region has the amino acid sequence of SEQ ID NO:42. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO:39 and the mature light chain variable region has the amino acid sequence of SEQ ID NO:43. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO:39 and the mature light chain variable region has the amino acid sequence of SEQ ID NO:44. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO:39 and the mature light chain variable region has the amino acid sequence of SEQ ID NO:45. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO:39 and the mature light chain variable region has the amino acid sequence of SEQ ID NO:46.
[0030] In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO: 40 and the mature light chain variable region has the amino acid sequence of SEQ ID NO: 41. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO: 40 and the mature light chain variable region has the amino acid sequence of SEQ ID NO: 42. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO: 40 and the mature light chain variable region has the amino acid sequence of SEQ ID NO: 43. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO: 40 and the mature light chain variable region has the amino acid sequence of SEQ ID NO: 44. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO: 40 and the mature light chain variable region has the amino acid sequence of SEQ ID NO: 45. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO: 40 and the mature light chain variable region has the amino acid sequence of SEQ ID NO: 46.
[0031] Some antibodies include the three light chain CDRs and three heavy chain CDRs of monoclonal antibody 6A10, which is a murine antibody characterized by a heavy chain variable region having an amino acid sequence comprising SEQ ID NO: 63 and a light chain variable region having an amino acid sequence comprising SEQ ID NO: 64. Some antibodies include three heavy chain CDRs defined by the Kabat / Chothia combination (SEQ ID NOs: 65, 66, and 67) and three light chain CDRs defined by the Kabat / Chothia combination (SEQ ID NOs: 68, 69, and 70).
[0032] For example, the antibody can be 6A10, or a chimeric, veneered, or humanized version thereof. Some antibodies have a variable heavy chain that is 85% or more identical to a human sequence. Some antibodies have a variable light chain that is 85% or more identical to a human sequence. Some antibodies have a variable heavy chain and a variable light chain that are each 85% or more identical to a human germline sequence.
[0033] Some antibodies are humanized antibodies. Some antibodies are humanized or chimeric 6A10 antibodies that specifically bind to human tau, where 6A10 is a murine antibody characterized by a mature heavy chain variable region of SEQ ID NO: 63 and a mature light chain variable region of SEQ ID NO: 64. Some antibodies comprise a humanized mature heavy chain variable region that includes the three heavy chain CDRs of 6A10 and a humanized mature light chain variable region that includes the three light chain CDRs of 6A10.
[0034] In some antibodies, the CDRs are by a definition selected from the group of Kabat, Chothia, Kabat / Chothia combination, AbM, and Contact. In some antibodies, the humanized mature heavy chain variable region comprises the three Kabat / Chothia combined heavy chain CDRs of 6A10 (SEQ ID NOs: 65-67), and the humanized mature light chain variable region comprises the three Kabat / Chothia combined light chain CDRs of 6A10 (SEQ ID NOs: 68-70). In some antibodies, the humanized mature heavy chain variable region comprises the three Kabat heavy chain CDRs of 6A10 (SEQ ID NOs: 71, 66, and 67), and the humanized mature light chain variable region comprises the three Kabat light chain CDRs of 6A10 (SEQ ID NOs: 68-70). In some antibodies, the humanized mature heavy chain variable region comprises the three Chothia heavy chain CDRs of 6A10 (SEQ ID NO: 72, SEQ ID NO: 74, and SEQ ID NO: 67), and the humanized mature light chain variable region comprises the three Chothia light chain CDRs of 6A10 (SEQ ID NO: 68-70). In some antibodies, the humanized mature heavy chain variable region comprises the three AbM heavy chain CDRs of 6A10 (SEQ ID NO: 65, SEQ ID NO: 75, and SEQ ID NO: 67), and the humanized mature light chain variable region comprises the three AbM light chain CDRs of 6A10 (SEQ ID NO: 68-70). In some antibodies, the humanized mature heavy chain variable region comprises the three Contact heavy chain CDRs of 6A10 (SEQ ID NO: 73, SEQ ID NO: 76, and SEQ ID NO: 77), and the humanized mature light chain variable region comprises the three Contact light chain CDRs of 6A10 (SEQ ID NO: 78-80).
[0035] Some antibodies comprise a humanized mature heavy chain variable region having an amino acid sequence at least 90% identical to any one of SEQ ID NOs: 85-87, and a humanized mature light chain variable region having an amino acid sequence at least 90% identical to any one of SEQ ID NOs: 88-90.
[0036] In some antibodies, an I is placed at position H48 in the VH region.
[0037] In some antibodies, at least one of the following positions is substituted with the amino acid specified below: H16 of the VH region is substituted with A or G, H48 is substituted with M or I, H69 is substituted with T or I, and H80 is substituted with M or L.
[0038] In some antibodies, the H48 position of the VH region is substituted with I. In some antibodies, the H16, H48, H69, and H80 positions of the VH region are substituted with G, I, I, and L, respectively.
[0039] In some antibodies, an L is placed at L46 in the VL region.
[0040] In some antibodies, at least one of the following positions is substituted with the amino acid specified below: L12 of the VL region is substituted with P or S, L17 is substituted with Q or E, and L46 is substituted with R or L.
[0041] In some antibodies, L46 of the VL region is replaced by L. In some antibodies, positions L12, L17, and L46 of the VL region are replaced by S, E, and L, respectively.
[0042] Some antibodies comprise a mature heavy chain variable region having an amino acid sequence at least 95% identical to any one of SEQ ID NOs: 85 to 87, and a mature light chain variable region having an amino acid sequence at least 95% identical to any one of SEQ ID NOs: 88 to 90. Some antibodies comprise a mature heavy chain variable region having an amino acid sequence at least 98% identical to any one of SEQ ID NOs: 85 to 87, and a mature light chain variable region having an amino acid sequence at least 98% identical to any one of SEQ ID NOs: 88 to 90.
[0043] In some antibodies, the mature heavy chain variable region has the amino acid sequence of any one of SEQ ID NOs: 85-87, and the mature light chain variable region has the amino acid sequence of any one of SEQ ID NOs: 88-90.
[0044] In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO: 85, and the mature light chain variable region has the amino acid sequence of SEQ ID NO: 88. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO: 85, and the mature light chain variable region has the amino acid sequence of SEQ ID NO: 89. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO: 85, and the mature light chain variable region has the amino acid sequence of SEQ ID NO: 90.
[0045] In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO: 86, and the mature light chain variable region has the amino acid sequence of SEQ ID NO: 88. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO: 86, and the mature light chain variable region has the amino acid sequence of SEQ ID NO: 89. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO: 86, and the mature light chain variable region has the amino acid sequence of SEQ ID NO: 90.
[0046] In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO: 87, and the mature light chain variable region has the amino acid sequence of SEQ ID NO: 88. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO: 87, and the mature light chain variable region has the amino acid sequence of SEQ ID NO: 89. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO: 87, and the mature light chain variable region has the amino acid sequence of SEQ ID NO: 90.
[0047] Some antibodies include the three light chain CDRs and three heavy chain CDRs of monoclonal antibody 8A4, which is a murine antibody characterized by a heavy chain variable region having an amino acid sequence comprising SEQ ID NO: 91, and a light chain variable region having an amino acid sequence comprising SEQ ID NO: 92. In some antibodies, the three heavy chain CDRs are defined by the Kabat / Chothia combination (SEQ ID NOs: 93, 94, and 95), and the three light chain CDRs are defined by the Kabat / Chothia combination (SEQ ID NOs: 96, 97, and 98).
[0048] Some antibodies are 8A4 or chimeric, veneered, or humanized versions thereof. In some antibodies, the variable heavy chain has 85% or more identity to human sequences. In some antibodies, the variable light chain has 85% or more identity to human sequences. In some antibodies, the variable heavy and variable light chains each have 85% or more identity to human germline sequences.
[0049] Some antibodies are humanized antibodies. Some antibodies are humanized or chimeric 8A4 antibodies that specifically bind to human tau, where 8A4 is a murine antibody characterized by a mature heavy chain variable region of SEQ ID NO: 91 and a mature light chain variable region of SEQ ID NO: 92. Some antibodies comprise a humanized mature heavy chain variable region that includes the three heavy chain CDRs of 8A4 and a humanized mature light chain variable region that includes the three light chain CDRs of 8A4.
[0050] In some antibodies, the CDRs are according to a definition selected from the group of Kabat, Chothia, Kabat / Chothia combination, AbM, and Contact. In some antibodies, the humanized mature heavy chain variable region comprises the three Kabat / Chothia combination heavy chain CDRs of 8A4 (SEQ ID NOs: 93-95), and the humanized mature light chain variable region comprises the three Kabat / Chothia combination light chain CDRs of 8A4 (SEQ ID NOs: 96-98). In some antibodies, the humanized mature heavy chain variable region comprises the three Kabat heavy chain CDRs of 8A4 (SEQ ID NOs: 99, 94, and 95), and the humanized mature light chain variable region comprises the three Kabat light chain CDRs of 8A4 (SEQ ID NOs: 96-98). In some antibodies, the humanized mature heavy chain variable region comprises the three Chothia heavy chain CDRs of 8A4 (SEQ ID NO: 100, SEQ ID NO: 102, and SEQ ID NO: 95), and the humanized mature light chain variable region comprises the three Chothia light chain CDRs of 8A4 (SEQ ID NO: 96-98). In some antibodies, the humanized mature heavy chain variable region comprises the three AbM heavy chain CDRs of 8A4 (SEQ ID NO: 93, SEQ ID NO: 103, and SEQ ID NO: 95), and the humanized mature light chain variable region comprises the three AbM light chain CDRs of 8A4 (SEQ ID NO: 96-98). In some antibodies, the humanized mature heavy chain variable region comprises the three Contact heavy chain CDRs of 8A4 (SEQ ID NO: 101, SEQ ID NO: 104, and SEQ ID NO: 105), and the humanized mature light chain variable region comprises the three Contact light chain CDRs of 8A4 (SEQ ID NO: 106-108).
[0051] Some antibodies comprise a humanized mature heavy chain variable region having an amino acid sequence at least 90% identical to any one of SEQ ID NOs: 113-115, and a humanized mature light chain variable region having an amino acid sequence at least 90% identical to any one of SEQ ID NOs: 116-118.
[0052] In some antibodies, an S is placed at the H93 position in the VH region.
[0053] In some antibodies, at least one of the following positions is filled with the amino acid specified below: H12 of the VH region is filled with V, H16 is filled with G, H20 is filled with L, and H68 is filled with T. In some antibodies, positions H12, H16, H20, and H68 of the VH region are filled with V, G, L, and T, respectively.
[0054] In some antibodies, at least one of the following positions is substituted with the amino acid specified below: H12 of the VH region is substituted with K or V, H16 is substituted with S or G, H20 is substituted with V or L, H48 is substituted with M or I, H67 is substituted with A or I, H68 is substituted with N or T, H85 is substituted with D or E, and H93 is substituted with S or A.
[0055] In some antibodies, the H93 position of the VH region is substituted with S. In some antibodies, the H12, H16, H20, H68, and H93 positions of the VH region are substituted with V, G, L, T, and S, respectively. In some antibodies, the H12, H16, H20, H48, H67, H68, and H85 positions of the VH region are substituted with V, G, L, I, A, T, and E, respectively.
[0056] In some antibodies, an E is placed at L17 of the VL region.
[0057] In some antibodies, at least one of the following positions is substituted with the amino acid specified below: L2 of the VL region is substituted with I or V, L17 is substituted with Q or E, and L36 is substituted with F or L.
[0058] In some antibodies, the L17 position of the VL region is replaced by an E. In some antibodies, the L2, L17, and L36 positions of the VL region are replaced by V, E, and L.
[0059] Some antibodies comprise a mature heavy chain variable region having an amino acid sequence at least 95% identical to any one of SEQ ID NOs: 113-115, and a mature light chain variable region having an amino acid sequence at least 95% identical to any one of SEQ ID NOs: 116-118.
[0060] Some antibodies comprise a mature heavy chain variable region having an amino acid sequence at least 98% identical to any one of SEQ ID NOs: 113-115, and a mature light chain variable region having an amino acid sequence at least 98% identical to any one of SEQ ID NOs: 116-118.
[0061] In some antibodies, the mature heavy chain variable region has the amino acid sequence of any one of SEQ ID NOs: 113-115, and the mature light chain variable region has the amino acid sequence of any one of SEQ ID NOs: 116-118.
[0062] In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO: 113, and the mature light chain variable region has the amino acid sequence of SEQ ID NO: 116. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO: 113, and the mature light chain variable region has the amino acid sequence of SEQ ID NO: 117. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO: 113, and the mature light chain variable region has the amino acid sequence of SEQ ID NO: 118.
[0063] In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO: 114, and the mature light chain variable region has the amino acid sequence of SEQ ID NO: 116. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO: 114, and the mature light chain variable region has the amino acid sequence of SEQ ID NO: 117. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO: 114, and the mature light chain variable region has the amino acid sequence of SEQ ID NO: 118.
[0064] In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO: 115, and the mature light chain variable region has the amino acid sequence of SEQ ID NO: 116. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO: 115, and the mature light chain variable region has the amino acid sequence of SEQ ID NO: 117. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO: 115, and the mature light chain variable region has the amino acid sequence of SEQ ID NO: 118.
[0065] Some antibodies comprise the three light chain CDRs and three heavy chain CDRs of monoclonal antibody 7G6, which is a murine antibody characterized by a heavy chain variable region having an amino acid sequence comprising SEQ ID NO: 119, and a light chain variable region having an amino acid sequence comprising SEQ ID NO: 120. In some antibodies, the three heavy chain CDRs are those defined by the Kabat / Chothia combination (SEQ ID NOs: 121, 122, and 123) and the three light chain CDRs are those defined by the Kabat / Chothia combination (SEQ ID NOs: 124, 125, and 126).
[0066] In some antibodies, the variable heavy chain is 7G6 or a chimeric, veneered, or humanized version thereof. In some antibodies, the variable light chain has 85% or more identity to a human sequence. In some antibodies, the variable heavy chain has 85% or more identity to a human sequence. In some antibodies, the variable light chain each has 85% or more identity to a human germline sequence.
[0067] Some antibodies are humanized antibodies. Some antibodies are humanized or chimeric 7G6 antibodies that specifically bind to human tau, where 7G6 is a murine antibody characterized by a mature heavy chain variable region of SEQ ID NO: 119 and a mature light chain variable region of SEQ ID NO: 120. Some antibodies comprise a humanized mature heavy chain variable region that includes the three heavy chain CDRs of 7G6 and a humanized mature light chain variable region that includes the three light chain CDRs of 7G6.
[0068] In some antibodies, the CDRs are by a definition selected from the group of Kabat, Chothia, Kabat / Chothia combination, AbM, and Contact. In some antibodies, the humanized mature heavy chain variable region comprises the three Kabat / Chothia combination heavy chain CDRs of 7G6 (SEQ ID NOs: 121-123), and the humanized mature light chain variable region comprises the three Kabat / Chothia combination light chain CDRs of 7G6 (SEQ ID NOs: 124-126). In some antibodies, the humanized mature heavy chain variable region comprises the three Kabat heavy chain CDRs of 7G6 (SEQ ID NOs: 127, 122, and 123), and the humanized mature light chain variable region comprises the three Kabat light chain CDRs of 7G6 (SEQ ID NOs: 124-126). In some antibodies, the humanized mature heavy chain variable region comprises the three Chothia heavy chain CDRs of 7G6 (SEQ ID NO:128, SEQ ID NO:130, and SEQ ID NO:123), and the humanized mature light chain variable region comprises the three Chothia light chain CDRs of 7G6 (SEQ ID NO:124-126). In some antibodies, the humanized mature heavy chain variable region comprises the three AbM heavy chain CDRs of 7G6 (SEQ ID NO:121, SEQ ID NO:131, and SEQ ID NO:123), and the humanized mature light chain variable region comprises the three AbM light chain CDRs of 7G6 (SEQ ID NO:124-126). In some antibodies, the humanized mature heavy chain variable region comprises the three Contact heavy chain CDRs of 7G6 (SEQ ID NO: 129, SEQ ID NO: 132, and SEQ ID NO: 133), and the humanized mature light chain variable region comprises the three Contact light chain CDRs of 7G6 (SEQ ID NO: 134, SEQ ID NO: 135, and SEQ ID NO: 136).
[0069] Some antibodies comprise a humanized mature heavy chain variable region having an amino acid sequence at least 90% identical to any one of SEQ ID NOs: 139-140, and a humanized mature light chain variable region having an amino acid sequence at least 90% identical to any one of SEQ ID NOs: 141-148.
[0070] In some antibodies, at least one of the following positions is filled with the amino acid specified below: H12 is filled with V, H20 is filled with L, H69 is filled with I, H76 is filled with N, H78 is filled with A, H80 is filled with L, H81 is filled with Q, H92 is filled with S, and H93 is filled with T in the VH region. In some antibodies, positions H12, H20, H69, H76, H78, H80, H81, H92, H93, and H101 in the VH region are filled with V, L, I, N, A, L, Q, S, and T, respectively.
[0071] In some antibodies, at least one of the following positions is substituted with an amino acid as specified below: H12 of the VH region is substituted with K or V, H20 is substituted with V or L, H38 is substituted with R or K, H69 is substituted with M or I, H76 is substituted with S or N, H78 is substituted with V or A, H80 is substituted with M or L, H81 is substituted with E or Q, H92 is substituted with C or S, and H93 is substituted with A or T.
[0072] In some antibodies, V, L, I, N, A, L, Q, S, and T are located at positions H12, H20, H69, H76, H78, H80, H81, H92, and H93, respectively, of the VH region. In some antibodies, V, L, K, I, N, A, L, Q, S, and T are located at positions H12, H20, H38, H69, H76, H78, H80, H81, H92, and H93, respectively, of the VH region.
[0073] In some antibodies, at least one of the following positions is filled with the amino acid specified below: L12 of the VL region is filled with S, and L103 is filled with K. In some antibodies, positions L12 and L103 of the VL region are filled with S and K, respectively.
[0074] In some antibodies, at least one of the following positions is filled with the amino acid specified below: L12 of the VL region is filled with S, L36 is filled with L, and L103 is filled with K. In some antibodies, positions L12, L36, and L103 of the VL region are filled with S, L, and K, respectively.
[0075] In some antibodies, at least one of the following positions is substituted with the amino acid specified below: L12 of the VL region is substituted with S, L37 is substituted with L, and L103 is substituted with K. In some antibodies, L12, L37, and L103 of the VL region are substituted with S, L, and K, respectively.
[0076] In some antibodies, at least one of the following positions is substituted with the amino acid specified below: L12 of the VL region is substituted with S, L36 is substituted with L, L37 is substituted with L, and L103 is substituted with K. In some antibodies, L12, L36, L37, and L103 of the VL region are substituted with S, L, L, and K, respectively.
[0077] In some antibodies, at least one of the following positions is filled with the amino acid specified below: L12 of the VL region is filled with S, L45 is filled with K, and L103 is filled with K. In some antibodies, positions L12, L45, and L103 of the VL region are filled with S, K, and K, respectively.
[0078] In some antibodies, at least one of the following positions is filled with the amino acid specified below: L12 of the VL region is filled with S, L100 is filled with G, and L103 is filled with K. In some antibodies, positions L12, L100, and L103 of the VL region are filled with S, G, and K, respectively.
[0079] In some antibodies, at least one of the following positions is substituted with the amino acid specified below: L36 of the VL region is substituted with F or L, L37 is substituted with Q or L, L45 is substituted with R or K, and L100 is substituted with Q or G.
[0080] In some antibodies, the positions of L12 and L103 in the VL region are arranged with S and K, respectively. In some antibodies, the positions of L12, L37, and L103 in the VL region are arranged with S, L, and K, respectively. In some antibodies, the positions of L12, L36, and L103 in the VL region are arranged with S, L, and K, respectively. In some antibodies, the positions of L12, L36, L37, and L103 in the VL region are arranged with S, L, L, and K, respectively. In some antibodies, the positions of L12, L45, and L103 in the VL region are arranged with S, K, and K, respectively. In some antibodies, the positions of L12, L36, L37, L45, and L103 in the VL region are arranged with S, L, L, K, and K, respectively. In some antibodies, such as hu7G6~VL_v7, the L12, L100, and L103 positions of the VL region are respectively arranged as S, G, and K. In some antibodies, the L12, L36, L37, L100, and L103 positions of the VL region are respectively arranged as S, L, L, G, and K.
[0081] Some antibodies comprise a mature heavy chain variable region having an amino acid sequence at least 95% identical to any one of SEQ ID NOs: 139-140, and a mature light chain variable region having an amino acid sequence at least 95% identical to any one of SEQ ID NOs: 141-148. Some antibodies comprise a mature heavy chain variable region having an amino acid sequence at least 98% identical to any one of SEQ ID NOs: 139-140, and a mature light chain variable region having an amino acid sequence at least 98% identical to any one of SEQ ID NOs: 141-148.
[0082] In some antibodies, the mature heavy chain variable region has the amino acid sequence of any one of SEQ ID NOs: 139-140, and the mature light chain variable region has the amino acid sequence of any one of SEQ ID NOs: 141-148.
[0083] In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO: 139 and the mature light chain variable region has the amino acid sequence of SEQ ID NO: 141. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO: 139 and the mature light chain variable region has the amino acid sequence of SEQ ID NO: 142. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO: 139 and the mature light chain variable region has the amino acid sequence of SEQ ID NO: 143. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO: 139 and the mature light chain variable region has the amino acid sequence of SEQ ID NO: 144. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO: 139 and the mature light chain variable region has the amino acid sequence of SEQ ID NO: 145. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO: 139 and the mature light chain variable region has the amino acid sequence of SEQ ID NO: 146. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO: 139, and the mature light chain variable region has the amino acid sequence of SEQ ID NO: 147. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO: 139, and the mature light chain variable region has the amino acid sequence of SEQ ID NO: 148.
[0084] In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO: 140 and the mature light chain variable region has the amino acid sequence of SEQ ID NO: 141. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO: 140 and the mature light chain variable region has the amino acid sequence of SEQ ID NO: 142. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO: 140 and the mature light chain variable region has the amino acid sequence of SEQ ID NO: 143. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO: 140 and the mature light chain variable region has the amino acid sequence of SEQ ID NO: 144. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO: 140 and the mature light chain variable region has the amino acid sequence of SEQ ID NO: 145. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO: 140 and the mature light chain variable region has the amino acid sequence of SEQ ID NO: 146. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO: 140, and the mature light chain variable region has the amino acid sequence of SEQ ID NO: 147. In some antibodies, the mature heavy chain variable region has the amino acid sequence of SEQ ID NO: 140, and the mature light chain variable region has the amino acid sequence of SEQ ID NO: 148.
[0085] For example, the antibody may be a chimeric antibody. For example, the antibody may be a veneered antibody. The antibody may be an intact antibody. The antibody may be a binding fragment. In one embodiment, the binding fragment is a single chain antibody, a Fab, or a Fab'2 fragment. The antibody may be a Fab fragment or a single chain Fv. Some antibodies may comprise a human IgG1, and other antibodies may comprise a human IgG2 or IgG4 isotype.
[0086] In some antibodies, the antibody comprises a mature light chain variable region fused to a light chain constant region and a mature heavy chain variable region fused to a heavy chain constant region. In some antibodies, the heavy chain constant region is a variant of a native human heavy chain constant region that has reduced binding to Fcγ receptors compared to the native human heavy chain constant region. In some antibodies, the heavy chain constant region is of the IgG1 isotype.
[0087] Some antibodies may have at least one mutation in the constant region that reduces complement binding or activation by the constant region, for example, one or more of positions 241, 264, 265, 270, 296, 297, 318, 320, 322, 329, and 331 (EU numbering). Some antibodies have alanines at positions 318, 320, and 322.
[0088] Some antibodies may be at least 95% w / w pure. Some antibodies are conjugated to a therapeutic agent, a cytotoxic agent, a cytostatic agent, a neurotrophic agent, or a neuroprotective agent.
[0089] In another aspect, the invention provides a pharmaceutical composition comprising any of the antibodies described herein and a pharma- ceutically acceptable carrier.
[0090] In another aspect, the invention provides nucleic acids encoding the heavy and / or light chains of any of the antibodies described herein, recombinant expression vectors comprising the nucleic acids, and host cells transformed with the recombinant expression vectors.
[0091] In another aspect, the invention provides a method of humanizing any of the non-human antibodies described herein (e.g., murine antibody 5G8, where 5G8 is characterized by a mature heavy chain variable region of SEQ ID NO: 7, and a mature light chain variable region of SEQ ID NO: 8). In another aspect, the invention provides a method of humanizing any of the non-human antibodies described herein (e.g., murine antibody 6A10, where 6A10 is characterized by a mature heavy chain variable region of SEQ ID NO: 63, and a mature light chain variable region of SEQ ID NO: 64). In another aspect, the invention provides a method of humanizing any of the non-human antibodies described herein (e.g., murine antibody 8A4, where 8A4 is characterized by a mature heavy chain variable region of SEQ ID NO: 91, and a mature light chain variable region of SEQ ID NO: 92). In another aspect, the invention provides a method of humanizing any of the non-human antibodies described herein (e.g., murine antibody 7G6, where 7G6 is characterized by a mature heavy chain variable region of SEQ ID NO: 119, and a mature light chain variable region of SEQ ID NO: 120). The method may include selecting one or more acceptor antibodies, identifying the amino acid residues of the murine antibody to retain, synthesizing a nucleic acid encoding a humanized heavy chain comprising the CDRs of the murine antibody heavy chain, and a nucleic acid encoding a humanized light chain comprising the CDRs of the murine antibody light chain, and expressing the nucleic acids in a host cell to produce the humanized antibody.
[0092] Also provided are methods for producing antibodies (e.g., humanized, chimeric, or veneered antibodies, e.g., humanized, chimeric, or veneered versions of 5G8, 6A10, 8A4, or 7G6) in which cells transformed with nucleic acids encoding the antibody heavy and light chains are cultured such that the cells secrete the antibody. The antibody can then be purified from the cell culture medium.
[0093] A cell line producing any of the antibodies described herein can be produced by introducing into cells a vector encoding the antibody heavy and light chains and a selectable marker, growing the cells under conditions that select for cells with increased copy number of the vector, isolating a single cell from the selected cells, and banking the cloned cells from the selected single cell based on antibody yield.
[0094] Some cells are capable of growing under selective conditions and have a concentration of at least 100 mg / L / 10 6 Cell lines that naturally express and secrete the antibody / 24h can be screened. From the selected cells, single cells can be isolated. Cells cloned from the single cells can then be banked. Single cells can be selected based on desirable properties, such as antibody yield. An exemplary cell line is a cell line that expresses 5G8.
[0095] The invention also provides methods of inhibiting or reducing tau aggregation in a subject having or at risk of developing tau-mediated amyloidosis, comprising administering to the subject an effective regimen of an antibody described herein, thereby inhibiting or reducing tau aggregation in the subject. Exemplary antibodies are humanized versions of 5G8, 6A10, 8A4, or 7G6.
[0096] Also provided is a method of treating or preventing a tau-related disease in a subject, comprising administering an effective regimen of the antibody described herein, thereby treating or preventing the disease. Exemplary diseases are Alzheimer's disease, Down's syndrome, mild cognitive impairment, primary age-related tauopathy, postencephalitic parkinsonism, posttraumatic dementia or dementia pugilistica, Pick's disease, Niemann-Pick type C disease, supranuclear palsy, frontotemporal dementia, frontotemporal lobar degeneration, argyrophilic grain disease, globular glial cell tauopathy, amyotrophic lateral sclerosis / parkinsonism dementia complex of Guam, corticobasal degeneration (CBD), dementia with Lewy bodies, Lewy body variant of Alzheimer's disease (LBVAD), or progressive supranuclear palsy (PSP). In some methods, the tau-related disease is Alzheimer's disease. In some methods, the patient is an ApoE4 carrier.
[0097] Also provided is a method of reducing the abnormal propagation of tau, comprising administering an effective regimen of an antibody described herein, thereby reducing the propagation of tau.
[0098] Also provided is a method of inducing phagocytosis of tau, comprising administering an effective regimen of an antibody described herein, thereby inducing phagocytosis of tau.
[0099] Also provided is a method of inhibiting tau aggregation or deposition comprising administering an effective regimen of the antibodies described herein, thereby inhibiting tau aggregation or deposition.
[0100] Also provided is a method of inhibiting the formation of tau tangles, comprising administering an effective regimen of the antibodies described herein.
[0101] Also provided are methods of detecting tau protein deposits in a subject having or at risk for a disease associated with tau aggregation or deposition, comprising administering to the subject an antibody described herein and detecting antibody bound to tau in the subject, exemplary of which diseases are Alzheimer's disease, Down's syndrome, mild cognitive impairment, primary age-related tauopathy, postencephalitic parkinsonism, post-traumatic dementia or dementia pugilistica, Pick's disease, Niemann-Pick type C, supranuclear palsy, frontotemporal dementia, frontotemporal lobar degeneration, argyrophilic grain disease, globular glial cell tauopathy, amyotrophic lateral sclerosis / parkinsonism dementia complex of Guam, corticobasal degeneration (CBD), dementia with Lewy bodies, Lewy body variant of Alzheimer's disease (LBVAD), or progressive supranuclear palsy (PSP).
[0102] In one embodiment, the antibody is administered intravenously into the subject's body. In one embodiment, the antibody is administered directly into the subject's brain by intracranial injection or by drilling a hole in the subject's skull. In one embodiment, the antibody is labeled. In one embodiment, the antibody is labeled with a fluorescent label, a paramagnetic label, or a radioactive label. In one embodiment, the radioactive label is detected using positron emission tomography (PET) or single photon emission computed tomography (SPECT).
[0103] The invention also provides a method for determining the efficacy of treatment in a subject undergoing treatment for a disease associated with tau aggregation or deposition, comprising the steps of measuring a first level of tau protein deposits in the subject prior to treatment of administering an antibody described herein to the subject, detecting a first amount of antibody bound to tau in the subject, and administering the treatment to the subject, measuring a second level of tau protein deposits in the subject prior to treatment of administering the antibody to the subject, and detecting antibody bound to tau in the subject, wherein a reduction in the level of tau protein deposits indicates a positive response to the treatment.
[0104] The invention also provides a method of determining the effectiveness of treatment in a subject undergoing treatment for a disease associated with tau aggregation or deposition, comprising the steps of measuring a first level of tau protein deposits in the subject and detecting a first amount of antibody bound to tau in the subject prior to treatment of administering an antibody described herein to the subject, administering the treatment to the subject, and measuring a second level of tau protein deposits in the subject and detecting the second amount of antibody bound to tau in the subject after treatment of administering the antibody to the subject, wherein no change in the level of tau protein deposits, or a slight increase in tau protein deposits, indicates a positive response to the treatment.
[0105] In one aspect, the present invention provides an isolated monoclonal antibody that specifically binds to a peptide consisting of residues 199 to 213 of SEQ ID NO:3.
[0106] In one aspect, the present invention provides an isolated monoclonal antibody that specifically binds to a peptide consisting of residues 262-276 of SEQ ID NO:3.
[0107] Some antibodies specifically bind to both a peptide consisting of residues 199-213 of SEQ ID NO:3 and a peptide consisting of residues 262-276 of SEQ ID NO:3.
[0108] In one aspect, the invention provides an isolated monoclonal antibody that specifically binds to a polypeptide of SEQ ID NO:3 at an epitope comprising at least one residue within 199-213 of SEQ ID NO:3.
[0109] Some antibodies bind to an epitope within residues 199-213 of SEQ ID NO:3.
[0110] In one aspect, the invention provides an isolated monoclonal antibody that specifically binds to a polypeptide of SEQ ID NO:3 at an epitope that includes at least one residue within 262-276 of SEQ ID NO:3.
[0111] Some antibodies bind to an epitope within residues 262-276 of SEQ ID NO:3.
[0112] Some antibodies specifically bind to an epitope that includes at least one residue from both 199-213 and 262-276 of SEQ ID NO:3.
[0113] The present invention also provides a method for treating or preventing a tau-related disease in a subject, comprising administering an immunogen comprising a tau peptide of up to 20 consecutive amino acids of SEQ ID NO: 3 to which antibody 5G8 specifically binds, wherein the peptide induces the formation of an antibody that specifically binds to tau in the subject. The present invention also provides a method for treating or preventing a tau-related disease in a subject, comprising administering an immunogen comprising a tau peptide of up to 20 consecutive amino acids of SEQ ID NO: 3 to which antibody 6A10 specifically binds, wherein the peptide induces the formation of an antibody that specifically binds to tau in the subject. The present invention also provides a method for treating or preventing a tau-related disease in a subject, comprising administering an immunogen comprising a tau peptide of up to 20 consecutive amino acids of SEQ ID NO: 3 to which antibody 8A4 specifically binds, wherein the peptide induces the formation of an antibody that specifically binds to tau in the subject. The invention also provides a method of treating or preventing a tau-related disease in a subject, comprising administering an immunogen comprising a tau peptide of up to 20 consecutive amino acids of SEQ ID NO: 3 to which antibody 7G6 specifically binds, wherein the peptide induces the formation of antibodies that specifically bind to tau in the subject.The invention also provides a method of treating or preventing a tau-related disease in a subject, comprising administering an immunogen comprising a tau peptide of up to 20 consecutive amino acids of SEQ ID NO: 3 to which antibody 3D6 specifically binds, wherein the peptide induces the formation of antibodies that specifically bind to tau in the subject.
[0114] In some such methods, at least two of the antibodies 5G8, 6A10, 8A4, 7G6, and 3D6 specifically bind to a tau peptide.
[0115] In some of the methods, the tau peptide epitope consists of 4-11 contiguous amino acids from residues 199-213 of SEQ ID NO: 3 or from residues 262-276 of SEQ ID NO: 3. In some of the methods, the tau peptide epitope consists of two contiguous segments of amino acids, one segment from residues 199-213 of SEQ ID NO: 3 and another segment from residues 262-276 of SEQ ID NO: 3, where the two contiguous segments together consist of 4-11 amino acids. [Brief description of the drawings]
[0116] [Figure 1] 1A, 1B and 1C show the results of an ELISA screening assay of selected mouse monoclonal anti-tau antibodies.
[0117] [Diagram 2] FIG. 2 shows the binding kinetics of selected mouse monoclonal anti-tau antibodies to recombinant human tau.
[0118] [Diagram 3] FIG. 3 shows the results of a functional blocking assay of selected mouse monoclonal anti-tau antibodies.
[0119] [Figure 4] FIG. 4 shows the results of experiments demonstrating that 5G8 immunocaptures tau from human Alzheimer's disease tissue.
[0120] [Diagram 5] Figure 5 shows an alignment of the heavy chain variable regions of the murine 5G8 antibody, the human acceptor aDabi-Fab2b-VH, and the humanized versions of the 5G8 antibody (hu5G8_VH-v1, hu5G8_VH-v2, hu5G8_VH-v3, hu5G8_VH-v4, hu5G8_VH-v5, hu5G8_VH-v6, hu5G8_VH-v7, hu5G8_VH-v8).
[0121] [Figure 6]Figure 6 shows an alignment of the light chain variable regions of the murine 5G8 antibody, the human acceptor aDabi-Fab2b-VL, and the humanized versions of the 5G8 antibody (hu5G8-VL-v1, hu5G8-VL-v2, hu5G8-VL-v3, hu5G8-VL-v4, hu5G8-VL-v5, and hu5G8-VL-v6).
[0122] [Figure 7] FIG. 7 shows the alignment of the heavy chain variable regions of the murine 6A10 antibody, the human acceptor ACR16112 VH, and the humanized versions of the 6A10 antibody (hu6A10_VH-v1, hu6A10_VH-v2, and hu6A10_VH-v3).
[0123] [Figure 8] FIG. 8 shows an alignment of the light chain variable regions of the murine 6A10 antibody, the human acceptor ABC66863 VL, and the humanized versions of the 6A10 antibody (hu6A10VL-v1, hu6A10-VL-v2, and hu6A10-VL-v3).
[0124] [Figure 9] FIG. 9 shows an alignment of the heavy chain variable regions of the murine 8A4 antibody, the human acceptor ADU57742 VH, and the humanized versions of the 8A4 antibody (hu8A4_VH-v1, hu8A4_VH-v2, and hu8A4_VH-v3).
[0125] [Figure 10] FIG. 10 shows an alignment of the light chain variable region of the murine 8A4 antibody, the human acceptor ABA26100 VL, and the humanized versions of the 8A4 antibody (hu8A4-VL-v1, hu8A4-VL-v2, and hu8A4-VL-v3).
[0126] [Figure 11] FIG. 11 shows the alignment of the heavy chain variable regions of the murine 7G6 antibody, the human acceptor 3U0T_VH, and the humanized versions of the 7G6 antibody (hu7G6_VH-v1, and hu7G6_VH-v2).
[0127] [Figure 12] FIG. 12 shows an alignment of the light chain variable regions of the murine 7G6 antibody, the human acceptor 3U0T_VL, and the humanized versions of the 7G6 antibody (hu7G6-VL-v1, hu7G6-VL-v2, hu7G6-VL-v3, hu7G6-VL-v4, hu7G6-VL-v5, hu7G6-VL-v6, hu7G6-VL-7, and hu7G6-VL-8). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0128] Sequence Listing Overview SEQ ID NO: 1 shows the amino acid sequence of a human tau isoform (Swiss-Prot P10636-8).
[0129] SEQ ID NO: 2 shows the amino acid sequence of a human tau isoform (Swiss-Prot P10636-7).
[0130] SEQ ID NO: 3 shows the amino acid sequence of an isoform of human tau (Swiss-Prot P10636-6), (4R0N human tau).
[0131] SEQ ID NO: 4 shows the amino acid sequence of a human tau isoform (Swiss-Prot P10636-5).
[0132] SEQ ID NO: 5 shows the amino acid sequence of a human tau isoform (Swiss-Prot P10636-4).
[0133] SEQ ID NO: 6 shows the amino acid sequence of a human tau isoform (Swiss-Prot P10636-2).
[0134] SEQ ID NO: 7 shows the amino acid sequence of the heavy chain variable region of the murine 5G8 antibody.
[0135] SEQ ID NO: 8 shows the amino acid sequence of the light chain variable region of the murine 5G8 antibody.
[0136] SEQ ID NO: 9 shows the nucleic acid sequence encoding the heavy chain variable region of the murine 5G8 antibody with a signal peptide.
[0137] SEQ ID NO: 10 shows the nucleic acid sequence encoding the light chain variable region of the murine 5G8 antibody with a signal peptide.
[0138] SEQ ID NO: 11 shows the amino acid sequence of the combined Kabat / Chothia CDR-H1 of the murine 5G8 antibody.
[0139] SEQ ID NO: 12 shows the amino acid sequence of the Kabat CDR-H2 of the mouse 5G8 antibody.
[0140] SEQ ID NO: 13 shows the amino acid sequence of the Kabat CDR-H3 of the murine 5G8 antibody.
[0141] SEQ ID NO: 14 shows the amino acid sequence of the Kabat CDR-L1 of the murine 5G8 antibody.
[0142] SEQ ID NO: 15 shows the amino acid sequence of the Kabat CDR-L2 of the murine 5G8 antibody.
[0143] SEQ ID NO: 16 shows the amino acid sequence of the Kabat CDR-L3 of the murine 5G8 antibody.
[0144] SEQ ID NO: 17 shows the amino acid sequence of the Kabat CDR-H1 of the murine 5G8 antibody.
[0145] SEQ ID NO: 18 shows the amino acid sequence of Chothia CDR-H1 of the murine 5G8 antibody.
[0146] SEQ ID NO: 19 shows the amino acid sequence of Contact CDR-H1 of mouse 5G8 antibody.
[0147] SEQ ID NO: 20 shows the amino acid sequence of Chothia CDR-H2 of the murine 5G8 antibody.
[0148] SEQ ID NO: 21 shows the amino acid sequence of AbM CDR-H2 of the murine 5G8 antibody.
[0149] SEQ ID NO: 22 shows the amino acid sequence of Contact CDR-H2 of mouse 5G8 antibody.
[0150] SEQ ID NO: 23 shows the amino acid sequence of Contact CDR-H3 of mouse 5G8 antibody.
[0151] SEQ ID NO: 24 shows the amino acid sequence of Contact CDR-L1 of mouse 5G8 antibody.
[0152] SEQ ID NO: 25 shows the amino acid sequence of Contact CDR-L2 of mouse 5G8 antibody.
[0153] SEQ ID NO: 26 shows the amino acid sequence of Contact CDR-L3 of mouse 5G8 antibody.
[0154] SEQ ID NO: 27 shows the amino acid sequence of the model sequence murine anti-prion antibody 3F4 heavy chain variable region Acc.# 1CR9_H.
[0155] SEQ ID NO: 28 shows the amino acid sequence of the acceptor sequence humanized anti-dabigatran Fab aDabi-Fab2b-VH Acc.# 4YHM_H.
[0156] SEQ ID NO: 29 shows the amino acid sequence of human germline sequence IGHV1-46 Acc.# P01743.2.
[0157] SEQ ID NO: 30 shows the amino acid sequence of the model sequence murine anti-prion antibody 3F4 light chain variable region Acc.# 1CR9_L.
[0158] SEQ ID NO: 31 shows the amino acid sequence of humanized anti-dabigatran Fab aDabi-Fab2b-VL Acc.# 4YHM_L of the human acceptor sequence.
[0159] SEQ ID NO: 32 shows the amino acid sequence of the human germline gene IGKV2-29 Acc.#A2NJV5.2.
[0160] SEQ ID NO: 33 shows the amino acid sequence of the heavy chain variable region of humanized 5G8 antibody hu5G8-VH_1.
[0161] SEQ ID NO: 34 shows the amino acid sequence of the heavy chain variable region of humanized 5G8 antibody hu5G8-VH_2.
[0162] SEQ ID NO: 35 shows the amino acid sequence of the heavy chain variable region of humanized 5G8 antibody hu5G8-VH_3.
[0163] SEQ ID NO: 36 shows the amino acid sequence of the heavy chain variable region of humanized 5G8 antibody hu5G8-VH_4.
[0164] SEQ ID NO: 37 shows the amino acid sequence of the heavy chain variable region of humanized 5G8 antibody hu5G8-VH_5.
[0165] SEQ ID NO: 38 shows the amino acid sequence of the heavy chain variable region of humanized 5G8 antibody hu5G8-VH_6.
[0166] SEQ ID NO: 39 shows the amino acid sequence of the heavy chain variable region of humanized 5G8 antibody hu5G8-VH_7.
[0167] SEQ ID NO: 40 shows the amino acid sequence of the heavy chain variable region of humanized 5G8 antibody hu5G8-VH_8.
[0168] SEQ ID NO: 41 shows the amino acid sequence of the light chain variable region of humanized 5G8 antibody hu5G8-VL_1.
[0169] SEQ ID NO: 42 shows the amino acid sequence of the light chain variable region of humanized 5G8 antibody hu5G8-VL_2.
[0170] SEQ ID NO: 43 shows the amino acid sequence of the light chain variable region of humanized 5G8 antibody hu5G8-VL_3.
[0171] SEQ ID NO: 44 shows the amino acid sequence of the light chain variable region of humanized 5G8 antibody hu5G8-VL_4.
[0172] SEQ ID NO: 45 shows the amino acid sequence of the light chain variable region of humanized 5G8 antibody hu5G8-VL_5.
[0173] SEQ ID NO: 46 shows the amino acid sequence of the light chain variable region of humanized 5G8 antibody hu5G8-VL_6.
[0174] SEQ ID NO: 47 shows the amino acid sequence of the heavy chain variable region of the murine 5G8 antibody with signal peptide.
[0175] SEQ ID NO: 48 shows the amino acid sequence of the light chain variable region of the murine 5G8 antibody with the signal peptide.
[0176] SEQ ID NO: 49 shows the amino acid sequence of the heavy chain variable region of the murine 6A10 antibody with the signal peptide.
[0177] SEQ ID NO: 50 shows the amino acid sequence of the light chain variable region of the murine 6A10 mouse antibody with signal peptide.
[0178] SEQ ID NO: 51 shows the amino acid sequence of the heavy chain variable region of the murine 7G6 antibody with its signal peptide.
[0179] SEQ ID NO: 52 shows the amino acid sequence of the light chain variable region of the murine 7G6 antibody with its signal peptide.
[0180] SEQ ID NO: 53 shows the amino acid sequence of the heavy chain variable region of the murine 8A4 antibody with its signal peptide.
[0181] SEQ ID NO: 54 shows the amino acid sequence of the light chain variable region of the murine 8A4 antibody with its signal peptide.
[0182] SEQ ID NO: 55 shows the amino acid sequence of the mature heavy chain variable region of the murine 3D6 antibody.
[0183] SEQ ID NO: 56 shows the amino acid sequence of the combined Kabat / Chothia CDR-H1 of the murine 3D6 antibody.
[0184] SEQ ID NO: 57 shows the amino acid sequence of the Kabat CDR-H2 of the murine 3D6 antibody.
[0185] SEQ ID NO: 58 shows the amino acid sequence of the Kabat CDR-H3 of the murine 3D6 antibody.
[0186] SEQ ID NO: 59 shows the amino acid sequence of the mature light chain variable region of the murine 3D6 antibody.
[0187] SEQ ID NO: 60 shows the amino acid sequence of the Kabat CDR-L1 of the murine 3D6 antibody.
[0188] SEQ ID NO: 61 shows the amino acid sequence of the Kabat CDR-L2 of the murine 3D6 antibody.
[0189] SEQ ID NO: 62 shows the amino acid sequence of the Kabat CDR-L3 of the murine 3D6 antibody.
[0190] SEQ ID NO: 63 shows the amino acid sequence of the mature heavy chain variable region of the murine 6A10 antibody.
[0191] SEQ ID NO: 64 shows the amino acid sequence of the mature light chain variable region of the murine 6A10 antibody.
[0192] SEQ ID NO: 65 shows the amino acid sequence of the combined Kabat / Chothia CDR-H1 of the murine 6A10 antibody.
[0193] SEQ ID NO: 66 shows the amino acid sequence of the Kabat CDR-H2 of the murine 6A10 antibody.
[0194] SEQ ID NO: 67 shows the amino acid sequence of the Kabat CDR-H3 of the murine 6A10 antibody.
[0195] SEQ ID NO: 68 shows the amino acid sequence of the Kabat CDR-L1 of the murine 6A10 antibody.
[0196] SEQ ID NO: 69 shows the amino acid sequence of the Kabat CDR-L2 of the murine 6A10 antibody.
[0197] SEQ ID NO: 70 shows the amino acid sequence of the Kabat CDR-L3 of the murine 6A10 antibody.
[0198] SEQ ID NO: 71 shows the amino acid sequence of the Kabat CDR-H1 of the murine 6A10 antibody.
[0199] SEQ ID NO: 72 shows the amino acid sequence of Chothia CDR-H1 of the murine 6A10 antibody.
[0200] SEQ ID NO: 73 shows the amino acid sequence of Contact CDR-H1 of mouse 6A10 antibody.
[0201] SEQ ID NO: 74 shows the amino acid sequence of Chothia CDR-H2 of the murine 6A10 antibody.
[0202] SEQ ID NO: 75 shows the amino acid sequence of AbM CDR-H2 of the murine 6A10 antibody.
[0203] SEQ ID NO: 76 shows the amino acid sequence of Contact CDR-H2 of mouse 6A10 antibody.
[0204] SEQ ID NO: 77 shows the amino acid sequence of Contact CDR-H3 of mouse 6A10 antibody.
[0205] SEQ ID NO: 78 shows the amino acid sequence of Contact CDR-L1 of mouse 6A10 antibody.
[0206] SEQ ID NO: 79 shows the amino acid sequence of Contact CDR-L2 of mouse 6A10 antibody.
[0207] SEQ ID NO: 80 shows the amino acid sequence of Contact CDR-L3 of mouse 6A10 antibody.
[0208] SEQ ID NO: 81 shows the amino acid sequence of the human heavy chain variable region of the acceptor sequence, accession number ACR16112.
[0209] SEQ ID NO: 82 shows the amino acid sequence of the human germline sequence IGHV1-2*02.
[0210] SEQ ID NO: 83 shows the amino acid sequence of the human kappa light chain variable region of the human acceptor sequence, accession number ABC66863.
[0211] SEQ ID NO: 84 shows the amino acid sequence of the human germline sequence IGKV2-30*02.
[0212] SEQ ID NO: 85 shows the amino acid sequence of the heavy chain variable region of humanized 6A10 antibody hu6A10-VH_1.
[0213] SEQ ID NO: 86 shows the amino acid sequence of the heavy chain variable region of humanized 6A10 antibody hu6A10-VH_2.
[0214] SEQ ID NO: 87 shows the amino acid sequence of the heavy chain variable region of humanized 6A10 antibody hu6A10-VH_3.
[0215] SEQ ID NO: 88 shows the amino acid sequence of the light chain variable region of humanized 6A10 antibody hu6A10-VL_1.
[0216] SEQ ID NO: 89 shows the amino acid sequence of the light chain variable region of humanized 6A10 antibody hu6A10-VL_2.
[0217] SEQ ID NO: 90 shows the amino acid sequence of the light chain variable region of humanized 6A10 antibody hu6A10-VL_3.
[0218] SEQ ID NO: 91 shows the amino acid sequence of the mature heavy chain variable region of the murine 8A4 antibody.
[0219] SEQ ID NO: 92 shows the amino acid sequence of the mature light chain variable region of the murine 8A4 antibody.
[0220] SEQ ID NO: 93 shows the amino acid sequence of the combined Kabat / Chothia CDR-H1 of the murine 8A4 antibody.
[0221] SEQ ID NO: 94 shows the amino acid sequence of the Kabat CDR-H2 of the murine 8A4 antibody.
[0222] SEQ ID NO: 95 shows the amino acid sequence of the Kabat CDR-H3 of the murine 8A4 antibody.
[0223] SEQ ID NO: 96 shows the amino acid sequence of the Kabat CDR-L1 of the murine 8A4 antibody.
[0224] SEQ ID NO: 97 shows the amino acid sequence of the Kabat CDR-L2 of the murine 8A4 antibody.
[0225] SEQ ID NO: 98 shows the amino acid sequence of the Kabat CDR-L3 of the murine 8A4 antibody.
[0226] SEQ ID NO: 99 shows the amino acid sequence of the Kabat CDR-H1 of the murine 8A4 antibody.
[0227] SEQ ID NO: 100 shows the amino acid sequence of Chothia CDR-H1 of the murine 8A4 antibody.
[0228] SEQ ID NO: 101 shows the amino acid sequence of Contact CDR-H1 of mouse 8A4 antibody.
[0229] SEQ ID NO: 102 shows the amino acid sequence of Chothia CDR-H2 of the murine 8A4 antibody.
[0230] SEQ ID NO: 103 shows the amino acid sequence of AbM CDR-H2 of the murine 8A4 antibody.
[0231] SEQ ID NO: 104 shows the amino acid sequence of Contact CDR-H2 of mouse 8A4 antibody.
[0232] SEQ ID NO: 105 shows the amino acid sequence of Contact CDR-H3 of mouse 8A4 antibody.
[0233] SEQ ID NO: 106 shows the amino acid sequence of Contact CDR-L1 of mouse 8A4 antibody.
[0234] SEQ ID NO: 107 shows the amino acid sequence of Contact CDR-L2 of mouse 8A4 antibody.
[0235] SEQ ID NO: 108 shows the amino acid sequence of Contact CDR-L3 of mouse 8A4 antibody.
[0236] SEQ ID NO: 109 shows the amino acid sequence of the model sequence 3JAUVH.
[0237] SEQ ID NO: 110 shows the amino acid sequence of the acceptor sequence human heavy chain variable region, accession number ADU57742.
[0238] SEQ ID NO: 111 shows the amino acid sequence of the model sequence 3JAUVL.
[0239] SEQ ID NO: 112 shows the amino acid sequence of the human kappa light chain variable region of the human acceptor sequence, accession number ABA26100.
[0240] SEQ ID NO: 113 shows the amino acid sequence of the heavy chain variable region of humanized 8A4 antibody hu8A4-VH_1.
[0241] SEQ ID NO: 114 shows the amino acid sequence of the heavy chain variable region of humanized 8A4 antibody hu8A4-VH_2.
[0242] SEQ ID NO: 115 shows the amino acid sequence of the heavy chain variable region of humanized 8A4 antibody hu8A4-VH_3.
[0243] SEQ ID NO: 116 shows the amino acid sequence of the light chain variable region of humanized 8A4 antibody hu8A4-VL_1.
[0244] SEQ ID NO: 117 shows the amino acid sequence of the light chain variable region of humanized 8A4 antibody hu8A4-VL_2.
[0245] SEQ ID NO: 118 shows the amino acid sequence of the light chain variable region of humanized 8A4 antibody hu8A4-VL_3.
[0246] SEQ ID NO: 119 shows the amino acid sequence of the mature heavy chain variable region of the murine 7G6 antibody.
[0247] SEQ ID NO: 120 shows the amino acid sequence of the mature light chain variable region of the murine 7G6 antibody.
[0248] SEQ ID NO: 121 shows the amino acid sequence of the combined Kabat / Chothia CDR-H1 of the murine 7G6 antibody.
[0249] SEQ ID NO: 122 shows the amino acid sequence of the Kabat CDR-H2 of the murine 7G6 antibody.
[0250] SEQ ID NO: 123 shows the amino acid sequence of the Kabat CDR-H3 of the murine 7G6 antibody.
[0251] SEQ ID NO: 124 shows the amino acid sequence of the Kabat CDR-L1 of the murine 7G6 antibody.
[0252] SEQ ID NO: 125 shows the amino acid sequence of the Kabat CDR-L2 of the murine 7G6 antibody.
[0253] SEQ ID NO: 126 shows the amino acid sequence of the Kabat CDR-L3 of the murine 7G6 antibody.
[0254] SEQ ID NO: 127 shows the amino acid sequence of the Kabat CDR-H1 of the murine 7G6 antibody.
[0255] SEQ ID NO: 128 shows the amino acid sequence of Chothia CDR-H1 of the murine 7G6 antibody.
[0256] SEQ ID NO: 129 shows the amino acid sequence of Contact CDR-H1 of mouse 7G6 antibody.
[0257] SEQ ID NO: 130 shows the amino acid sequence of Chothia CDR-H2 of the murine 7G6 antibody.
[0258] SEQ ID NO: 131 shows the amino acid sequence of AbM CDR-H2 of the murine 7G6 antibody.
[0259] SEQ ID NO: 132 shows the amino acid sequence of Contact CDR-H2 of mouse 7G6 antibody.
[0260] SEQ ID NO: 133 shows the amino acid sequence of Contact CDR-H3 of mouse 7G6 antibody.
[0261] SEQ ID NO: 134 shows the amino acid sequence of Contact CDR-L1 of mouse 7G6 antibody.
[0262] SEQ ID NO: 135 shows the amino acid sequence of Contact CDR-L2 of mouse 7G6 antibody.
[0263] SEQ ID NO: 136 shows the amino acid sequence of Contact CDR-L3 of mouse 7G6 antibody.
[0264] SEQ ID NO: 137 shows the amino acid sequence of the human heavy chain variable region of the acceptor sequence, accession number PDB 3U0T_VH.
[0265] SEQ ID NO: 138 shows the amino acid sequence of the human kappa light chain variable region of the human acceptor sequence, accession number PDB 3U0T_VL.
[0266] SEQ ID NO: 139 shows the amino acid sequence of the heavy chain variable region of humanized 7G6 antibody hu7G6-VH_1.
[0267] SEQ ID NO: 140 shows the amino acid sequence of the heavy chain variable region of humanized 7G6 antibody hu7G6-VH_2.
[0268] SEQ ID NO: 141 shows the amino acid sequence of the light chain variable region of humanized 7G6 antibody hu7G6-VL_1.
[0269] SEQ ID NO: 142 shows the amino acid sequence of the light chain variable region of humanized 7G6 antibody hu7G6-VL_2.
[0270] SEQ ID NO: 143 shows the amino acid sequence of the light chain variable region of humanized 7G6 antibody hu7G6-VL_3.
[0271] SEQ ID NO: 144 shows the amino acid sequence of the light chain variable region of humanized 7G6 antibody hu7G6-VL_4.
[0272] SEQ ID NO: 145 shows the amino acid sequence of the light chain variable region of humanized 7G6 antibody hu7G6-VL_5.
[0273] SEQ ID NO: 146 shows the amino acid sequence of the light chain variable region of humanized 7G6 antibody hu7G6-VL_6.
[0274] SEQ ID NO: 147 shows the amino acid sequence of the light chain variable region of humanized 7G6 antibody hu7G6-VL_7.
[0275] SEQ ID NO: 148 shows the amino acid sequence of the light chain variable region of humanized 7G6 antibody hu7G6-VL_8.
[0276] SEQ ID NO: 149 shows the amino acid sequence of the human germline sequence IGHV1-69-2*01.
[0277] definition The monoclonal antibody or other biological entity is typically provided in isolated form. This means that the antibody or other biological entity is typically at least 50% w / w pure from interfering proteins and other contaminants resulting from its production or purification, but does not exclude the possibility that the monoclonal antibody may be combined with a surplus of pharma-ceutically acceptable carriers or other vehicles intended to facilitate its use. The monoclonal antibody may be at least 60%, 70%, 80%, 90%, 95% or 99% pure from interfering proteins and contaminants from production or purification. An isolated monoclonal antibody or other biological entity is often the predominant macromolecular species remaining after purification.
[0278] The specific binding of an antibody to its target antigen is at least 10 6 , 10 7 , 10 8 , 10 9 , 10 10 , 10 11 , or 10 12 M -1 Specific binding refers to the affinity and / or avidity of an antibody to one or more targets. Specific binding is detectably greater than or equal to the non-specific binding that occurs to at least one unrelated target. Specific binding can be the result of the formation of bonds between specific functional groups or in a specific spatial fit (e.g., lock and key type), whereas non-specific binding is usually the result of van der Waals forces. However, specific binding does not necessarily mean that an antibody binds to one and only one target.
[0279] The basic antibody structural unit is a tetramer of subunits. Each tetramer contains two identical pairs of polypeptide chains, each pair having one "light" chain (about 25 kDa) and one "heavy" chain (about 50-70 kDa). The amino-terminal portion of each chain contains a variable region of about 100-110 or more amino acids primarily responsible for antigen recognition. This variable region is first expressed and linked to a cleavable signal peptide. The variable region without the signal peptide is sometimes referred to as the mature variable region. Thus, for example, light chain mature variable region means the light chain variable region without the light chain signal peptide. The carboxy-terminal portion of each chain defines a constant region primarily responsible for effector function.
[0280] Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, and define the antibody's isotype as IgG, IgM, IgA, IgD, and IgE, respectively. Within light and heavy chains, the variable and constant regions are joined by a "J" region of about 12 or more amino acids, with the heavy chain also including a "D" region of about 10 more amino acids. See generally Fundamental Immunology, Paul, W., ed., 2nd ed. Raven Press, NY, 1989, Ch. 7 (incorporated by reference in its entirety for all purposes).
[0281] An immunoglobulin light or heavy chain variable region (also referred to herein as a "light chain variable domain" ("VL domain") or "heavy chain variable domain" ("VH domain"), respectively) consists of a "framework" region interrupted by three "complementarity determining regions" or "CDRs". The framework regions serve to align the CDRs for specific binding to an epitope of an antigen. The CDRs contain the amino acid residues of an antibody primarily responsible for antigen binding. From the amino to carboxyl terminus, both VL and VH domains contain the following framework region (FR) and CDR regions: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. CDR1, 2, and 3 of the VL domain are also referred to herein as CDR-L1, CDR-L2, and CDR-L3, respectively, and CDR1, 2, and 3 of the VH domain are also referred to herein as CDR-H1, CDR-H2, and CDR-H3, respectively. Where the present application discloses a VL sequence having R as the C-terminal residue, R may alternatively be considered to be the N-terminal residue of the light chain constant region, and therefore the present application should be understood as disclosing a VL sequence without the C-terminal R.
[0282] The assignment of amino acids to each domain of VL and VH follows the conventional definition of CDR, including the Kabat definition (Kabat, Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, MD, 1987 and 1991)), the Chothia definition (Chothia & Lesk, J. Mol. Biol. 196:901-917, 1987; Chothia et al., Nature 342:878-883, 1989); the Chothia-Kabat definition, in which CDR-H1 is a combination of the Chothia and Kabat CDRs. CDR combinations; the AbM definition used in the Oxford Molecular Antibody Modeling Software; and the Contact definition by Martin et al. (bioinfo.org.uk / abs) (see Table 1). Kabat provides a widely used numbering scheme (Kabat numbering) in which corresponding residues between different heavy chains or different light chains are assigned the same number. When an antibody is said to contain a CDR according to a certain definition of CDR (e.g., Kabat), that definition specifies the minimum number of CDR residues present in the antibody (i.e., Kabat CDRs). It does not exclude that other residues exist that fall within the scope of other conventional CDR definitions but are outside the specified definition. For example, an antibody that contains a CDR defined by Kabat includes, among other possibilities, an antibody in which the CDR contains Kabat CDR residues and no other CDR residues, and an antibody in which the CDR H1 is the CDR H1 of the Chothia-Kabat combination and the other CDRs contain Kabat CDR residues and no additional CDR residues based on other definitions. [Table 1]
[0283] The term "antibody" includes intact antibodies and binding fragments thereof. Typically, fragments compete with the intact antibody from which they are derived for specific binding to a target, including separate heavy and light chains, Fab, Fab', F(ab')2, F(ab)c, Dabs, nanobodies, and Fv. Fragments can be produced by recombinant DNA methods or by enzymatic or chemical separation of intact immunoglobulins. The term "antibody" also includes bispecific and / or humanized antibodies. Bispecific or bifunctional antibodies are artificial hybrid antibodies having two different heavy / light chain pairs and two different binding sites (see, e.g., Songsivilai and Lachmann, Clin. Exp. Immunol., 79:315-321 (1990); Kostelny et al., J. Immunol., 148:1547-53 (1992)). In some bispecific antibodies, the two different heavy / light chain pairs include a humanized 5G8, 6A10, 8A4, or 7G6 heavy / light chain pair and a heavy / light chain pair specific for an epitope on tau different from that bound by 5G8, 6A10, 8A4, or 7G6.
[0284] Some bispecific antibodies have one heavy / light chain pair that is a humanized 5G8 antibody, a humanized 6A10 antibody, a humanized 8A4 antibody, or a humanized 7G6 antibody, as further disclosed below, and the other heavy / light chain pair that is derived from an antibody that binds to a receptor expressed at the blood-brain barrier, such as the insulin receptor, the insulin-like growth factor (IGF) receptor, the leptin receptor, or the lipoprotein receptor, or the transferrin receptor (Friden et al., Proc. Natl. Acad. Sci. USA 88:4771-4775, 1991; Friden et al., Science 259:373-377, 1993). Such bispecific antibodies can migrate across the blood-brain barrier by receptor-mediated transcytosis. Brain uptake of bispecific antibodies can be further enhanced by engineering the bispecific antibody to reduce its affinity for the blood-brain barrier receptor. The reduced affinity for the receptor resulted in a wider distribution in the brain (see, e.g., Atwal et al., Sci. Trans. Med. 3, 84ra43, 2011; Yu et al., Sci. Trans. Med. 3, 84ra44, 2011).
[0285] Exemplary bispecific antibodies can be (1) dual variable domain antibodies (DVD-Ig) in which each light and heavy chain contains two variable domains in tandem via a short peptide linkage (Wu et al., Generation and Characterization of a Dual Variable Domain Immunoglobulin (DVD-Ig(tm)) Molecule, In: Antibody Engineering, Springer Berlin Heidelberg (2010)); (2) Tandabs, which are fusions of two single chain diabodies resulting in a tetravalent bispecific antibody with two binding sites for each target antigen; (3) Flexibodies, which are combinations of scFvs with diabodies resulting in multivalent molecules; (4) so-called "dock-and-lock" molecules based on the "dimerization and docking domains" in protein kinase A, which when applied to Fabs can result in trivalent bispecific binding proteins consisting of two identical Fab fragments linked to different Fab fragments; or (5) so-called scorpion molecules, which contain, for example, two scFvs fused to both ends of a human Fc region. Examples of useful platforms for preparing bispecific antibodies include BiTE (Micromet), DART (MacroGenics), Fcab and Mab2 (F-star), Fc engineered IgG1 (Xencor) or DuoBody (based on the exchange of Fab arms, Genmab).
[0286] The term "epitope" refers to a site on an antigen to which an antibody binds. Epitopes can be formed from contiguous amino acids or from non-contiguous amino acids juxtaposed by tertiary folding of one or more proteins. Epitopes formed from contiguous amino acids (also known as linear epitopes) are typically retained on exposure to denaturing solvents, whereas epitopes formed by tertiary folding (also known as conformational epitopes) are typically lost on treatment with denaturing solvents. An epitope usually comprises at least 3, more usually at least 5, or 8-10 amino acids in its unique spatial conformation. Methods for determining the spatial conformation of an epitope include, for example, X-ray crystallography and two-dimensional nuclear magnetic resonance. See, for example, Epitope Mapping Protocols, in Methods in Molecular Biology, Vol. 66, Glenn E. Morris, Ed. (1996).
[0287] Antibodies that recognize the same or overlapping epitopes can be identified in a simple immunoassay showing the ability of one antibody to compete with the binding of another antibody to a target antigen. An antibody's epitope can also be identified by X-ray crystallography of the antibody bound to the antigen, identifying contact residues. Alternatively, two antibodies have the same epitope if all of the amino acid mutations in the antigen that reduce or eliminate binding of one antibody also reduce or eliminate binding of the other. Two antibodies have overlapping epitopes if some of the amino acid mutations that reduce or eliminate binding of one antibody also reduce or eliminate binding of the other.
[0288] Competition between antibodies is measured by an assay in which the antibody under test inhibits specific binding of a reference antibody to a common antigen (see, e.g., Junghans et al., Cancer Res. 50:1495, 1990). A test antibody competes with a reference antibody if an excess of the test antibody (e.g., at least 2x, 5x, 10x, 20x, or 100x) inhibits binding of the reference antibody by at least 50% as measured in a competitive binding assay. Some test antibodies inhibit binding of the reference antibody by at least 75%, 90% or 99%. Antibodies identified by competitive assays (competing antibodies) include antibodies that bind to the same epitope as the reference antibody and antibodies that bind to adjacent epitopes that are close enough together to sterically interfere with the epitope bound by the reference antibody.
[0289] The term "pharmaceutically acceptable" means the carrier, diluent, excipient or adjuvant must be compatible with the other ingredients of the formulation and not substantially deleterious to the recipient thereof.
[0290] The term "patient" includes human and other mammalian subjects receiving either prophylactic or therapeutic treatment.
[0291] An individual is at greater risk for a disease if they have at least one known risk factor (e.g., genetic, biochemical, family history, and situational exposure) that places the individual with the risk factor at a statistically significantly higher risk of developing the disease than individuals without that risk factor.
[0292] The term "biological sample" refers to a sample of biological material in or obtainable from a biological source, e.g., a human or mammalian subject. Such samples can be organs, organelles, tissues, tissue sections, body fluids, peripheral blood, plasma, serum, cells, molecules such as proteins and peptides, and portions or combinations derived therefrom. The term biological sample can include any material produced by processing a sample. The material produced can include cells or their progeny. Processing of a biological sample can involve one or more of filtration, distillation, extraction, concentration, fixation, inactivation of interfering components, and the like.
[0293] The term "control sample" refers to a biological sample that is not known or suspected to contain an area affected by a tau-related disease, or at least not known or suspected to contain a particular type of disease area. A control sample can be obtained from an individual not affected by a tau-related disease. Alternatively, a control sample can be obtained from a patient suffering from a tau-related disease. Such a sample can be obtained at the same time as a biological sample suspected to contain a tau-related disease, or at a different time. Both the biological sample and the control sample can be obtained from the same tissue. Preferably, the control sample consists essentially or entirely of a normal, healthy area, and can be used in comparison with a biological sample suspected to contain an area affected by a tau-related disease. Preferably, the tissue of the control sample is of the same type as the tissue of the biological sample. Preferably, the cells suspected to be in the biological sample affected by a tau-related disease originate from the same cell type (e.g., neuron or glia) as the type of cells in the control sample.
[0294] The term "disease" refers to any abnormal condition in which physiological function is impaired. The term is used broadly to encompass any disorder, ill-health, abnormality, pathology, illness, medical condition, or syndrome in which physiological function is impaired, regardless of the nature of the etiology.
[0295] The term "symptom" refers to subjective evidence of disease, such as an altered gait, as recognized by the subject. "Sign" refers to objective evidence of disease, as observed by a physician.
[0296] The term "positive response to treatment" refers to a more favorable response of an individual patient or the average response of a patient population compared to the average response of a control population not receiving the treatment.
[0297] For the purposes of classifying amino acid substitutions as conservative or non-conservative, amino acids are grouped as follows: Group I (hydrophobic side chains): met, ala, val, leu, ile; Group II (neutral hydrophilic side chains): cys, ser, thr; Group III (acidic side chains): asp, glu; Group IV (basic side chains): asn, gln, his, lys, arg; Group V (residues that influence chain orientation): gly, pro; and Group VI (aromatic side chains): trp, tyr, phe. Conservative substitutions involve substitutions between amino acids within the same class. Non-conservative substitutions constitute the exchange of a member of one of these classes for a member of another class.
[0298] Percent sequence identity is determined by maximally aligned antibody sequences according to the Kabat numbering system. After sequence comparison, if a region of a test antibody (e.g., the entire mature variable region of a heavy or light chain) is being compared to the same region of a reference antibody, the percent sequence identity between the region of the test antibody and the region of the reference antibody is the number of positions where identical amino acids are located in both the region of the test antibody and the region of the reference antibody, divided by the total number of aligned positions of the two regions, not counting gaps, and multiplied by 100 to convert to a percentage.
[0299] A composition or method that "comprising" or "including" one or more recited elements may include other elements not specifically recited. For example, a composition that "comprises" or "includes" an antibody may contain the antibody alone or in combination with other components.
[0300] The specification of a range of values includes all integers within or defining that range, and all subranges defined by integers within that range.
[0301] Unless otherwise clear from the context, the term "about" encompasses minor variations, such as, for example, values within the standard error (eg, SEM) of measurement of the referenced value.
[0302] Statistical significance means p≦0.05.
[0303] The singular forms of the articles "a," "an," and "the" include plural references unless the context clearly dictates otherwise. For example, the term "a compound" or "at least one compound" can include a plurality of compounds, including mixtures thereof.
[0304] Detailed Description I. General The present invention provides antibodies that specifically bind to tau. Some exemplary binding specificities of the antibodies of the invention are characterized by specific binding to a peptide consisting of residues 199-213 of SEQ ID NO:3 or a peptide consisting of residues 262-276 (corresponding to residues 257-271 or 320-334 of SEQ ID NO:1, respectively), or both peptides. Exemplary antibodies of the invention are 5G8, 6A10, 8A4, and 7G6. Some antibodies bind to an epitope that includes at least one residue of residues 199-213 of SEQ ID NO:3 or at least one residue of residues 262-276 of SEQ ID NO:3, or both. Some antibodies bind to an epitope where all residues of the epitope are within residues 119-213 or residues 262-276 of SEQ ID NO:3, or both. Some antibodies bind to an epitope formed from amino acids within both residues 199-213 and 262-276 of SEQ ID NO:3. Some antibodies bind to an epitope within residues 199-213 of SEQ ID NO:3 or residues 262-276 of SEQ ID NO:3. Some antibodies bind tau regardless of phosphorylation state. Some antibodies prevent or slow the worsening of tau-related pathologies and associated symptoms. Although an understanding of the mechanism is not necessary to practice the invention, reduced toxicity may occur by, among other mechanisms, the antibody inducing phagocytosis of tau, inhibiting tau from inter- or intra-molecular aggregation or from binding to other molecules, stabilizing a non-toxic conformation, inhibiting inter- or intracellular transmission of pathogenic tau forms, by blocking phosphorylation of tau, by preventing tau binding to cells, or by inducing proteolytic cleavage of tau. The antibodies of the invention or agents which induce such antibodies can be used in methods of treating or preventing Alzheimer's disease and other diseases associated with tau.
[0305] II. Target molecule Unless the context clearly indicates otherwise, reference to tau refers to native human tau, including all isoforms, whether or not post-translational modifications (e.g., phosphorylation, glycosylation, or acetylation) are present. Six major isoforms (splice variants) of tau occur in the human brain. The longest of these variants has 441 amino acids with the first methionine residue truncated. Residues are numbered according to the 441 isoform. Thus, for example, reference to phosphorylation at position 404 refers to position 404 in the 441 isoform, or the corresponding position in any other isoform when maximally aligned with the 441 isoform. The amino acid sequences and Swiss Prot numbers of the isoforms are shown below. JPEG0007587304000002.jpg105163 JPEG0007587304000003.jpg95163 JPEG0007587304000004.jpg93163 JPEG0007587304000005.jpg93163 JPEG0007587304000006.jpg99163 JPEG0007587304000007.jpg110163
[0306] Reference to tau includes the approximately 30 known naturally occurring variants listed in the Swiss-Prot database and their permutations, as well as mutations associated with tau pathologies such as dementia, Pick's disease, supranuclear palsy, etc. (see, e.g., Swiss-Prot database and Poorkaj, et al. Ann Neurol. 43:815-825 (1998)). Some examples of tau mutations numbered by the 441 isoform include a lysine to threonine mutation at amino acid residue 257 (K257T), an isoleucine to valine mutation at amino acid position 260 (I260V), a glycine to valine mutation at amino acid position 272 (G272V), an asparagine to lysine mutation at amino acid position 279 (N279K), an asparagine to histidine mutation at amino acid position 296 (N296H), a proline to serine mutation at amino acid position 301 (P301S), a proline to leucine mutation at amino acid position 301 (P301S), and a glycine to valine mutation at amino acid position 272 (G272V). L), a glycine to valine mutation at amino acid position 303 (G303V), a serine to asparagine mutation at position 305 (S305N), a glycine to serine mutation at amino acid position 335 (G335S), a valine to methionine mutation at position 337 (V337M), a glutamic acid to valine mutation at position 342 (E342V), a lysine to isoleucine mutation at amino acid position 369 (K3691), a glycine to arginine mutation at amino acid position 389 (G389R), and an arginine to tryptophan mutation at position 406 (R406W).
[0307] Tau can be phosphorylated at one or more amino acid residues, including tyrosines at amino acid positions 18, 29, 97, 310, and 394, serines at amino acid positions 184, 185, 198, 199, 202, 208, 214, 235, 237, 238, 262, 293, 324, 356, 396, 400, 404, 409, 412, 413, and 422, and threonines at amino acid positions 175, 181, 205, 212, 217, 231, and 403. Unless the context clearly indicates otherwise, reference to tau or a fragment thereof includes the naturally occurring human amino acid sequence, including isoforms, mutants, and allelic variants thereof.
[0308] III. Antibodies A. Binding Specificity and Functional Properties The present invention provides antibodies that bind to tau. Some antibodies bind to tau regardless of phosphorylation state. Some antibodies bind to epitopes that do not contain residues that are subject to phosphorylation. These antibodies can be obtained by immunization with tau polypeptides purified from natural sources or recombinantly expressed. Antibodies can be screened for binding to unphosphorylated forms of tau and to forms of tau that are phosphorylated at one or more residues that are subject to phosphorylation. Such antibodies preferably bind with indistinguishable affinity or bind to phosphorylated tau within a factor of at least 1.5-fold, 2-fold, or 3-fold (i.e., are "pan-specific") compared to unphosphorylated tau. 5G8, 6A10, 8A4, and 7G6 are examples of pan-specific monoclonal antibodies. The present invention also provides antibodies that bind to epitopes that are the same as or overlap with the epitopes of, for example, 5G8, 6A10, 8A4, or 7G6. Also included are antibodies that compete with, for example, 5G8, 6A10, 8A4, or 7G6 for binding to tau.
[0309] The above antibodies can be generated de novo by immunization with full-length tau polypeptide or peptide fragments thereof. Such peptides are preferably conjugated to heterologous conjugate molecules that facilitate the induction of an antibody response against the peptide. Conjugation can be direct or via a spacer peptide or spacer amino acid. Cysteine is used as a spacer amino acid, since the free SH group facilitates the attachment of the carrier molecule. Polyglycine linkers (e.g., 2-6 glycines) can also be used, with or without a cysteine residue between the glycine and the peptide. The carrier molecule serves to provide a T-cell epitope that facilitates the induction of an antibody response against the peptide. Some carriers are keyhole limpet hemocyanin (KLH), ovalbumin and bovine serum albumin (BSA), among others, which are commonly used. Peptide spacers can be added to the peptide immunogen as part of solid-phase peptide synthesis. The carrier is typically added by chemical cross-linking. Some examples of chemical cross-linking agents that can be used include cross-N-maleimido-6-aminocaproyl ester or m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) (see, e.g., Harlow, E. et al., Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 1988; Sinigaglia et al., Nature, 336:778-780 (1988); Chicz et al., J. Exp. Med., 178:27-47 (1993); Hammer et al., Cell 74:197-203 (1993); Falk K. et al., Immunogenetics, 39:230-242 (1994); WO 98 / 23635; and, Southwood et al. J. Immunology, 160:3363-3373). (1998). When a carrier and spacer are present, they can be attached to both ends of the immunogen.
[0310] Peptides with any spacer and carrier can be used to immunize laboratory animals or B cells, as described in more detail below. Hybridoma supernatants can be tested for their ability to bind phosphorylated and non-phosphorylated forms of tau, such as the full-length isoform of tau with position 404 in phosphorylated form. The peptides can be conjugated to a carrier or other tag to facilitate screening assays. In this case, the carrier or tag is differentiated to have a higher priority than the combination of spacer and carrier molecules used for immunization, in order to eliminate antibodies specific for the spacer or carrier rather than the tau peptide. Any isoform of tau can be used.
[0311] The present invention provides monoclonal antibodies that bind to an epitope within tau. The antibody designated 5G8 is one such exemplary murine antibody. Unless otherwise clear from the context, reference to 5G8 should be understood to refer to any of the murine, chimeric, veneered and humanized forms of this antibody. This antibody has been deposited under [Accession Number]. This antibody is characterized by its ability to bind to both phosphorylated and non-phosphorylated tau, both non-pathological and pathological forms and conformations of tau, and misfolded / aggregated forms of tau.
[0312] Further antibodies that compete with 5G8 for binding to tau and / or bind to the same or overlapping epitopes as 5G8 have been isolated as 6A10, 8A4, 7G6, and 3D6 and have been produced from hybridomas of the same name. 6A10 has variable heavy and light regions characterized by SEQ ID NO: 49 and SEQ ID NO: 50, respectively, and is of mouse isotype IgG1 / kappa. 6A10 has mature variable heavy and light regions (after cleavage of the signal peptide) characterized by SEQ ID NO: 63 and SEQ ID NO: 64, respectively. Unless otherwise clear from the context, reference to 6A10 should be understood to refer to any of the murine, chimeric, veneered, and humanized forms of this antibody. 6A10 has been deposited under [deposit number]. 6A10 is further characterized by its ability to bind to both phosphorylated and non-phosphorylated tau, both non-pathological and pathological forms and conformations of tau, and misfolded / aggregated forms of tau.
[0313] 7G6 has variable heavy and light regions characterized by SEQ ID NO:51 and SEQ ID NO:52, respectively, and is of mouse isotype IgG2b / kappa. 7G6 has mature variable heavy and light regions (after cleavage of the signal peptide) characterized by SEQ ID NO:119 and SEQ ID NO:120, respectively. Unless otherwise clear from the context, reference to 7G6 should be understood to refer to any of the murine, chimeric, veneered, and humanized forms of this antibody. 7G6 has been deposited under [deposit number]. 7G6 is further characterized by its ability to bind to both phosphorylated and non-phosphorylated tau, both non-pathological and pathological forms and conformations of tau, and misfolded / aggregated forms of tau.
[0314] 8A4 has variable heavy and light regions characterized by SEQ ID NO:53 and SEQ ID NO:54, respectively, and is of mouse isotype IgG1 / kappa. 8A4 has mature variable heavy and light regions (after cleavage of the signal peptide) characterized by SEQ ID NO:91 and SEQ ID NO:92, respectively. Unless otherwise clear from the context, reference to 8A4 should be understood to refer to any of the murine, chimeric, veneered, and humanized forms of this antibody. 8A4 has been deposited under [deposit number]. 8A4 is further characterized by its ability to bind to both phosphorylated and non-phosphorylated tau, both non-pathological and pathological forms and conformations of tau, and misfolded / aggregated forms of tau.
[0315] 3D6 has variable heavy and light regions characterized by SEQ ID NO:55 and SEQ ID NO:59, respectively, and is of mouse isotype IgG1 / kappa. For 3D6, the three heavy chain CDRs are defined by the Kabat / Chothia combination (SEQ ID NO:56, 57, and 58), and the three light chain CDRs are defined by Kabat (SEQ ID NO:60, 61, and 62). For 3D6 and its humanized variants, reference is made to PCT / IB2017 / 052544, which is incorporated by reference in its entirety for all purposes. Unless otherwise clear from the context, reference to 3D6 should be understood to refer to any of the murine, chimeric, veneered, and humanized forms of this antibody. 3D6 has been deposited under [Deposit No.]. 3D6 is further characterized by its ability to bind to both phosphorylated and non-phosphorylated tau, both non-pathological and pathological forms and conformations of tau, and misfolded / aggregated forms of tau.
[0316] Optionally, the antibodies of the present invention do not include the 6A10 antibody disclosed in PCT / IB2017 / 052544. Optionally, the antibodies of the present invention do not include the 8A4 antibody. Optionally, the antibodies of the present invention do not include the 7G6 antibody. Optionally, the antibodies of the present invention do not include the 3D6 antibody disclosed in PCT / IB2017 / 052544.
[0317] Some antibodies of the invention bind to the same or overlapping epitopes as antibodies designated 5G8, 6A10, 8A4, 7G6, or 3D6. The sequences of the heavy and light chain mature variable regions of 5G8 are set forth in SEQ ID NOs: 7 and 8, respectively. The sequences of the heavy and light chain mature variable regions of 6A10 are set forth in SEQ ID NOs: 63 and 64, respectively. The sequences of the heavy and light chain mature variable regions of 8A4 are set forth in SEQ ID NOs: 91 and 92, respectively. The sequences of the heavy and light chain mature variable regions of 7G6 are set forth in SEQ ID NOs: 119 and 120, respectively. The sequences of the heavy and light chain mature variable regions of 3D6 are set forth in SEQ ID NOs: 55 and 59, respectively. Other antibodies with such binding specificities can be produced by immunizing mice with tau or a portion thereof containing the desired epitope, and screening the resulting antibodies for binding to tau that compete with antibodies optionally having the variable regions of mouse 5G8, 6A10, 8A4, 7G6, or 3D6 (IgG1 kappa). Fragments of tau containing the epitope of interest can be conjugated to a carrier that promotes the induction of an antibody response to the fragment, or can be combined with an adjuvant that promotes the induction of such a response. Such antibodies can be screened for differential binding to tau or a fragment thereof compared to mutants of the specified residues. Screening against such mutants will determine more precisely the binding specificity allowing the identification of antibodies whose binding is inhibited by mutagenesis of specific residues, and thus may share the functional properties of the other exemplified antibodies. Mutations can be systematic substitutions with alanine (or serine, if alanine is already present), one at a time, or more widely spaced, throughout the entire target or a section thereof where the epitope is known to reside. If the same set of mutations significantly reduces binding of the two antibodies, then the two antibodies bind to the same epitope.
[0318] Antibodies having the binding specificity of a selected murine antibody (e.g., 5G8, 6A10, 8A4, 7G6, or 3D6) can also be produced using a variation of the phage display method. See Winter, WO 92 / 20791. This method is particularly suitable for producing human antibodies. In this method, either the heavy or light chain variable region of the selected murine antibody is used as the starting material. For example, if a light chain variable region is selected as the starting material, a phage library is constructed in which members display the same light chain variable region (i.e., the murine starting material) and a different heavy chain variable region. The heavy chain variable region can be obtained, for example, from a library of rearranged human heavy chain variable regions. Phages (e.g., at least 10 8 and preferably at least 10 9 M -1 ) are selected. The heavy chain variable region from this phage then serves as the starting material for constructing a further phage library, in which each phage displays the same heavy chain variable region (i.e., the region identified from the first display library) and a different light chain variable region. The light chain variable region can be obtained, for example, from a library of rearranged human variable light chain regions. Again, phage that show strong specific binding to tau or a fragment thereof are selected. The resulting antibodies typically have the same or similar epitope specificity as the murine starting material.
[0319] The combined Kabat / Chothia CDRs of the heavy chain of 5G8 are shown in SEQ ID NOs: 11, 12, and 13, respectively, and the Kabat CDRs of the light chain of 5G8 are shown in SEQ ID NOs: 14, 15, and 16, respectively.
[0320] Table 2 shows the 5G8 CDRs as defined by Kabat, Chothia, the combination of Chothia and Kabat (also referred to herein as the "Kabat / Chothia combination"), AbM, and Contact. [Table 2]
[0321] The combined Kabat / Chothia CDRs of the heavy chain of 6A10 are designated SEQ ID NOs:65-67, respectively, and the Kabat CDRs of the light chain of 6A10 are designated SEQ ID NOs:68-70, respectively.
[0322] Table 3 shows the 6A10 CDRs as defined by Kabat, Chothia, a combination of Chothia and Kabat (also referred to herein as the "Kabat / Chothia combination"), AbM, and Contact. [Table 3-1] [Table 3-2]
[0323] The combined Kabat / Chothia CDRs of the heavy chain of 8A4 are designated SEQ ID NOs:93-95, respectively, and the Kabat CDRs of the light chain of 8A4 are designated SEQ ID NOs:96-98, respectively.
[0324] Table 4 shows the 8A4 CDRs as defined by Kabat, Chothia, a combination of Chothia and Kabat (also referred to herein as the "Kabat / Chothia combination"), AbM, and Contact. [Table 4]
[0325] The combined Kabat / Chothia CDRs of the heavy chain of 7G6 are designated SEQ ID NOs: 121-123, respectively, and the Kabat CDRs of the light chain of 7G6 are designated SEQ ID NOs: 124-126, respectively.
[0326] Table 5 shows the 7G6 CDRs as defined by Kabat, Chothia, a combination of Chothia and Kabat (also referred to herein as the "Kabat / Chothia combination"), AbM, and Contact.
[0327] Other antibodies can be obtained by mutagenesis of cDNAs encoding the heavy and light chains of exemplary antibodies such as 5G8, 6A10, 8A4, 7G6, or 3D6. Also included in the present invention are monoclonal antibodies that are at least 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% identical in amino acid sequence to 5G8, 6A10, 8A4, or 7G6 in the mature heavy and / or light chain variable region and retain their functional properties, and / or that differ from the respective antibodies by a small number of functionally insignificant amino acid substitutions (e.g., conservative substitutions), deletions, or insertions. Also included are monoclonal antibodies that have at least one or all six CDRs according to any conventional definition, preferably Kabat's definition, that are 90%, 95%, 99% or 100% identical to the corresponding CDRs of 5G8, 6A10, 8A4, or 7G6, as defined by Kabat. [Table 5]
[0328] The present invention also provides antibodies having some or all (e.g., 3, 4, 5, and 6) CDRs that are completely or substantially derived from 5G8, 6A10, 8A4, or 7G6. Such antibodies can include a heavy chain variable region having at least two, and usually all three, CDRs that are completely or substantially derived from the heavy chain variable region of 5G8, 6A10, 8A4, or 7G6, and / or a light chain variable region having at least two, and usually all three, CDRs that are completely or substantially derived from the light chain variable region of 5G8, 6A10, 8A4, or 7G6. The antibody can include both a heavy chain and a light chain. The CDRs are substantially derived from the corresponding 5G8, 6A10, 8A4, or 7G6 CDRs, except that when the CDRs include no more than 4, 3, 2, or 1 substitutions, insertions, or deletions, the CDR-H2 (as defined by Kabat) can have no more than 6, 5, 4, 3, 2, or 1 substitutions, insertions, or deletions. Such antibodies may have at least 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% identity in amino acid sequence to 5G8, 6A10, 8A4, or 7G6 in the mature heavy and / or light chain variable region and may retain the functional properties thereof and / or may differ from the 5G8 antibodies by a small number of functionally insignificant amino acid substitutions (e.g., conservative substitutions), deletions, or insertions.
[0329] Some antibodies identified by such assays can bind to monomeric, misfolded, aggregated, phosphorylated, or non-phosphorylated forms of tau, etc. Similarly, some antibodies are immunoreactive to non-pathological and pathological forms and conformations of tau.
[0330] B. Non-human antibodies Production of other non-human antibodies, e.g., murine, guinea pig, primate, rabbit or rat antibodies against tau or fragments thereof, can be achieved, for example, by immunizing the animals with tau or fragments thereof. See Harlow & Lane, Antibodies, A Laboratory Manual (CSHP NY, 1988) (incorporated by reference for all purposes). Such immunogens can be obtained from natural sources, by peptide synthesis or recombinant expression. Optionally, they can be administered fused or otherwise conjugated to a carrier protein. Optionally, the immunogens can be administered with an adjuvant. Several types of adjuvants can be used, as described below. Complete Freund's adjuvant followed by incomplete adjuvant is preferred for immunizing laboratory animals. Rabbits or guinea pigs are typically used to generate polyclonal antibodies. Mice are typically used to generate monoclonal antibodies. Antibodies are screened for specific binding to tau or an epitope within tau. Such screening can be accomplished by measuring binding of an antibody to a collection of tau variants and determining which deletion variants bind to the antibody. Binding can be assessed, for example, by Western blot, FACS or ELISA.
[0331] C. Humanized Antibodies A humanized antibody is a genetically engineered antibody in which CDRs from a non-human "donor" antibody are grafted onto human "acceptor" antibody sequences (see, e.g., Queen, US 5,530,101 and 5,585,089; Winter, US 5,225,539; Carter, US 6,407,213; Adair, US 5,859,205; and Foote, US 6,881,557). The acceptor antibody sequences can be, for example, mature human antibody sequences, combinations of such sequences, consensus sequences of human antibody sequences, or sequences of germline regions. Thus, a humanized antibody is an antibody having at least three, four, five or all of the CDRs, completely or substantially, derived from a donor antibody, as well as variable region framework sequences and, if present, constant regions, completely or substantially, derived from human antibody sequences. Similarly, a humanized heavy chain has at least one, two, and usually all three CDRs entirely or substantially from a donor antibody heavy chain, and, if present, a heavy chain variable region framework sequence and a heavy chain constant region substantially from human heavy chain variable region framework and constant region sequences. Similarly, a humanized light chain has at least one, two, and usually all three CDRs entirely or substantially from a donor antibody light chain, and, if present, a light chain variable region framework sequence and a light chain constant region substantially from human light chain variable region framework and constant region sequences. Other than nanobodies and dAbs, humanized antibodies include humanized heavy chains and humanized light chains. The CDRs in a humanized antibody are derived from the corresponding CDRs in a substantially non-human antibody when at least 85%, 90%, 95%, or 100% of the corresponding residues (defined by any conventional method, but preferably by Kabat) are identical between the respective CDRs. The variable region framework sequence of an antibody chain or the constant region of an antibody chain is derived substantially from a human variable region framework sequence or a human constant region, respectively, if at least 85%, 90%, 95% or 100% of the corresponding residues as defined by Kabat are identical.To be classified as humanized according to the 2014 World Health Organization (WHO) International Nonproprietary Name (INN) definition for humanized antibodies, there must be at least 85% identity with the human germline antibody sequence (i.e., prior to somatic hypermutation). A mixed antibody is one in which one antibody chain (e.g., heavy chain) meets the threshold and the other chain (e.g., light chain) does not. If neither chain meets the threshold, the antibody is classified as chimeric, even if the variable framework regions of both chains are substantially human with some back mutations. See Jones et al. (2016) The INNs and outs of antibody nonproprietary names, mAbs 8:1, 1-9, DOI: 10.1080 / 19420862.2015.1114320. See also "WHO-INN: International nonproprietary names (INN) for biological and biotechnological substances (a review)" (Internet) 2014. http: / / www.who.int / medicines / services / inn / BioRev2014.pdf) (hereby incorporated by reference). For the avoidance of doubt, the term "humanized" as used herein is not intended to be limited to the 2014 WHO INN definition of humanized antibody. Some humanized antibodies provided herein have at least 85% sequence identity to human germline sequences, and some humanized antibodies provided herein have less than 85% sequence identity to human germline sequences. Some heavy chains of humanized antibodies provided herein have sequence identity of about 60% to 100% to human germline sequences, such as about 60% to 69%, 70% to 79%, 80% to 84%, or 85% to 89%, etc.Some heavy chains fall below the 2014 WHO INN definition, e.g., have about 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, or 82%, 83% or 84% sequence identity to human germline sequences, while other heavy chains meet the 2014 WHO INN definition and have about 85%, 86%, 87%, 88%, 89% or more sequence identity to human germline sequences. Some light chains of the humanized antibodies provided herein have sequence identities of about 60%-100% to human germline sequences, such as in the range of 80%-84%, or 85%-89%. Some light chains fall below the 2014 WHO INN definition, for example, having about 81%, 82%, 83%, or 84% sequence identity to human germline sequences, while other light chains meet the 2014 WHO INN definition and have about 85%, 86%, 87%, 88%, 89% or more sequence identity to human germline sequences. Some humanized antibodies provided herein that are "chimeric" according to the 2014 WHO INN definition have a heavy chain with less than 85% identity to human germline sequences and a light chain with less than 85% identity to human germline sequences. For example, some humanized antibodies provided herein that have a heavy chain with at least 85% identity to human germline sequences and a light chain with less than 85% identity to human germline sequences are "mixed" according to the 2014 WHO INN definition, or vice versa. Some humanized antibodies provided herein meet the 2014 WHO INN definition of "humanized" and have a heavy chain paired with a light chain that has at least 85% identity to a human germline sequence. Exemplary 5G8 antibodies that meet the 2014 WHO INN definition of "humanized" include antibodies having a mature heavy chain having the amino acid sequence of SEQ ID NO:39 paired with a mature light chain sequence having the amino acid sequence of SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:45, or SEQ ID NO:46.Further humanized 5G8 antibodies of the present invention include antibodies having a pair of a mature heavy chain having an amino acid sequence of any one of SEQ ID NOs: 33 to 40 and a mature light chain having an amino acid sequence of any one of SEQ ID NOs: 41 to 46. Humanized 6A10 antibodies of the present invention include antibodies having a pair of a mature heavy chain having an amino acid sequence of any one of SEQ ID NOs: 85 to 87 and a mature light chain having an amino acid sequence of any one of SEQ ID NOs: 88 to 90. Humanized 8A4 antibodies of the present invention include antibodies having a pair of a mature heavy chain having an amino acid sequence of any one of SEQ ID NOs: 113 to 115 and a mature light chain having an amino acid sequence of any one of SEQ ID NOs: 116 to 118. Humanized 7G6 antibodies of the present invention include antibodies having a pair of a mature heavy chain having an amino acid sequence of any one of SEQ ID NOs: 139 to 140 and a mature light chain having an amino acid sequence of any one of SEQ ID NOs: 141 to 148.
[0332] Humanized antibodies often include all six CDRs (defined by any conventional method, but preferably as defined by Kabat) from the murine antibody, but can also be made with fewer than all of the CDRs from the murine antibody (e.g., at least three, four, or five CDRs) (e.g., Pascalis et al., J. Immunol. 169:3076, 2002; Vajdos et al., J. of Mol. Biol., 320: 415-428, 2002; Iwahashi et al., Mol. Immunol. 36:1079-1091, 1999; Tamura et al, J. Immunol., 164:1432-1441, 2000).
[0333] In some antibodies, only a portion of the CDRs, i.e., a subset of the CDR residues required for binding, called SDRs, are required to retain binding in the humanized antibody. CDR residues that do not contact the antigen and are not present in the SDRs can be identified by molecular modeling and / or empirical analysis from regions of the Kabat CDRs outside the Chothia hypervariable loops (Chothia, J. Mol. Biol. 196:901, 1987) based on previous studies (e.g., residues H60-H65 in CDR H2 are often not required), or as described in Gonzales et al., Mol. Immunol. 41: 863, 2004. In such humanized antibodies, in positions where one or more donor CDR residues are absent or where the entire donor CDR has been removed, the amino acid occupying that position may be the amino acid occupying the corresponding position (according to Kabat numbering) in the acceptor antibody sequence. The number of such substitutions of acceptor for donor amino acids included in the CDR reflects a balance of competing considerations. Such substitutions are potentially advantageous in that they reduce the number of murine amino acids in the humanized antibody, thereby reducing potential immunogenicity, and / or to comply with the WHO INN definition of "humanization". However, substitutions may also result in altered affinity, and significant decreases in affinity are preferably avoided. The position of substitution within the CDRs and the amino acids to be substituted can also be selected empirically.
[0334] The human acceptor antibody sequence can optionally be selected from among the many known human antibody sequences to provide a high degree of sequence identity (e.g., 65-85% identity) between the variable region framework of the human acceptor sequence and the corresponding variable region framework of the donor antibody chain.
[0335] An example of an acceptor sequence for the 5G8 heavy chain is the humanized anti-dabigatran aDabi-Fab2b-VH with NCBI accession code 4YHM_H (SEQ ID NO: 28). Another example of an acceptor sequence for the 5G8 heavy chain is the human germline gene IGHV1-46 with NCBI accession code P01743.2 (SEQ ID NO: 29). An example of an acceptor sequence for the 5G8 light chain is the humanized anti-dabigatran aDabi-Fab2b-VL with NCBI accession code 4YHM_L (SEQ ID NO: 31). Another example of an acceptor sequence for the 5G8 light chain is the human germline gene IGKV2-29 with NCBI accession code A2NJV5.2 (SEQ ID NO: 32).
[0336] An example of an acceptor sequence for the 6A10 heavy chain is the human heavy chain variable region of Accession No. ACR16112 (SEQ ID NO: 81). Another example of an acceptor sequence for the 6A10 light chain is the human kappa light chain variable region of Accession No. ABC66863 (SEQ ID NO: 83).
[0337] An example of an acceptor sequence for the 8A4 heavy chain is the human heavy chain variable region of Accession No. ADU57742 (SEQ ID NO: 110). Another example of an acceptor sequence for the 8A4 light chain is the human kappa light chain variable region of Accession No. ABA26100 (SEQ ID NO: 112).
[0338] An example of an acceptor sequence for the 7G6 heavy chain is the VH region of the human antibody with accession number PDB 3U0T_VH (SEQ ID NO: 137). Another example of an acceptor sequence for the 7G6 light chain is the VL region of the human antibody with accession number PDB 3U0T_VL (SEQ ID NO: 138).
[0339] If more than one human acceptor antibody sequence is selected, a combination or hybrid of these acceptors can be used and the amino acids used at the different positions of the humanized light and heavy chain variable regions can be selected from any of the human acceptor antibody sequences used.
[0340] Particular amino acids from the human variable region framework residues can be selected for substitution based on their possible effects on CDR conformation and / or binding to antigen. Study of such possible effects can be by modeling, examination of the characteristics of the amino acid at a particular position, or empirical observation of the effects of substituting or mutagenesing particular amino acids.
[0341] For example, if an amino acid differs between the murine variable region framework residue and a selected human variable region framework residue, the human framework amino acid can be replaced with the equivalent framework amino acid from the mouse antibody, where the amino acid is: (1) Direct non-covalent binding to antigens; (2) adjacent to the CDR regions or within the CDRs defined by Chothia but not Kabat; (3) otherwise interacts with the CDR region (e.g., is within about 6 angstroms of the CDR region) (e.g., identified by modeling the light or heavy chain on the solved structure of a homologous known immunoglobulin chain), or (4) Residues involved in the VL-VH interface: It is reasonable to assume that.
[0342] The present invention provides humanized murine 5G8 antibodies, including eight exemplary humanized heavy chain mature variable regions (hu5G8-VH_v1 (SEQ ID NO:33), hu5G8-VH_v2 (SEQ ID NO:34), hu5G8-VH_v3 (SEQ ID NO:35), hu5G8-VH_v4 (SEQ ID NO:36), hu5G8-VH_v5 (SEQ ID NO:37), hu5G8-VH_v6 (SEQ ID NO:38), hu5G8-VH_v7 (SEQ ID NO:39), and hu5G8-VH_v8 (SEQ ID NO:40)) and six exemplary humanized light chain mature variable regions (hu5G8-VL_v1 (SEQ ID NO:41, hu5G8-VL_v2 (SEQ ID NO:42), hu5G8-VL_v3 (SEQ ID NO:43), hu5G8-VL_v4 (SEQ ID NO:44), hu5G8-VL_v5 (SEQ ID NO:45), and hu5G8-VH_v6 (SEQ ID NO:46). (SEQ ID NO: 45), and hu5G8-VL_v6 (SEQ ID NO: 46).
[0343] The present invention provides humanized versions of the murine 6A10 antibody, including three exemplary humanized heavy chain mature variable regions, hu6A10-VH_v1 (SEQ ID NO:85), hu6A10-VH_v2 (SEQ ID NO:86), and hu6A10-VH_v3 (SEQ ID NO:87), and three exemplary humanized light chain mature variable regions, hu6A10-VL_v1 (SEQ ID NO:88), hu6A10-VL_v2 (SEQ ID NO:89), and hu6A10-VL_v3 (SEQ ID NO:90).
[0344] The present invention provides humanized versions of the murine 8A4 antibody, including three exemplary humanized heavy chain mature variable regions, hu8A4-VH_v1 (SEQ ID NO:113), hu8A4-VH_v2 (SEQ ID NO:114), and hu8A4-VH_v3 (SEQ ID NO:115) and three exemplary humanized light chain mature variable regions, hu8A4-VL_v1 (SEQ ID NO:116), hu8A4-VL_v2 (SEQ ID NO:117), and hu8A4-VL_v3 (SEQ ID NO:118).
[0345] The present invention provides humanized versions of the murine 7G6 antibody, including two exemplary humanized heavy chain mature variable regions, hu7G6-VH_v1 (SEQ ID NO:139) and hu7G6-VH_v2 (SEQ ID NO:140), and eight exemplary humanized light chain mature variable regions, hu7G6-VL_v1 (SEQ ID NO:141), hu7G6-VL_v2 (SEQ ID NO:142), hu7G6-VL_v3 (SEQ ID NO:143), hu7G6-VL_v4 (SEQ ID NO:144), hu7G6-VL_v5 (SEQ ID NO:145), hu7G6-VL_v6 (SEQ ID NO:146), hu7G6-VL_v7 (SEQ ID NO:147), and hu7G6-VL_v8 (SEQ ID NO:148).
[0346] In one embodiment, humanized sequences are generated using QuikChange site-directed mutagenesis methodology [Wang, W. and Malcolm, BA (1999) BioTechniques 26:680-682)], using a two-step PCR protocol that allows for the introduction of multiple mutations, deletions, and insertions.
[0347] As defined by Queen, US 5,530,101, framework residues of classes (1)-(3) are sometimes alternately referred to as canonical and Vernier residues. Framework residues that help determine the conformation of the CDR loops are sometimes referred to as canonical residues (Chothia & Lesk, J. Mol. Biol. 196:901-917 (1987); Thornton & Martin, J. Mol. Biol. 263:800-815 (1996)). Framework residues that support the conformation of the antigen-binding loops and serve to fine-tune the fit of the antibody to the antigen are sometimes referred to as Vernier residues (Foote & Winter, J. Mol. Biol 224:487-499 (1992)).
[0348] Other framework residues that are candidates for substitution create potential glycosylation sites. Still other substitution candidates are acceptor human framework amino acids that are unusual for that position for human immunoglobulins. These amino acids can be substituted with amino acids from the equivalent positions of the mouse donor antibody or with amino acids from the equivalent positions of more typical human immunoglobulins.
[0349] Other framework residues that are candidates for substitution are the N-terminal glutamine residues (Q), which may be substituted with glutamic acid (E) to minimize the possibility of pyroglutamic acid conversion [Y. Diana Liu, et al., 2011, J. Biol. Chem., 286: 11211-11217]. Conversion of glutamic acid (E) to pyroglutamic acid (pE) occurs more slowly than from glutamine (Q). Due to the loss of primary amines upon conversion of glutamine to pE, the antibody becomes more acidic. Incomplete conversion leads to antibody heterogeneity, which can be observed as multiple peaks by charge-based analytical methods. Differences in heterogeneity may indicate poor process control. Exemplary humanized antibodies with N-terminal glutamine to glutamic acid substitutions are SEQ ID NO:35 (hu5G8-VH_v3), SEQ ID NO:36 (hu5G8-VH_v4), SEQ ID NO:37 (hu5G8-VH_v5), SEQ ID NO:38 (hu5G8-VH_v6), and SEQ ID NO:40 (hu5G8-VH_v8).
[0350] An exemplary humanized antibody is a humanized version of murine 5G8 designated Hu5G8.
[0351] Murine antibody 5G8 comprises mature heavy and light chain variable regions having amino acid sequences comprising SEQ ID NOs: 7 and 8, respectively. The invention provides eight exemplary humanized mature heavy chain variable regions: hu5G8-VH_v1, hu5G8-VH_v2, hu5G8-VH_v3, hu5G8-VH_v4, hu5G8-VH_v5, hu5G8-VH_v6, hu5G8-VH_v7, and hu5G8-VH_v8. The invention further provides six exemplary human mature light chain variable regions: hu5G8-VL_v1, hu5G8-VL_v2, hu5G8-VL_v3, hu5G8-VL_v4, hu5G8-VL_v5, and hu5G8-VL_v6. Alignment of murine 5G8 and various humanized antibodies is shown for the light chain variable region (Table 6 and Figure 6) and the heavy chain variable region (Table 7 and Figure 5).
[0352] For reasons such as potential impact on CDR conformation and / or binding to antigen, mediating interactions between heavy and light chains, interactions with constant regions, being sites for desirable or undesirable post-translational modifications, potentially immunogenic due to being an unusual residue for its position in a human variable region, acquiring aggregation potential, and other reasons as demonstrated by Example 6, the following 23 variable region framework positions of 5G8 were considered as potential substitutions in six exemplary human mature light chain variable regions and eight exemplary human mature heavy chain variable regions: L2 (I2V), L7 (T7S), L17 (Q17E), L36 (Y36L), L45 (K45Q), L46 (G46R), L70 (G70D), H1 (Q1E), H11 (V11L), H12 (K12V), H19 (K19R), H20 (V20L), H23 (K23R), H24 (K24R), H25 (K25R), H26 (K26R), H27 (K27R), H28 (K28R), H29 (K29R), H30 (K30R), H31 (K31R), H32 (K32R), H33 (K33R), H34 (K34R), H35 (K35R), H36 (K36R), H37 (K37R), H38 (K38R), H39 (K39R), H40 (K40R), H41 (K41R), H42 (K42R), H43 (K43R), H44 (K44R), H45 (K45R), H46 (K43R), H45 (K45R), H46 (K43R), H47 (K43R), H48 (K43R), H49 (K43R), H50 (K43R), H51 (K43R), H52 (K43R), H5 (K23A), H46 (E46D), H48 (M48I), H66 (K66R), H67 (A67V), H71 (R71S), H76 (S76N), H78 (A78V), H80 (M80L), H93 (T93S or T93A), H94 (I94P or I94R).
[0353] Here, as elsewhere, the first mentioned residue is the residue of a humanized antibody formed by grafting a Kabat CDR, or in the case of CDR-H1, the combined Chothia-Kabat CDR, onto a human acceptor framework, and the second mentioned residue is the residue being considered for replacing such residue. Thus, the first mentioned residue in the variable region framework is human and the first mentioned residue in the CDR is murine.
[0354] Exemplary antibodies include any permutation or combination of the following exemplary 5G8 mature heavy and light chain variable regions: e.g., hu5G8VH_v1 / hu5G8VL_v1, hu5G8VH_v1 / hu5G8VL_v2, hu5G8VH_v1 / hu5G8VL_v3, hu5G8VH_v1 / hu5G8VL_v4, hu5G8VH_v1 / hu5G8VL_v5, hu5G8VH_v1 / hu5G8VL_v6, hu5G8VH_v2 / hu5G8VL_v1, hu5G8VH_v2 / hu5G8VL_v2, hu5G8VH_v2 / hu5G8VL_v3, hu5G8VH_v2 ... hu5G8VL_v4, hu5G8VH_v2 / hu5G8VL_v5, hu5G8VH_v2 / hu5G8VL_v6, hu5G8VH_v3 / hu5G8VL_v1, hu5G8VH_v3 / hu5G8VL_v2, hu5G8VH_v3 / hu5G8VL_v3, hu5G8VH_v3 / hu5G8VL_v4, hu5G8VH_v3 / hu5G8VL_v5, hu5G8VH_v3 / hu5G8VL_v6, hu5G8VH_v4 / hu5G8VL_v1, hu5G8VH_v4 / hu5G8VL_v2, hu5G8VH_v4 / hu5G8VL_v3, hu5G8VH_v4 / hu5G8VL_v4, hu5G8VH_v4 / hu5G8VL_v5, hu5G8VH_v4 / hu5G8VL_v6, hu5G8VH_v5 / hu5G8VL_v1, hu5G8VH_v5 / hu5G8VL_v2, hu5G8VH_v5 / hu5G8VL_v3, hu5G8VH_v5 / hu5G8VL_v4, hu5G8VH_v5 / hu5G8VL_v5, hu5G8VH_v5 / hu5G8VL_v6, hu5G8VH_v6 / hu5G8VL_v1, hu5G8VH_v6 / hu5G8VL_v2, hu5G8VH_v6 / hu5G8VL_v3, hu5G8VH_v6 / hu5G8VL_v4, hu5G8VH_v6 / hu5G8VL_v5, hu5G8VH_v6 / hu5G8VL_v6, hu5G8VH_v7 / hu5G8VL_v1, hu5G8VH_v7 / hu5G8VL_v2, hu5G8VH_v7 / hu5G8VL_v3, hu5G8VH_v7 / hu5G8VL_v4, hu5G8VH_v7 / hu5G8VL_v5, hu5G8VH_v7 / hu5G8VL_v6, hu5G8VH_v8 / hu5G8VL_v1, hu5G8VH_v8 / hu5G8VL_v2, hu5G8VH_v8 / hu5G8VL_v3, hu5G8VH_v8 / hu5G8VL_v4, hu5G8VH_v8 / hu5G8VL_v5, or hu5G8VH_v8 / hu5G8VL_v6.
[0355] The present invention provides variants of the 5G8 humanized antibody, in which the humanized mature heavy chain variable region exhibits at least 90%, 95%, 96%, 97%, 98%, or 99% identity to hu5G8-VH_v1, hu5G8-VH_v2, hu5G8-VH_v3, hu5G8-VH_v4, hu5G8-VH_v5, hu5G8-VH_v6, hu5G8-VH_v7, and hu5G8-VH_v8. (SEQ ID NOs: 33-40) and the humanized mature light chain variable region exhibits at least 90%, 95%, 96%, 97%, 98%, or 99% identity to hu5G8-VH_v1, hu5G8-VL_v2, hu5G8-VL_v3, hu5G8-VL_v4, hu5G8-VL_v5, and hu5G8-VL_v6. (SEQ ID NOs: 41 to 46) show at least 90%, 95%, 96%, 97%, 98%, or 99% identity. Some such antibodies retain at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or all 23 back mutations or other mutations in SEQ ID NOs: 33 to 40 and SEQ ID NOs: 41 to 46.
[0356] In some humanized 5G8 antibodies, at least one of the following positions is substituted with the amino acid specified below: H48 is substituted with I, H71 is substituted with S, H93 is substituted with S, and H94 is substituted with P. In some humanized 5G8 antibodies, H48, H71, H93, and H94 of the VH region are substituted with I, S, S, and P, respectively.
[0357] In some humanized 5G8 antibodies, at least one of the following positions is substituted with the amino acid specified below: H1 is substituted with E, H48 is substituted with I, H71 is substituted with S, H93 is substituted with S, and H94 is substituted with P. In some humanized 5G8 antibodies, H1, H48, H71, H93, and H94 of the VH region are substituted with E, I, S, S, and P, respectively.
[0358] In some humanized 5G8 antibodies, at least one of the following positions is substituted with the amino acid specified below: H1 is substituted with E, H46 is substituted with D, H48 is substituted with I, H71 is substituted with S, H93 is substituted with S, and H94 is substituted with P. In some humanized 5G8 antibodies, H1, H46, H48, H71, H93, and H94 of the VH region are substituted with E, D, I, S, S, and P, respectively.
[0359] In some humanized 5G8 antibodies, at least one of the following positions is substituted with the amino acid specified below: H1 is substituted with E, H11 is substituted with L, H12 is substituted with V, H19 is substituted with R, H20 is substituted with L, H46 is substituted with D, H48 is substituted with I, H71 is substituted with S, H76 is substituted with N, H80 is substituted with L, H93 is substituted with S, and H94 is substituted with P. In some humanized 5G8 antibodies, H1, H11, H12, H19, H20, H46, H48, H71, H76, H80, H93, and H94 of the VH region are substituted with E, L, V, R, L, D, I, S, N, L, S, and P, respectively.
[0360] In some humanized 5G8 antibodies, at least one of the following positions is substituted with the amino acid specified below: H66 is substituted with R, H67 is substituted with V, and H78 is substituted with V. In some humanized 5G8 antibodies, H66, H67, and H78 of the VH region are substituted with R, V, and V, respectively.
[0361] In some humanized 5G8 antibodies, at least one of the following positions is substituted with the amino acid specified below: H1 is substituted with Q or E, H11 is substituted with V or L, H12 is substituted with K or V, H19 is substituted with K or R, H20 is substituted with V or L, H23 is substituted with K or A, H46 is substituted with E or D, H48 is substituted with M or I, H66 is substituted with K or R, H67 is substituted with A or V, H71 is substituted with R or S, H76 is substituted with S or N, H78 is substituted with A or V, H80 is substituted with M or L, H93 is substituted with T, S or A, and H94 is substituted with I, P or R.
[0362] In some humanized 5G8 antibodies, I, S, S, and P are arranged at H48, H71, H93, and H94, respectively, of the VH region, such as hu5G8-VH_v2. In some humanized 5G8 antibodies, E, I, S, S, and P are arranged at H1, H48, H71, H93, and H94, respectively, of the VH region, such as hu5G8-VH_v3. In some humanized 5G8 antibodies, E, D, I, S, S, and P are arranged at H1, H46, H48, H71, H93, and H94, respectively, of the VH region, such as hu5G8-VH_v4. In some humanized 5G8 antibodies, such as hu5G8-VH_v5, E, L, V, R, L, D, I, S, N, L, S, and P are arranged at H1, H11, H12, H19, H20, H46, H48, H71, H76, H80, H93, and H94 of the VH region, respectively. In some humanized 5G8 antibodies, such as hu5G8-VH_v6, E, L, V, R, L, A, D, I, S, N, L, S, and P are arranged at H1, H11, H12, H19, H20, H23, H46, H48, H71, H76, H80, H93, and H94 of the VH region, respectively. In some humanized 5G8 antibodies, such as hu5G8-VH_v7, R, V, V, A, and R are arranged at H66, H67, H78, H93, and H94, respectively, of the VH region. In some humanized 5G8 antibodies, such as hu5G8-VH_v8, E, D, I, R, V, S, V, S, and P are arranged at H1, H46, H48, H66, H67, H71, H78, H93, and H94, respectively, of the VH region.
[0363] In some humanized 5G8 antibodies, at least one of the following positions is substituted with the amino acids specified below: L2 is substituted with V, L36 is substituted with L, and L46 is substituted with R. In some humanized 5G8 antibodies, L2, L36, and L46 of the VL region are substituted with V, L, and R, respectively.
[0364] In some humanized 5G8 antibodies, at least one of the following positions is substituted with the amino acids specified below: L2 is substituted with V, L36 is substituted with L, L46 is substituted with R, and L70 is substituted with D. In some humanized 5G8 antibodies, L2, L36, L46, and L70 of the VL region are substituted with V, L, R, and D, respectively.
[0365] In some humanized 5G8 antibodies, at least one of the following positions is substituted with the amino acid specified below: L45 is substituted with Q and L70 is substituted with D. In some humanized 5G8 antibodies, L45 and L70 of the VL region are substituted with Q and D, respectively.
[0366] In some humanized 5G8 antibodies, at least one of the following positions is substituted with the amino acid specified below: L2 is substituted with I or V, L7 is substituted with T or S, L17 is substituted with Q or E, L36 is substituted with Y or L, L45 is substituted with K or Q, L46 is substituted with L or R, and L70 is substituted with G or D.
[0367] In some humanized 5G8 antibodies, V, L, and R are arranged at L2, L36, and L46, respectively, of the VL region, such as hu5G8-VL_v2. In some humanized 5G8 antibodies, V, L, R, and D are arranged at L2, L36, L46, and L70, respectively, of the VL region, such as hu5G8-VL_v3. In some humanized 5G8 antibodies, V, S, E, L, R, and D are arranged at L2, L7, L17, L36, L46, and L70, respectively, of the VL region, such as hu5G8-VL_v4. In some humanized 5G8 antibodies, Q and D are arranged at L45 and L70, respectively, of the VL region, such as hu5G8-VL_v5. In some humanized 5G8 antibodies, such as hu5G8-VL_v6, V, L, Q, R, and D are arranged at L2, L36, L45, L46, and L70, respectively, of the VL region.
[0368] An exemplary humanized antibody is a humanized version of murine 6A10, designated Hu6A10.
[0369] Murine antibody 6A10 comprises mature heavy and light chain variable regions having amino acid sequences comprising SEQ ID NOs: 63 and 64, respectively. The present invention provides three exemplary humanized 6A10 mature heavy chain variable regions: hu6A10-VH_v1, hu6A10-VH_v2, and hu6A10-VH_v3. The present invention further provides three exemplary human 6A10 mature light chain variable regions: hu6A10-VL_v1, hu6A10-VL_v2, and hu6A10-VL_v3. Alignments of murine 6A10 and various humanized antibodies with respect to the light chain variable region (Table 12 and Figure 8) and heavy chain variable region (Table 13 and Figure 7) are shown.
[0370] For reasons such as potential impact on CDR conformation and / or binding to antigen, mediating interactions between heavy and light chains, interactions with constant regions, being sites for desirable or undesirable post-translational modifications, potentially immunogenic due to being an unusual residue for its position in a human variable region, acquiring aggregation potential, and other reasons, as demonstrated by Example 7, the following seven variable region framework positions were considered as potential substitutions in three exemplary human mature light chain variable regions and three exemplary human mature heavy chain variable regions: L12 (P12S), L17 (Q17E), L46 (R46L), H16 (A16G), H48 (M48I), H69 (T69I), and H80 (M80L).
[0371] Here, as elsewhere, the first mentioned residue is the residue of a humanized antibody formed by grafting a Kabat CDR, or in the case of CDR-H1, the combined Chothia-Kabat CDR, onto a human acceptor framework, and the second mentioned residue is the residue being considered for replacing such residue. Thus, the first mentioned residue in the variable region framework is human and the first mentioned residue in the CDR is murine.
[0372] Exemplary 6A10 antibody examples include any permutation or combination of the following exemplary mature heavy and light chain variable regions: for example, hu6A10VH_v1 / hu6A10VL_v1, hu6A10VH_v1 / hu6A10VL_v2, hu6A10VH_v1 / hu6A10VL_v3, hu6A10VH_v2 / hu6A10VL_v1, hu6A10VH_v2 / hu6A10VL_v2, hu6A10VH_v2 / hu6A10VL_v3, hu6A10VH_v3 / hu6A10VL_v1, hu6A10VH_v3 / hu6A10VL_v2, or hu6A10VH_v3 / hu6A10VL_v3.
[0373] The invention provides variants of the 6A10 humanized antibody, in which the humanized mature heavy chain variable region exhibits at least 90%, 95%, 96%, 97%, 98%, or 99% identity to hu6A10-VH_v1, hu6A10-VH_v2, and hu6A10-VH_v3, (SEQ ID NOs: 85-87), and the humanized mature light chain variable region exhibits at least 90%, 95%, 96%, 97%, 98%, or 99% identity to hu6A10-VL_v1, hu6A10-VL_v2, and hu6A10-VL_v3, (SEQ ID NOs: 88-90). In some such antibodies, at least 1, 2, 3, 4, 5, 6, or all 7 back mutations or other mutations in SEQ ID NOs: 85-87 and SEQ ID NOs: 88-90 are retained.
[0374] In some humanized 6A10 antibodies, H48 in the VH region is substituted with I.
[0375] In some humanized 6A10 antibodies, at least one of the following positions in the VH region is substituted with the amino acid specified below: H16 is substituted with A or G, H48 is substituted with M or I, H69 is substituted with T or I, and H80 is substituted with M or L.
[0376] In some humanized 6A10 antibodies, such as hu6A10-VH_v2, I is placed at H48 in the VH region. In some humanized 6A10 antibodies, such as hu6A10-VH_v3, G, I, I, and L are placed at H16, H48, H69, and H80 in the VH region, respectively.
[0377] In some humanized 6A10 antibodies, H46 in the VL region is configured as L.
[0378] In some humanized 6A10 antibodies, at least one of the following positions in the VL region is substituted with the amino acid specified below: L12 is substituted with P or S, L17 is substituted with Q or E, and L46 is substituted with R or L.
[0379] In some humanized 6A10 antibodies, such as hu6A10-VL_v2, L is placed at L46 in the VL region. In some humanized 6A10 antibodies, such as hu6A10-VL_v3, S, E, and L are placed at L12, L17, and L46, respectively, in the VL region.
[0380] An exemplary humanized antibody is a humanized version of murine 8A4, designated Hu8A4.
[0381] Murine antibody 8A4 comprises mature heavy and light chain variable regions having amino acid sequences comprising SEQ ID NOs: 91 and 92, respectively. The invention provides three exemplary humanized mature heavy chain variable regions: hu8A4-VH_v1, hu8A4-VH_v2, and hu8A4-VH_v3. The invention further provides three exemplary human mature light chain variable regions: hu8A4-VL_v1, hu8A4-VL_v2, and hu8A4-VL_v3. Alignments of murine 8A4 and various humanized antibodies with respect to the light chain variable regions (Table 18 and Figure 10) and heavy chain variable regions (Table 19 and Figure 9) are shown.
[0382] For reasons such as potential impact on CDR conformation and / or binding to antigen, mediating interactions between heavy and light chains, interactions with constant regions, being sites for desirable or undesirable post-translational modifications, potentially immunogenic due to being an unusual residue for its position in a human variable region, acquiring aggregation potential, and other reasons, as demonstrated by Example 8, the following eleven variable region framework positions of 8A4 were considered as candidates for substitution in three exemplary human mature light chain variable regions and three exemplary human mature heavy chain variable regions: L2 (I2V), L17 (Q17E), L36 (F36L), H12 (K12V), H16 (S16G), H20 (V20L), H48 (M48I), H67 (I67A), H68 (N68T), H85 (D85E), and H93 (A93S).
[0383] Here, as elsewhere, the first mentioned residue is the residue of a humanized antibody formed by grafting a Kabat CDR, or in the case of CDR-H1, the combined Chothia-Kabat CDR, onto a human acceptor framework, and the second mentioned residue is the residue being considered for replacing such residue. Thus, the first mentioned residue in the variable region framework is human and the first mentioned residue in the CDR is murine.
[0384] Exemplary 8A4 antibodies include any permutation or combination of the following exemplary mature heavy and light chain variable regions: for example, hu8A4VH_v1 / hu8A4VL_v1, hu8A4VH_v1 / hu8A4VL_v2, hu8A4VH_v1 / hu8A4VL_v3, hu8A4VH_v2 / hu8A4VL_v1, hu8A4VH_v2 / hu8A4VL_v2, hu8A4VH_v2 / hu8A4VL_v3, hu8A4VH_v3 / hu8A4VL_v1, hu8A4VH_v3 / hu8A4VL_v2, or hu8A4VH_v3 / hu8A4VL_v3.
[0385] The invention provides variants of the 8A4 humanized antibody, in which the humanized mature heavy chain variable region exhibits at least 90%, 95%, 96%, 97%, 98%, or 99% identity to hu8A4-VH_v1, hu8A4-VH_v2, and hu8A4-VH_v3, (SEQ ID NOs: 113-115), and the humanized mature light chain variable region exhibits at least 90%, 95%, 96%, 97%, 98%, or 99% identity to hu8A4-VL_v1, hu8A4-VL_v2, and hu8A4-VL_v3 (SEQ ID NOs: 116-118). In some such antibodies, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 back mutations or other mutations in SEQ ID NOs: 113-115 and SEQ ID NOs: 116-118 are retained.
[0386] In some humanized 8A4 antibodies, H93 in the VH region is substituted with S.
[0387] In some humanized 8A4 antibodies, at least one of the following positions in the VH region is filled with the amino acids specified below: H12 is filled with V, H16 is filled with G, H20 is filled with L, and H68 is filled with T. In some humanized 8A4 antibodies, H12, H16, H20, and H68 in the VH region are filled with V, G, L, and T, respectively.
[0388] In some humanized 8A4 antibodies, at least one of the following positions in the VH region is substituted with the amino acid specified below: H12 is substituted with K or V, H16 is substituted with S or G, H20 is substituted with V or L, H48 is substituted with M or I, H67 is substituted with A or I, H68 is substituted with N or T, H85 is substituted with D or E, and H93 is substituted with S or A.
[0389] In some humanized 8A4 antibodies, such as hu8A4VH_v1, S is placed at H93 in the VH region. In some humanized 8A4 antibodies, such as hu8A4VH_v2, V, G, L, T, and S are placed at H12, H16, H20, H68, and H93, respectively, in the VH region. In some humanized 8A4 antibodies, such as hu8A4VH_v3, V, G, L, I, A, T, and E are placed at H12, H16, H20, H48, H67, H68, and H85, respectively, in the VH region.
[0390] In some humanized 8A4 antibodies, L17 of the VL region is substituted with E.
[0391] In some humanized 8A4 antibodies, at least one of the following positions in the VL region is substituted with the amino acid specified below: L2 is substituted with I or V, L17 is substituted with Q or E, and L36 is substituted with F or L.
[0392] In some humanized 8A4 antibodies, such as hu8A4-VL_v2, an E is placed at L17 of the VL region. In some humanized 8A4 antibodies, such as hu8A4-VL_v3, a V, an E, and an L are placed at L2, L17, and L36, respectively, of the VL region.
[0393] An exemplary humanized antibody is a humanized version of murine 7G6, designated Hu7G6.
[0394] Murine antibody 7G6 comprises mature heavy and light chain variable regions having amino acid sequences comprising SEQ ID NOs: 119 and 120, respectively. The present invention provides two exemplary humanized mature heavy chain variable regions: hu7G6-VH_v1 and hu7G6-VH_v2. The present invention further provides eight exemplary human mature light chain variable regions: hu7G6-VL_v1, hu7G6-VL_v2, hu7G6-VL_v3, hu7G6-VL_v4, hu7G6-VL_v5, hu7G6-VL_v6, hu7G6-VL_v7, and hu7G6-VL_v8. Alignments of murine 7G6 and various humanized antibodies with respect to the light chain variable region (Table 25 and Figure 12) and the heavy chain variable region (Table 26 and Figure 11) are shown.
[0395] For reasons such as potential impact on CDR conformation and / or binding to antigen, mediating interactions between heavy and light chains, interactions with constant regions, being sites for desirable or undesirable post-translational modifications, potentially immunogenic due to being an unusual residue for its position in a human variable region, acquiring aggregation potential, and other reasons as demonstrated by Example 9, the following 16 variable region framework positions of 7G6 were considered as potential substitutions in eight exemplary human mature light chain variable regions and two exemplary human mature heavy chain variable regions: L12 (P12S), L36 (F36L), L37 (Q37L), L45 (R45K), L100 (Q100G), L103 (R103K), H12 (K12V), H20 (V20L), H38 (R39K), H69 (M69I), H76 (S76N), H78 (S76N), H80 (S80N), H82 (S82N), H84 (S84N), H86 (S84N), H8 ... (V78A), H80 (M80L), H81 (E81Q), H92 (C92S), and H93 (A93T).
[0396] Here, as elsewhere, the first mentioned residue is the residue of a humanized antibody formed by grafting a Kabat CDR, or in the case of CDR-H1, the combined Chothia-Kabat CDR, onto a human acceptor framework, and the second mentioned residue is the residue being considered for replacing such residue. Thus, the first mentioned residue in the variable region framework is human and the first mentioned residue in the CDR is murine.
[0397] Exemplary 7G6 antibodies include any permutation or combination of the following exemplary mature heavy and light chain variable regions: e.g., hu7G6VH_v1 / hu7G6VL_v1, hu7G6VH_v1 / hu7G6VL_v2, hu7G6VH_v1 / hu7G6VL_v3, hu7G6VH_v1 / hu7G6VL_v4, hu7G6VH_v1 / hu7G6VL_v5, hu7G6VH_v1 / hu7G6VL_v6, hu7G6VH_v1 / hu7G6VL_v7, hu7G6VH_v1 / hu7G6VL_v8, hu7G6VH_v2 / hu7G6VL_v1, hu7G6VH_v2 / hu7G6VL_v2, hu7G6VH_v2 / hu7G6VL_v3, hu7G6VH_v2 / hu7G6VL_v4, hu7G6VH_v2 / hu7G6VL_v5, hu7G6VH_v2 / hu7G6VL_v6, hu7G6VH_v2 / hu7G6VL_v7, or hu7G6VH_v2 / hu7G6VL_v8.
[0398] The present invention provides variants of the 7G6 humanized antibody, in which the humanized mature heavy chain variable region exhibits at least 90%, 95%, 96%, 97%, 98%, or 99% identity to hu7G6-VH_v1, and hu7G6-VH_v2, (SEQ ID NOs: 139-140), and the humanized mature light chain variable region exhibits at least 90%, 95%, 96%, 97%, 98%, or 99% identity to hu7G6-VL_v1, hu7G6-VL_v2, hu7G6-VL_v3, hu7G6-VL_v4, hu7G6-VL_v5, hu7G6-VL_v6, hu7G6-VL_v7, and hu7G6-VL_v8 (SEQ ID NOs: 141-148). Some such antibodies retain at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or all 17 backmutations or other mutations in SEQ ID NOs: 139-140 and SEQ ID NOs: 141-148.
[0399] In some humanized 7G6 antibodies, at least one of the following positions in the VH region is substituted with the amino acids specified below: H12 is substituted with V, H20 is substituted with L, H69 is substituted with I, H76 is substituted with N, H78 is substituted with A, H80 is substituted with L, H81 is substituted with Q, H92 is substituted with S, and H93 is substituted with T. In some humanized 7G6 antibodies, H12, H20, H69, H76, H78, H80, H81, H92, and H93 in the VH region are substituted with V, L, I, N, A, L, Q, S, and T, respectively.
[0400] In some humanized 7G6 antibodies, at least one of the following positions in the VH region is substituted with the amino acids specified below: H12 is substituted with K or V, H20 is substituted with V or L, H38 is substituted with R or K, H69 is substituted with M or I, H76 is substituted with S or N, H78 is substituted with V or A, H80 is substituted with M or L, H81 is substituted with E or Q, H92 is substituted with C or S, and H93 is substituted with A or T.
[0401] In some humanized 7G6 antibodies, such as 7G6-VH_v1, V, L, I, N, A, L, Q, S, and T are arranged at H12, H20, H69, H76, H78, H80, H81, H92, and H93 of the VH region, respectively. In some humanized 7G6 antibodies, such as hu7G6-VH_v2, V, L, K, I, N, A, L, Q, S, and T are arranged at H12, H20, H38, H69, H76, H78, H80, H81, H92, and H93 of the VH region, respectively.
[0402] In some humanized 7G6 antibodies, at least one of the following positions in the VL region is filled with the amino acid specified below: L12 is filled with S and L103 is filled with K. In some humanized 7G6 antibodies, L12 and L103 in the VL region are filled with S and K, respectively.
[0403] In some humanized 7G6 antibodies, at least one of the following positions in the VL region is filled with the amino acid specified below: L12 is filled with S, L36 is filled with L, and L103 is filled with K. In some humanized 7G6 antibodies, L12, L36, and L103 in the VL region are filled with S, L, and K, respectively.
[0404] In some humanized 7G6 antibodies, at least one of the following positions in the VL region is substituted with the amino acid specified below: L12 is substituted with S, L37 is substituted with L, and L103 is substituted with K. In some humanized 7G6 antibodies, L12, L37, and L103 in the VL region are substituted with S, L, and K, respectively.
[0405] In some humanized 7G6 antibodies, at least one of the following positions in the VL region is substituted with the amino acids specified below: L12 is substituted with S, L36 is substituted with L, L37 is substituted with L, and L103 is substituted with K. In some humanized 7G6 antibodies, L12, L36, L37, and L103 in the VL region are substituted with S, L, L, and K, respectively.
[0406] In some humanized 7G6 antibodies, at least one of the following positions in the VL region is filled with the amino acid specified below: L12 is filled with S, L45 is filled with K, and L103 is filled with K. In some humanized 7G6 antibodies, L12, L45, and L103 in the VL region are filled with S, K, and K, respectively.
[0407] In some humanized 7G6 antibodies, at least one of the following positions in the VL region is filled with the amino acids specified below: L12 is filled with S, L100 is filled with G, and L103 is filled with K. In some humanized 7G6 antibodies, L12, L100, and L103 in the VL region are filled with S, G, and K, respectively.
[0408] In some humanized 7G6 antibodies, at least one of the following positions in the VL region is substituted with the amino acid specified below: L36 is substituted with F or L, L37 is substituted with Q or L, L45 is substituted with R or K, and L100 is substituted with Q or G.
[0409] In some humanized 7G6 antibodies, S and K are placed at L12 and L103, respectively, in the VL region, such as hu7G6-VL_v1. In some humanized 7G6 antibodies, S, L, and K are placed at L12, L37, and L103, respectively, in the VL region, such as hu7G6-VL_v2. In some humanized 7G6 antibodies, S, L, and K are placed at L12, L36, and L103, respectively, in the VL region, such as hu7G6-VL_v3. In some humanized 7G6 antibodies, S, L, L, and K are placed at L12, L36, L37, and L103, respectively, in the VL region, such as hu7G6-VL_v4. In some humanized 7G6 antibodies, S, K, and K are placed at L12, L45, and L103, respectively, in the VL region, such as hu7G6-VL_v5. In some humanized 7G6 antibodies, S, L, L, K, and K are placed at L12, L36, L37, L45, and L103, respectively, in the VL region, such as hu7G6-VL_v6. In some humanized 7G6 antibodies, S, G, and K are placed at L12, L100, and L103, respectively, in the VL region, such as hu7G6-VL_v7. In some humanized 7G6 antibodies, S, L, L, G, and K are placed at L12, L36, L37, L100, and L103, respectively, in the VL region, such as hu7G6-VL_v8.
[0410] In some humanized 5G8, 6A10, 8A4, and 7G6 antibodies, the variable heavy chain has 85% or more identity to a human sequence. In some humanized 5G8, 6A10, 8A4, and 7G6 antibodies, the variable light chain has 85% or more identity to a human sequence. In some humanized 5G8, 6A10, 8A4, and 7G6 antibodies, the variable heavy chain and the variable light chain each have 85% or more identity to a human germline sequence.
[0411] The CDR regions of such humanized 5G8, 6A10, 8A4, and 7G6 antibodies may be identical or substantially identical to the CDR regions of 5G8, 6A10, 8A4, or 7G6, respectively. The CDR regions may be defined by any conventional definition (e.g., Chothia, or a combination of Chothia and Kabat), but are preferably as defined by Kabat.
[0412] Unless otherwise specified, variable region framework positions correspond to Kabat numbering. Other such variants typically differ from the exemplary Hu5G8, Hu6A10, Hu8A4, or Hu7G6 heavy and light chain sequences by only a small number (e.g., typically 1, 2, 3, 5, 10, or 15) of substitutions, deletions, or insertions.
[0413] One possibility for additional diversity in humanized 5G8, 6A10, 8A4, and 7G6 variants is additional backmutations in the variable region framework. Many of the framework residues that do not contact the CDRs in the humanized mAb are amenable to substitution with amino acids at the corresponding positions in the donor mouse mAb or other mouse or human antibodies, and many more potential CDR contact residues are also amenable to substitution. Even amino acids within the CDRs can be changed, for example, with residues found at the corresponding positions in the human acceptor sequence used to provide the variable region framework. Furthermore, different human acceptor sequences can be used, for example, for the heavy and / or light chains. If a different acceptor sequence is used, one or more of the backmutations recommended above may not be performed, since the corresponding donor and acceptor residues are already free of backmutations.
[0414] It is preferred that the substitutions or back mutations (whether conservative or not) in the humanized 5G8, 6A10, 8A4, and 7G6 variants do not substantially affect the binding affinity or potency of the humanized mAb, i.e., its ability to bind tau.
[0415] The humanized 5G8, 6A10, 8A4, and 7G6 antibodies are further characterized by their ability to bind to any or all phosphorylated, non-phosphorylated, and misfolded / aggregated forms of tau. The humanized 5G8, 6A10, 8A4, and 7G6 antibodies are further characterized by their ability to compete with 5G8, 6A10, 8A4, or 7G6 for binding to any or all phosphorylated, non-phosphorylated, and misfolded / aggregated forms of tau.
[0416] D. Chimeric and Veneered Antibodies The present invention further provides non-human antibodies, particularly chimeric and veneered versions of the exemplary 5G8, 6A10, 8A4, or 7G6 antibodies.
[0417] Chimeric antibodies are antibodies that combine the mature variable regions of the light and heavy chains of a non-human antibody (e.g., mouse) with human light and heavy chain constant regions. Such antibodies substantially or completely retain the binding specificity of the mouse antibody and contain approximately two-thirds of the human sequence.
[0418] A veneered antibody is a type of humanized antibody that retains some, and usually all, of the CDRs and some of the non-human variable region framework residues of the non-human antibody, but replaces other variable region framework residues that may contribute to B- or T-cell epitopes, e.g., exposed residues (Padlan, Mol. Immunol. 28:489, 1991), with residues from the corresponding positions in a human antibody sequence. The result is an antibody in which the CDRs are entirely or substantially derived from a non-human antibody and the variable region framework of the non-human antibody has been made more human-like by the replacement. Veneered versions of the 5G8, 6A10, 8A4, and 7G6 antibodies are included in the present invention.
[0419] E. Human Antibodies Human antibodies against tau or fragments thereof can be obtained by various techniques, as described below. Some human antibodies are selected by the phage display method of Winter, by competitive binding experiments, as described above or otherwise, to have the same epitope specificity as a particular mouse antibody, such as one of the mouse monoclonal antibodies described in the Examples. Human antibodies can also be screened for a particular epitope specificity by using only a fragment of tau as the target antigen and / or by screening antibodies against a collection of tau variants.
[0420] Methods for producing human antibodies include the trioma method of Oestberg et al., Hybridoma 2:361-367 (1983); Oestberg, US Patent No. 4,634,664; and Engleman et al., US Patent 4,634,666, the use of transgenic mice containing human immunoglobulin genes (e.g., Lonberg et al., WO93 / 12227 (1993); US 5,877,397; US 5,874,299; US 5,814,318; US 5,789,650; US 5,770,429; US 5,661,016; US 5,633,425; US 5,625,126; US 5,569,825; US 5,545,806; Neuberger, Nat. Biotechnol. 14:826 (1996); and Kucherlapati, WO 91 / 10741 (1991)), phage display methods (see, e.g., Dower et al., WO 91 / 17271; McCafferty et al., WO 92 / 01047; US 5,877,218; US 5,871,907; US 5,858,657; US 5,837,242; US 5,733,743; and US 5,565,332)), and the methods described in WO 2008 / 081008 (e.g., immortalizing memory B cells isolated from humans (e.g., using EBV), screening for the desired properties, and cloning and expressing the recombinant forms).
[0421] F. Selection of Constant Regions The heavy and light chain variable regions of a chimeric, veneered, or humanized antibody can be linked to at least a portion of a human constant region. The choice of constant region depends, in part, on whether antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis, and / or complement-dependent cytotoxicity are desired. For example, human isotypes IgG1 and IgG3 have complement-dependent cytotoxicity, whereas human isotypes IgG2 and IgG4 do not. Human IgG1 and IgG3 also induce stronger cell-mediated effector functions than human IgG2 and IgG4. The light chain constant region can be lambda or kappa. Numbering conventions for constant regions include EU numbering (Edelman, GM et al., Proc. Natl. Acad. USA, 63, 78-85 (1969)), Kabat numbering (Kabat, Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, MD, 1991), IMGT unique numbering (Lefranc M.-P. et al., IMGT unique numbering for immunoglobulin and T cell receptor constant domains and Ig superfamily C-like domains, Dev. Comp. Immunol., 29, 185-203 (2005), and IMGT exon numbering (Lefranc, supra).
[0422] One or several amino acids at the amino or carboxy termini of the light and / or heavy chains, such as the C-terminal lysine of the heavy chain, may be missing or derivatized in part or all of the molecule. Substitutions may be made in the constant region to reduce or increase effector functions such as complement-mediated cytotoxicity or ADCC (see, for example, Winter et al., US Patent No. 5,624,821; Tso et al., US Patent No. 5,834,597; and Lazar et al., Proc. Natl. Acad. Sci. USA 103:4005, 2006), or to extend half-life in humans (see, for example, Hinton et al., J. Biol. Chem. 279:6213, 2004). Exemplary substitutions to increase the half-life of the antibody include Gln at position 250 and / or Leu at position 428 (EU numbering of the constant region is used in this paragraph). Substitutions at any or all of positions 234, 235, 236 and / or 237 reduce affinity for Fcγ receptors, particularly FcγRI receptors (see, e.g., US 6,624,821). Alanine substitutions at positions 234, 235 and 237 of human IgG1 can be used to reduce effector function. Some antibodies have alanine substitutions at positions 234, 235 and 237 of human IgG1 to reduce effector function. Optionally, 234, 236 and / or 237 in human IgG2 are substituted with alanine and position 235 is substituted with glutamine (see, e.g., US 5,624,821). Some antibodies use mutations at one or more of positions 241, 264, 265, 270, 296, 297, 322, 329 and 331 of human IgG1 according to EU numbering. In some antibodies, mutations at one or more of positions 318, 320, and 322 of human IgG1, EU numbering, are used. In some antibodies, positions 234 and / or 235 are substituted with alanine and / or position 329 is substituted with glycine. In some antibodies, positions 234 and 235 are substituted with alanine. In some antibodies, the isotype is human IgG2 or IgG4.
[0423] Antibodies can be expressed as tetramers containing two light chains and two heavy chains, as separate heavy and light chains, as Fab, Fab', F(ab')2, and Fv, or as single chain antibodies in which the mature variable domains of the heavy and light chains are linked via a spacer.
[0424] Human constant regions exhibit allotypic and isoallotypic variation among different individuals. That is, the constant region may differ in different individuals at one or more polymorphic positions. Isoallotypes differ from allotypes in that sera that recognize the isoallotype bind to non-polymorphic regions of one or more other isotypes. Thus, for example, another heavy chain constant region is IgG1 G1m3, with or without a C-terminal lysine. Reference to a human constant region includes any naturally occurring allotype or constant region with any permutation of residues occupying positions in the naturally occurring allotypes.
[0425] G. Expression of Recombinant Antibodies Several methods are known for the production of chimeric and humanized antibodies using antibody-expressing cell lines (e.g., hybridomas). For example, the immunoglobulin variable regions of antibodies can be cloned and sequenced using well-known methods. In one method, the heavy chain variable VH region is cloned by RT-PCR using mRNA prepared from hybridoma cells. Consensus primers are used for the VH region leader peptide encompassing the translation initiation as the 5' primer and the g2b constant region as the specific 3' primer. Exemplary primers are described in U.S. Patent Application Publication No. 2005 / 0009150 to Schenk et al. (hereinafter "Schenk"). Sequences from multiple independently derived clones can be compared to ensure that no changes were introduced during amplification. The sequence of the VH region can also be determined or confirmed by sequencing the VH fragment obtained by 5'RACE RT-PCR and 3'g2b specific primers.
[0426] The light chain variable VL region can be cloned in a similar manner. In one approach, a consensus primer set is designed for amplification of the VL region with a 5' primer designed to hybridize to the VL region encompassing the translation initiation codon and a 3' primer specific for the Ck region downstream of the VJ joining region. In a second approach, a 5' RACE RT-PCR method is used to clone the VL-encoding cDNA. Exemplary primers are described in Schenk, supra. The cloned sequence is then combined with sequences encoding human (or other non-human species) constant regions.
[0427] In one approach, the heavy and light chain variable regions are reengineered to encode splice donor sequences downstream of their respective VDJ or VJ junctions and inserted into mammalian expression vectors such as pCMV-hγ1 for the heavy chain and pCMV-Mcl for the light chain. These vectors encode the human γ1 and Ck constant regions as exon fragments downstream of the inserted variable region cassettes. After sequence verification, the heavy and light chain expression vectors can be co-transfected into CHO cells to produce chimeric antibodies. Culture supernatants are collected 48 hours after transfection and analyzed for antibody production by Western blot analysis or antigen binding by ELISA. The chimeric antibodies are humanized as described above.
[0428] Chimeric, veneered, humanized and human antibodies are typically produced by recombinant expression. Recombinant polynucleotide constructs typically contain expression control sequences operably linked to antibody chain coding sequences, including naturally associated or heterologous expression control sequences, e.g., promoters. The expression control sequences may be promoter systems in vectors capable of transforming or transfecting eukaryotic host cells. After the vector has been incorporated into an appropriate host, the host is maintained under conditions suitable for high level expression of the nucleotide sequences, and the recovery and purification of cross-reacting antibodies.
[0429] These expression vectors are typically replicable in the host organisms either as episomes or as an integral part of the host chromosomal DNA. Commonly, expression vectors contain selection markers, such as ampicillin resistance or hygromycin resistance, to permit detection of those cells transformed with the DNA sequences of interest.
[0430] E. coli is one type of prokaryotic host useful for expressing antibodies, particularly antibody fragments. Microorganisms such as yeast are also useful for expression. Saccharomyces is a yeast host with suitable vectors, including expression control sequences, origins of replication, and termination sequences, as needed. Exemplary promoters include 3-phosphoglycerate kinase and other glycolytic enzymes. Inducible yeast promoters include, among others, promoters from alcohol dehydrogenase, isocytochrome C, and enzymes involved in maltose and galactose utilization.
[0431] Mammalian cells can be used to express nucleotide segments encoding immunoglobulins or fragments thereof. See Winnacker, From Genes~Clones, (VCH Publishers, NY, 1987). Several suitable host cell lines capable of secreting intact heterologous proteins have been developed, including CHO cell lines, various COS cell lines, HeLa cells, HEK293 cells, L cells, and non-antibody producing myelomas including SP2 / 0 and NS0. The cells can be non-human. Expression vectors for these cells can include expression control sequences such as origins of replication, promoters, enhancers (Queen et al., Immunol. Rev. 89:49 (1986)), and necessary information processing sites such as ribosome binding sites, RNA splice sites, polyadenylation sites, and transcription termination sequences. Expression control sequences can include promoters derived from endogenous genes, cytomegalovirus, SV40, adenovirus, bovine papilloma virus, and the like. See Co et al., J. Immunol. 148:1149 (1992).
[0432] Alternatively, the antibody coding sequence can be incorporated into a transgene for introduction into the genome of a transgenic animal and subsequent expression in the milk of the transgenic animal (see, e.g., US Pat. No. 5,741,957; US Pat. No. 5,304,489; and US Pat. No. 5,849,992). Suitable transgenes include coding sequences for the light and / or heavy chains operably linked to a promoter and enhancer from a mammary gland-specific gene, e.g., casein or beta-lactoglobulin.
[0433] A vector containing a DNA segment of interest can be introduced into a host cell using a method that depends on the type of host cell. For example, calcium chloride transfection is typically used for prokaryotic cells, while calcium phosphate treatment, electroporation, lipofection, gene guns, or viral-based transfection can be used for other cellular hosts. Other methods used to transform mammalian cells include the use of polybrene, protoplast fusion, liposomes, electroporation, and microinjection. For the production of transgenic animals, transgenes can be microinjected into fertilized oocytes or integrated into the genome of embryonic stem cells, the nuclei of which can be introduced into enucleated oocytes.
[0434] Vectors (single or multiple) encoding antibody heavy and light chains can be introduced into the cell culture, and cell pools can be screened for growth productivity and product quality in serum-free medium. The highest producing cell pools can then be subjected to FACS-based single cell cloning to generate monoclonal lines. Specific productivities of over 50 pg or 100 pg per cell per day can be used, corresponding to product titers of over 7.5 g / L of culture. The antibodies produced by the single cell clones can also be tested for turbidity, filtration characteristics, PAGE, IEF, UV scan, HP-SEC, carbohydrate-oligosaccharide mapping, mass spectrometry, and binding assays such as ELISA or Biacore. Selected clones can then be placed into multiple vials and stored frozen for later use.
[0435] Once expressed, antibodies can be purified according to standard procedures in the art, including protein A capture, HPLC purification, column chromatography, gel electrophoresis, etc. (for a review, see Scopes, Protein Purification (Springer-Verlag, NY, 1982)).
[0436] Methodologies for commercial production of antibodies can be used including codon optimization, promoter selection, transcriptional element selection, terminator selection, serum-free single cell cloning, cell storage, use of selectable markers for copy number amplification, CHO terminators, or improved protein titer (see, e.g., US 5,786,464; US 6,114,148; US 6,063,598; US 7,569,339; W02004 / 050884; W02008 / 012142; W02008 / 012142; W02005 / 019442; W02008 / 107388; W02009 / 027471; and US 5,888,809).
[0437] IV. Active immunogens The present invention also provides a method of treating or preventing a tau-related disease in a subject, comprising administering an agent that induces an immune response against tau. Such agents used in active immunization serve to induce the same types of antibodies in the patient as described above in connection with passive immunization. Some such methods comprise administering to the subject an immunogen that includes an epitope that antibody 5G8 specifically binds to in a regimen effective to generate antibodies against tau. In some methods, the immunogen includes a tau peptide of up to 20 consecutive amino acids of SEQ ID NO: 3 to which antibody 5G8 specifically binds. In other methods, an immunogen is administered that includes an epitope that antibody 6A10 specifically binds to. In some methods, the immunogen includes a tau peptide of up to 20 consecutive amino acids of SEQ ID NO: 3 to which antibody 6A10 specifically binds to. In some methods, an immunogen is administered that includes an epitope that antibody 8A4 specifically binds to. In some methods, the immunogen includes a tau peptide of up to 20 consecutive amino acids of SEQ ID NO: 3 to which antibody 8A4 specifically binds to. In other methods, an immunogen is administered that includes an epitope to which antibody 7G6 specifically binds. In some methods, an immunogen is administered that includes an epitope to which antibody 3D6 specifically binds. In some methods, the immunogen includes a tau peptide of up to 20 contiguous amino acids of SEQ ID NO: 3 to which antibody 3D6 specifically binds. In some methods, the immunogen includes a tau peptide of up to 20 contiguous amino acids of SEQ ID NO: 3 is administered, where at least two of antibodies 5G8, 6A10, 8A4, 7G6, and 3D6 specifically bind to the tau peptide. In some methods, the immunogen includes an epitope to which two or more of the above antibodies specifically bind, where the epitope consists of a peptide of 4-11 contiguous amino acids from residues 199-213 of SEQ ID NO: 3 or residues 262-276 of SEQ ID NO: 3 or 4-11 contiguous amino acids from residues 199-213 of SEQ ID NO: 3 and residues 262-276 of SEQ ID NO: 3. In some methods, the tau peptide epitope consists of 4 to 11 contiguous amino acids from residues 199-213 of SEQ ID NO:3 or residues 262-276 of SEQ ID NO:3.In other methods, the tau peptide epitope consists of two consecutive segments of amino acids, one segment from residues 199-213 of SEQ ID NO:3 and the other segment from residues 262-276 of SEQ ID NO:3, wherein both consecutive segments are composed of 4-11 amino acids.
[0438] To induce antibodies that bind to the same or overlapping epitopes as 5G8, 6A10, 8A4, 7G6, or 3D6, the epitope specificity of these antibodies can be mapped (e.g., by testing binding to a series of overlapping peptides spanning tau). Fragments of tau that consist of, contain, or overlap the epitopes can then be used as immunogens. Such fragments are typically used in their non-phosphorylated form.
[0439] Heterologous carriers and adjuvants, if used, may be the same as those used to generate monoclonal antibodies, but may be selected for better pharmaceutical suitability for use in humans. Suitable carriers include serum albumin, keyhole limpet hemocyanin, immunoglobulin molecules, thyroglobulin, ovalbumin, tetanus toxoid, or toxoids or attenuated toxin derivatives from other pathogenic bacteria, such as diphtheria (e.g., CRM197), E. coli, cholera, or H. pylori. T-cell epitopes are also suitable carrier molecules. Some conjugates can be formed by linking the agents of the invention to immunostimulatory polymer molecules (e.g., tripalmitoyl-S-glyceryl cysteine (Pam3Cys), mannan (mannose polymer), or glucan (aβ1→2 polymer)), cytokines (e.g., IL-1, IL-1 alpha and IL-1β peptides, IL-2, γ-INF, IL-10, GM-CSF), and chemokines (e.g., MIP1-α and β, and RANTES). Immunogens may be linked to carriers with or without spacer amino acids (e.g., gly-gly). Further carriers include virus-like particles. Virus-like particles (VLPs), also called pseudovirions or virus-derived particles, display subunit structures composed of multiple copies of viral capsid and / or envelope proteins capable of self-assembly in vivo into defined spherically symmetric VLPs (Powilleit, et al., (2007) PLoS ONE 2(5):e415). Alternatively, the peptide immunogen can be linked to at least one artificial T cell epitope capable of binding to a large proportion of MHC class II molecules, such as the pan-DR epitope ("PADRE"). PADRE is described in US 5,736,142, WO 95 / 07707, and Alexer J et al, Immunity, 1:751-761 (1994). The active immunogen can exist in a multimeric form, in which multiple copies of the immunogen and / or its carrier are present as a single covalently linked molecule.
[0440] The fragments are often administered with a pharma- ceutically acceptable adjuvant. The adjuvant increases the titer of induced antibodies and / or the binding affinity of induced antibodies compared to the situation when the peptide is used alone. A variety of adjuvants can be used in combination with immunogenic fragments of tau to elicit an immune response. Preferred adjuvants increase the intrinsic response to the immunogen without causing conformational changes in the immunogen that affect the qualitative form of the response. Preferred adjuvants include aluminum salts, such as aluminum hydroxide and aluminum phosphate, 3De-O-acylated monophosphoryl lipid A (MPL), and other adjuvants. TM ) (see GB 2220211 (RIBI ImmunoChem Research Inc., Hamilton, Montana (now part of Corixa)). TMQS-21 is a triterpene glycoside or saponin isolated from the bark of Quillaja Saponaria Molina, found in South America (see Kensil et al., in Vaccine Design: The Subunit Adjuvant Approach (eds. Powell & Newman, Plenum Press, NY, 1995); US 5,057,540), (Aquila BioPharmaceuticals, Framingham, MA (now Antigenics, Inc., New York, NY). Other adjuvants are optionally monophosphoryl lipid A (Stoute et al., N. Engl. J. Med. 336, 86-91). (1997)), pluronic polymers, and oil-in-water emulsions (such as squalene or peanut oil) combined with immunostimulants such as killed mycobacteria. Ribi adjuvant is an oil-in-water emulsion. Ribi contains a metabolizable oil (squalene) emulsified in saline containing Tween 80. Ribi also contains purified mycobacterial products and bacterial monophosphoryl lipid A which function as immunostimulants. Another adjuvant is CpG (WO 98 / 40100). Adjuvants can be administered as components of a therapeutic composition together with the active agent, or can be administered separately, before, simultaneously with, or after administration of the therapeutic agent.
[0441] Analogs of natural fragments of tau that induce antibodies against tau can also be used. For example, one or more or all L-amino acids can be replaced with D-amino acids in such peptides. Also, the order of amino acids can be reversed (retro peptides). Optionally, the peptide contains all D-amino acids in reverse order (retro-inverso peptides). Peptides and other compounds do not necessarily have significant amino acid sequence similarity with tau peptides, but nevertheless function as mimics of tau peptides and induce a similar immune response. Anti-idiotypic antibodies against tau monoclonal antibodies can also be used as described above. Such anti-Id antibodies mimic the antigen and result in an immune response against it (see Essential Immunology, Roit ed., Blackwell Scientific Publications, Palo Alto, CA 6th ed., p. 181).
[0442] The peptide (and optionally a carrier fused to the peptide) can also be administered in the form of a nucleic acid encoding the peptide to allow in situ expression in the patient's body. The nucleic acid segment encoding the immunogen is typically linked to regulatory elements such as a promoter and enhancer that allow expression of the DNA segment in the intended target cells of the patient. For expression in blood cells, which is desirable for the induction of an immune response in situ, promoter and enhancer elements from light or heavy chain immunoglobulin genes or the CMV major-intermediate-early promoter and enhancer are suitable for inducing expression. The linked regulatory elements and coding sequence are often inserted into a vector. The antibody can also be administered in the form of a nucleic acid encoding the heavy and / or light chain of the antibody. If both heavy and light chains are present, the chains are preferably linked as single chain antibodies. Antibodies for passive administration can also be prepared, for example, by affinity chromatography from serum of patients treated with the peptide immunogen.
[0443] DNA can be delivered in naked form (i.e., without colloidal or encapsulating material). Alternatives include retroviral systems (see, e.g., Lawrie and Tumin, Cur. Opin. Genet. Develop. 3, 102-109 (1993)), adenovirus vectors (see, e.g., Bett et al., J. Virol. 67, 591 1 (1993)), adeno-associated virus vectors (see, e.g., Zhou et al., J. Exp. Med. 179, 1867 (1994)); viral vectors from the pox family, including vaccinia virus and avian poxviruses, alphavirus vectors such as those derived from Sindbis and Semliki Forest viruses (see, e.g., Dubensky et al., J. Virol. 70, 508-519 (1996)), Venezuelan equine encephalitis virus (US Several viral vector systems can be used, including rhabdoviruses such as vesicular stomatitis virus (see WO 96 / 34625) and papillomaviruses (Ohe et al., Human Gene Therapy 6, 325-333 (1995); Woo et al, WO 94 / 12629 and Xiao & Brsma, Nucleic Acids. Res. 24, 2630-2622 (1996)).
[0444] The DNA encoding the immunogen, or a vector containing it, can be packaged into a liposome. Suitable lipids and related analogues are described in US 5,208,036, US 5,264,618, US 5,279,833, and US 5,283,185. The vector and DNA encoding the immunogen can also be adsorbed or bound to a particulate carrier, examples of which include polymethylmethacrylate polymers and polylactides and poly(lactide-co-glycolides) (see, for example, McGee et al., J. Micro Encap. 1996).
[0445] H. Antibody Screening Assays As noted above, antibodies can first be screened for the desired binding specificity. Active immunogens can similarly be screened for the ability to induce antibodies with such binding specificity. In this case, the active immunogen is used to immunize laboratory animals and the resulting sera are tested for the appropriate binding specificity.
[0446] Antibodies with the desired binding specificity can then be tested in cell and animal models. Neuronal cells should be preferred as the cells used for such screening. Cellular models of tau pathology have been reported in which neuroblastoma cells are genetically transfected with the 4 repeat domain of tau, optionally with a mutation associated with tau pathology (e.g., Delta K280, see Khlistunova, Current Alzheimer Research 4, 544-546 (2007)). In another model, tau is induced in the neuroblastoma N2a cell line by adding doxycycline. This cellular model makes it possible to study the toxicity of tau to cells in the soluble or aggregated state, the appearance of tau aggregates after switching on tau gene expression, the dissolution of tau aggregates after switching off gene expression again, and the efficiency of antibodies in inhibiting the formation of tau aggregates or disaggregating them.
[0447] Antibodies or active immunogens can also be screened in transgenic animal models of tau-associated diseases. Such transgenic animals may contain a tau transgene (e.g., any of the human isoforms) and optionally a human APP transgene, such as a kinase that phosphorylates tau, ApoE, presenilin, or alpha-synuclein, among others. Such transgenic animals have been treated to develop at least one sign or symptom of a tau-associated disease.
[0448] An exemplary transgenic animal is the K3 strain of mice (Itner et al., Proc. Natl. Acad. Sci. USA 105(41):15997-6002 (2008)). These mice have a K369I mutation (which is associated with Pick's disease) and a human tau transgene with the Thy 1.2 promoter. This model shows a rapid course of neurodegeneration, motor impairment, and degeneration of afferent fibers and cerebellar granule cells. Another exemplary animal is the JNPL3 strain of mice. These mice have a P301L mutation (which is associated with frontotemporal dementia) and a human tau transgene with the Thy 1.2 promoter (Taconic, Germantown, NY, Lewis, et al., Nat Genet. 25:402-405 (2000)). These mice have a slower course of neurodegeneration. These mice develop neurofibrillary tangles in several brain regions and spinal cord, which is incorporated herein by reference in its entirety. This is an excellent model for studying the consequences of tangle development and for screening therapeutics that can inhibit the generation of these aggregates. Another advantage of these animals is the relatively early onset of pathology. In homozygous strains, tau pathology and associated behavioral abnormalities can be observed as early as 3 months, but these animals remain relatively healthy until at least 8 months of age. That is, at 8 months of age, these animals are able to walk around, feed themselves, and perform behavioral tasks well enough to allow monitoring of treatment effects. Active immunization of these mice with AI wI KLH-PHF-1 for 6-13 months resulted in titers of approximately 1,000, fewer neurofibrillary tangles, less pSer422, and reduced weight loss compared to untreated control mice.
[0449] The activity of the antibody or active agent can be evaluated by various criteria, including reduction in the amount of total tau or phosphorylated tau, reduction in other pathological features such as amyloid deposits of Aβ, and suppression or delay of behavioral defects. Active immunogens can also be tested for induction of antibodies in serum. Both passive and active immunogens can be tested for passage of antibodies through the blood-brain barrier into the brain of transgenic animals. Antibodies or antibody-inducing fragments can also be tested in non-human primates that naturally or through induction develop symptoms of a disease characterized by tau. Testing of the antibody or active agent is typically performed simultaneously with a control experiment that is performed in parallel except that the antibody or active agent is not present (e.g., replaced by vehicle). The reduction, delay or suppression of signs or symptoms of the disease caused by the antibody or active agent under test can then be evaluated compared to the control.
[0450] V. Patients to be Treated The presence of neurofibrillary tangles has been found in several diseases, including Alzheimer's disease, Down's syndrome, mild cognitive impairment, primary age-related tauopathy, postencephalitic parkinsonism, posttraumatic dementia or dementia pugilistica, Pick's disease, Niemann-Pick type C, supranuclear palsy, frontotemporal dementia, frontotemporal lobar degeneration, argyrophilic grain disease, globular glial cell tauopathy, Guam amyotrophic lateral sclerosis / parkinsonism dementia complex, corticobasal degeneration (CBD), Lewy body dementia, Lewy body variant of Alzheimer's disease (LBVAD), and progressive supranuclear palsy (PSP). The present regimen can also be used to treat or prevent any of these diseases. Due to the widespread relationship between neurological diseases and conditions and tau, the present regimen can be used to treat or prevent any subject that exhibits elevated levels of tau or phosphorylated tau (e.g., in CSF) compared to the average value of individuals without neurological disease. The regimen can also be used to treat or prevent neurological disorders in individuals who have a tau mutation associated with the neurological disorder. The method is particularly suited to treating or preventing Alzheimer's disease, and in particular in patients.
[0451] Patients eligible for treatment include individuals at risk for the disease but who do not show symptoms and those who currently show symptoms. Patients at risk for the disease include those with a known genetic risk for the disease. Such individuals include those who have relatives who have experienced the disease and those whose risk has been determined by analysis of genetic or biochemical markers. Genetic markers of risk include tau mutations, such as those mentioned above, as well as mutations in other genes associated with neurological diseases. For example, homozygous as well as heterozygous ApoE4 alleles are associated with risk of Alzheimer's disease. Other markers of risk for Alzheimer's disease include mutations in the APP gene, particularly at position 717 and at positions 670 and 671, known as the Hardy and Swedish mutations, mutations in PS1 and PS2 of the presenilin genes, family history of AD, hypercholesterolemia, or atherosclerosis. Individuals currently suffering from Alzheimer's disease can be recognized by PET imaging due to the characteristic dementia and the presence of the risk factors mentioned above. In addition, several diagnostic tests are available to identify individuals with AD. These include measuring CSF tau or phosphorylated tau and Aβ42 levels. Elevated levels of tau or phosphorylated tau and decreased levels of Aβ42 indicate the presence of AD. Several mutations are associated with Parkinson's disease. Mutations in other genes, such as Ala30Pro or Ala53, or PARK8, a leucine-rich repeat kinase, are associated with Parkinson's disease. Individuals may also be diagnosed with any of the above-mentioned neurological disorders by DSM IV TR criteria.
[0452] In asymptomatic patients, treatment can begin at any age (e.g., 10, 20, 30). However, typically, it is not necessary to begin treatment until the patient reaches 40, 50, 60, or 70 years of age. Treatment typically requires multiple doses over a period of time. Treatment can be monitored by assaying antibody levels over time. If the response drops, booster doses are required. In cases of potential Down's syndrome patients, treatment can begin prenatally by administering a therapeutic agent to the mother or immediately after birth.
[0453] I. Nucleic acids The present invention provides nucleic acids encoding any of the above heavy and light chains (e.g., SEQ ID NO: 7-8, 47-48, 49-50, 51-52, 53-54, 55, 59). For example, SEQ ID NO: 9 encodes the amino acid sequence of SEQ ID NO: 47 of the murine 5G8 heavy chain variable region, and SEQ ID NO: 10 encodes the amino acid sequence of SEQ ID NO: 48 of the murine 5G8 light chain variable region. Optionally, such nucleic acids can further encode a signal peptide and express the signal peptide linked to the constant region. The coding sequence of the nucleic acid can be operably linked to regulatory sequences to ensure expression of the coding sequence, such as promoters, enhancers, ribosome binding sites, transcription termination signals, etc. The nucleic acids encoding the heavy and light chains can occur in isolated form or can be inserted into one or more vectors. The nucleic acids can be synthesized, for example, by solid phase synthesis or PCR of overlapping oligonucleotides. The nucleic acids encoding the heavy and light chains can be linked, for example, as one contiguous nucleic acid in an expression vector, or can be inserted separately, for example, into their own expression vectors.
[0454] J. Conjugated Antibodies Conjugated antibodies that specifically bind to an antigen such as tau can be used to detect the presence of tau; monitor and evaluate the efficacy of therapeutic agents used to treat patients diagnosed with Alzheimer's disease, Down's syndrome, mild cognitive impairment, primary age-related tauopathy, postencephalitic parkinsonism, post-traumatic dementia or dementia pugilistica, Pick's disease, Niemann-Pick type C, supranuclear palsy, frontotemporal dementia, frontotemporal lobar degeneration, argyrophilic grain disease, globular glial cell tauopathy, amyotrophic lateral sclerosis / parkinsonism dementia complex of Guam, corticobasal degeneration (CBD), dementia with Lewy bodies, Lewy body variant of Alzheimer's disease (LBVAD), or progressive supranuclear palsy (PSP); Inhibiting or reducing tau aggregation; inhibiting or reducing tau fibril formation; reducing or eliminating tau deposits; stabilizing a non-toxic conformation of tau; or treating or preventing Alzheimer's disease, Down's syndrome, mild cognitive impairment, primary age-related tauopathy, postencephalitic parkinsonism, post-traumatic dementia or dementia pugilistica, Pick's disease, Niemann-Pick type C, supranuclear palsy, frontotemporal dementia, frontotemporal lobar degeneration, argyrophilic grain disease, globular glial cell tauopathy, amyotrophic lateral sclerosis / parkinsonism dementia complex of Guam, corticobasal degeneration (CBD), dementia with Lewy bodies, Lewy body variant of Alzheimer's disease (LBVAD), or progressive supranuclear palsy (PSP) in a patient. For example, such antibodies can be conjugated to other therapeutic moieties, other proteins, other antibodies, and / or detectable labels. See WO 03 / 057838, US 8,455,622. Such therapeutic moieties may be any agent that can be used to treat, combat, ameliorate, prevent, or ameliorate an undesirable condition or disease in a patient, such as Alzheimer's disease, Down's syndrome, mild cognitive impairment, primary age-related tauopathy, postencephalitic parkinsonism, post-traumatic dementia or dementia pugilistica, Pick's disease, Niemann-Pick type C, supranuclear palsy, frontotemporal dementia, frontotemporal lobar degeneration, argyrophilic grain disease, globular glial cell tauopathy, amyotrophic lateral sclerosis / parkinsonism dementia complex of Guam, corticobasal degeneration (CBD), dementia with Lewy bodies, Lewy body variant of Alzheimer's disease (LBVAD), or progressive supranuclear palsy (PSP).
[0455] The conjugated therapeutic moiety may include a cytotoxic drug, a cytostatic drug, a neurodifferentiator, a neuroprotectant, a radiotherapeutic drug, an immunomodulatory agent, or any bioactive agent that promotes or enhances the activity of the antibody. A cytotoxic drug may be any agent that is toxic to cells. A cytotoxic drug may be any agent that inhibits cell proliferation. A neurodifferentiator may be any agent, including chemical or proteinaceous agents, that promotes neuronal maintenance, proliferation, or differentiation. A neuroprotectant may be an agent, including chemical or proteinaceous agents, that protects neurons from acute insults or degenerative processes. An immunomodulator may be any agent that stimulates or suppresses the development or maintenance of an immune response. A radiotherapeutic drug may be any molecule or compound that emits radiation. When such a therapeutic moiety is conjugated to a tau-specific antibody, such as the antibodies described herein, the conjugated therapeutic moiety will have a specific affinity for cells affected by a tau-related disease over normal cells. Thus, administration of the conjugated antibody directly targets cancer cells with minimal damage to the surrounding healthy tissue. This may be particularly useful when the therapeutic moieties are too toxic to be administered alone. Additionally, smaller amounts of the therapeutic agent moiety can be used.
[0456] Some such antibodies can be modified to act as immunotoxins. See, e.g., U.S. Patent No. 5,194,594. For example, ricin, a plant-derived cytotoxin, can be conjugated to antibodies using the bifunctional reagents S-acetylmercaptosuccinic anhydride for the antibody and succinimidyl 3-(2-pyridyldithio)propionate for the ricin. See Pietersz et al., Cancer Res. 48(16):4469-4476 (1998). Conjugation reduces the B-chain binding activity of ricin, but does not destroy either the toxic potential of the A-chain of ricin or the activity of the antibody. Similarly, saporin, an inhibitor of ribosome assembly, can be conjugated to antibodies via disulfide bonds between chemically inserted sulfhydryl groups. See Polito et al., Leukemia 18:1215-1222 (2004).
[0457] Some such antibodies can be linked to a radioisotope. Examples of radioisotopes include, for example, yttrium. 90 (90Y) Indium 111 (111In), 131 I, 99 mTc, radioactive silver-111, radioactive silver-199, and bismuth 213 , and the like. Linking of radioisotopes to antibodies can be performed with conventional bifunctional chelates. For linking radioactive silver-111 and radioactive silver-199, sulfur-based linkers can be used. See Hazra et al., Cell Biophys. 24-25:1-7 (1994). Linking of silver radioisotopes may require reduction of the immunoglobulin with ascorbic acid. For radioisotopes such as 111In and 90Y, ibritumomab tiuxetan can be used, which reacts with such isotopes to form 111In-ibritumomab tiuxetan and 90Y-ibritumomab tiuxetan, respectively. See Witzig, Cancer Chemother. Pharmacol., 48 Suppl 1:S91-S95 (2001).
[0458] Some such antibodies can be linked to other therapeutic moieties. Such therapeutic moieties can be, for example, cytotoxic, cytostatic, neurotrophic, or neuroprotective. For example, the antibodies can be linked to toxic chemotherapeutic agents such as tubulin inhibitors, such as maytansine, geldanamycin, tubulin binding agents (e.g., auristatins), or minor groove binding agents, such as calicheamicin. Other representative therapeutic moieties include agents known to be useful in treating, managing, or ameliorating a patient's condition including Alzheimer's disease, Down's syndrome, mild cognitive impairment, primary age-related tauopathy, post-encephalitic parkinsonism, post-traumatic dementia or dementia pugilistica, Pick's disease, Niemann-Pick type C, supranuclear palsy, frontotemporal dementia, frontotemporal lobar degeneration, argyrophilic grain disease, globular glial cell tauopathy, amyotrophic lateral sclerosis / parkinsonism dementia complex of Guam, corticobasal degeneration (CBD), dementia with Lewy bodies, Lewy body variant of Alzheimer's disease (LBVAD), or progressive supranuclear palsy (PSP).
[0459] Antibodies can also be conjugated to other proteins. For example, antibodies can be conjugated to finomers. Fynomers are small binding proteins (e.g., 7 kDa) derived from the SH3 domain of the human oncogene Fyn. They can be stable and soluble, and may lack cysteine residues and disulfide bonds. Fynomers can be genetically engineered to bind target molecules with the same affinity and specificity as antibodies. They are suitable for generating antibody-based multispecific fusion proteins. For example, finomers can be fused to the N-terminus and / or C-terminus of antibodies to generate bi- or trispecific FynomAbs with different structures. Fynomers can be selected through screening techniques using FACS, Biacore, and cell-based assays, which allow efficient selection of finomers with optimal properties against finomer libraries. Examples of finomers are disclosed in Grabulovski et al., J. Biol. Chem. 282:3196-3204 (2007); Bertschinger et al., Protein Eng. Des. Sel. 20:57-68 (2007); Schlatter et al., MAbs. 4:497-508 (2011); Banner et al., Acta. Crystallogr. D. Biol. Crystallogr. 69(Pt6):1124-1137 (2013); and Brack et al., Mol. Cancer Ther. 13:2030-2039 (2014).
[0460] The antibodies disclosed herein can also be bound or conjugated to one or more other antibodies (e.g., to form an antibody heteroconjugate). Such other antibodies can bind to a different epitope within tau or can bind to a different target antigen.
[0461] The antibody can also be conjugated to a detectable label. Such an antibody can be used to assess the efficacy of, for example, the diagnosis and / or treatment of Alzheimer's disease, Down's syndrome, mild cognitive impairment, primary age-related tauopathy, postencephalitic parkinsonism, posttraumatic dementia or dementia pugilistica, Pick's disease, Niemann-Pick type C disease, supranuclear palsy, frontotemporal dementia, frontotemporal lobar degeneration, argyrophilic grain disease, globular glial cell tauopathy, amyotrophic lateral sclerosis / parkinsonism dementia complex of Guam, corticobasal degeneration (CBD), dementia with Lewy bodies, Lewy body variant of Alzheimer's disease (LBVAD), or progressive supranuclear palsy (PSP). Such antibodies are particularly useful for making such determinations in subjects with or susceptible to Alzheimer's disease, Down's syndrome, mild cognitive impairment, primary age-related tauopathy, post-encephalitic parkinsonism, post-traumatic dementia or dementia pugilistica, Pick's disease, Niemann-Pick type C, supranuclear palsy, frontotemporal dementia, frontotemporal lobar degeneration, argyrophilic grain disease, globular glial cell tauopathy, amyotrophic lateral sclerosis / parkinsonism dementia complex of Guam, corticobasal degeneration (CBD), dementia with Lewy bodies, Lewy body variant of Alzheimer's disease (LBVAD), or progressive supranuclear palsy (PSP), or in suitable biological samples obtained from such subjects. Representative detectable labels which can be bound or linked to an antibody include various enzymes, such as horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; prosthetic groups such as streptavidin / biotin and avidin / biotin; fluorescent materials, such as umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride, or phycoerythrin; luminescent materials, such as luminol; bioluminescent materials, such as luciferase, luciferin, and aequorin; radioactive silver-111, radioactive silver-199, bismuth, etc. 213 , iodine ( 131 I, 125 I, 123 I, 121 I), Carbon ( 14 C), sulfur ( 5 S), tritium ( 3 H), Indium (115 In, 113 In, 112 In, 111 In), Technetium ( 99 Tc), thallium ( 201 Tl), Gallium ( 68 Ga, 67 Ga), palladium ( 103 Pd), Molybdenum ( 99 Mo), Xenon ( 133 Xe), fluorine ( 18 F), 153 Sm, 177 Lu, 159 Gd, 149 Pm, 140 La, 175 Yb, 166 Ho, 90 Y, 47 Sc, 186 Re, 188 Re, 142 Pr, 105 Rh, 97 Ru, 68 Ge, 57 Co, 65 Zn, 85 Sr, 32 P, 153 Gd, 169 Yb, 51 Cr, 54 Mn, 75 Se, 113 Sn, and 117 These include radioactive materials such as Tin; positron emitting metals using various positron emission tomography techniques; non-radioactive paramagnetic metal ions; and molecules that are radiolabeled or conjugated to specific radioisotopes.
[0462] Linking of radioisotopes to antibodies can be performed with conventional bifunctional chelates. For linking radioactive silver-111 and radioactive silver-199, sulfur-based linkers can be used. See Hazra et al., Cell Biophys. 24-25:1-7 (1994). Linking of silver radioisotopes may require reduction of the immunoglobulin with ascorbic acid. For radioisotopes such as 111In and 90Y, ibritumomab tiuxetan can be used, which reacts with such isotopes to form 111In-ibritumomab tiuxetan and 90Y-ibritumomab tiuxetan, respectively. See Witzig, Cancer Chemother. Pharmacol., 48 Suppl 1:S91-S95 (2001).
[0463] Therapeutic drug moieties, other proteins, other antibodies, and / or detectable labels can be attached or conjugated directly or indirectly through an intermediary (eg, a linker) to an antibody of the invention. For example, Arnon et al., "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy," in Monoclonal Antibodies Cancer Therapy, Reisfeld et al. (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom et al., "Antibodies For Drug Delivery," in Controlled Drug Delivery (2nd Ed.), Robinson et al. (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review," in Monoclonal Antibodies 84: Biological Clinical Applications, Pinchera et al. (eds.), pp. 475-506 (1985); "Analysis, Results, Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy," in Monoclonal Antibodies For Cancer Detection Therapy, Baldwin et al. (eds.), pp. 303-16 (Academic Press 1985); and Thorpe et al., Immunol. Rev., 62:119-58 (1982). Suitable linkers include, for example, cleavable and non-cleavable linkers.Different linkers can be used that release the attached therapeutic drug moiety, protein, antibody, and / or detectable label upon exposure to specific proteases under acidic or reducing conditions, or under other defined conditions.
[0464] VI. Pharmaceutical Compositions and Methods of Use In preventive applications, the antibody or agent for inducing the antibody or pharmaceutical composition thereof is administered to a patient susceptible to or at risk of a disease (e.g., Alzheimer's disease) in a regimen (dosage, frequency and route of administration) effective to reduce the risk of the disease, reduce the severity of the disease, or delay the onset of at least one sign or symptom of the disease. In particular, the regimen is preferably effective to inhibit or delay tau or phosphorylated tau and filament pairs formed therefrom in the brain, and / or inhibit or delay its toxic effects, and / or inhibit or delay the onset of behavioral deficits. In therapeutic applications, the antibody or agent for inducing the antibody is administered to a patient suspected of or already suffering from a disease (e.g., Alzheimer's disease) in a regimen (dosage, frequency and route of administration) effective to improve or at least inhibit further deterioration of at least one sign or symptom of the disease. In particular, the regime is preferably effective to reduce or at least inhibit further increases in the levels of tau, phosphorylated tau, or filament pairs formed therefrom, and associated toxicity and / or behavioral impairment.
[0465] A regimen is considered to be effective for treatment or prophylaxis if each treated patient achieves a better outcome than the average outcome in a control population of comparable patients not treated by the methods of the invention, or if a controlled clinical trial (e.g., a Phase II, Phase II / III or Phase III trial) demonstrates a better outcome for treated patients versus control patients at a level of p<0.05 or 0.01, or even 0.001.
[0466] The effective dose will vary depending on many different factors, including the means of administration, the target site, the physiological condition of the patient, whether the patient is an ApoE carrier, whether the patient is a human or an animal, whether other agents are administered, and whether the treatment is prophylactic or therapeutic.
[0467] Exemplary dosage ranges for the antibody are about 0.01-60 mg / kg, or about 0.1-3 mg / kg, or 0.15-2 mg / kg, or 0.15-1.5 mg / kg of patient body weight. The antibody can be administered at such dosages daily, every other day, weekly, biweekly, monthly, quarterly, or according to any other schedule determined by empirical analysis. Exemplary treatments entail administration in multiple doses over an extended period of time, e.g., for at least six months. Further exemplary treatment regimes entail administration every two weeks, or once a month, or once every three to six months.
[0468] The amount of drug for active administration varies from 0.1 to 500 μg per patient, more commonly 1 to 100 or 1 to 10 μg per injection for administration to humans. The timing of injections can vary widely from once a day to once a year to once every decade. A typical regime consists of immunization followed by booster injections at time intervals such as 6 week intervals or 2 months. Another regime consists of immunization followed by booster injections 1, 2 and 12 months later. Another regime involves injections every 2 months for the life of the patient. Alternatively, booster injections can be irregular as indicated by monitoring the immune response.
[0469] The antibody or agent for inducing the antibody is preferably administered via a peripheral route (i.e., a route by which the administered or induced antibody crosses the blood-brain barrier and reaches the intended site in the brain). Routes of administration include topical, intravenous, oral, subcutaneous, intra-arterial, intracranial, intrathecal, intraperitoneal, intranasal, intraocular or intramuscular administration. Preferred routes of administration for antibodies are intravenous and subcutaneous. Preferred routes for active immunization are subcutaneous and intramuscular. This type of injection is most typically given in the arm or leg muscles. In some methods, the agent is injected directly into the specific tissue where the deposits have accumulated, e.g., intracranially.
[0470] Pharmaceutical compositions for parenteral administration are preferably sterile, substantially isotonic and manufactured under GMP conditions. Pharmaceutical compositions may be provided in unit dosage form (i.e., dosages for single administration). Pharmaceutical compositions may be formulated with one or more physiologically acceptable carriers, diluents, excipients or adjuvants. The formulation depends on the route of administration selected. For injection, the antibody may be formulated in an aqueous solution, preferably in a physiologically compatible buffer such as Hank's solution, Ringer's solution, or physiological saline or acetate buffer (to reduce discomfort at the injection site). The solution may contain formulatory agents such as suspending, stabilizing and / or dispersing agents. Alternatively, the antibody may be in lyophilized form for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water, before use.
[0471] The regimen may be administered in combination with another agent effective in the treatment or prevention of the disease being treated. For example, in the case of Alzheimer's disease, the regimen may be combined with immunotherapy against Aβ (WO / 2000 / 072880), cholinesterase inhibitors or memantine, or in the case of immunotherapy for Parkinson's disease, with immunotherapy against α-synuclein (WO / 2008 / 103472), levodopa, dopamine agonists, COMT inhibitors, MAO-B inhibitors, amantadine, or anticholinergics.
[0472] The antibody is administered in an effective regimen, which refers to a dosing plan including a dosage, route of administration, and frequency of administration that delays onset, reduces severity, inhibits further deterioration, and / or ameliorates at least one sign or symptom of the disorder being treated. If the patient is already suffering from the disorder, the regimen may also be referred to as a therapeutically effective regimen. If the patient is at high risk for the disorder compared to the general population, but is not yet symptomatic, the regimen may also be referred to as a prophylactically effective regimen. In some cases, therapeutic or prophylactic efficacy may be observed in an individual patient against historical controls or past experience of the same patient. In other cases, therapeutic or prophylactic efficacy may be demonstrated during preclinical or clinical trials of a treated patient population compared to a control population of untreated patients.
[0473] Exemplary dosages of the antibody are 0.1-60 mg / kg (e.g., 0.5, 3, 10, 30, or 60 mg / kg), or 0.5-5 mg / kg body weight (e.g., 0.5, 1, 2, 3, 4, or 5 mg / kg), or as a fixed dose, 10-4000 mg or 10-1500 mg. The dosage will depend, among other things, on the condition of the patient and their response to previous treatment, if any, whether the treatment is prophylactic or therapeutic, and whether the disorder is acute or chronic.
[0474] Administration can be parenteral, topical, intravenous, oral, subcutaneous, intraarterial, intracranial, intrathecal, intraperitoneal, intranasal, or intramuscular. Some antibodies can be administered intravenously or subcutaneously into the systemic circulation. Intravenous administration can be, for example, by infusion over 30-90 minutes.
[0475] The frequency of administration depends, inter alia, on the half-life of the antibody in circulation, the condition of the patient, and the route of administration. The frequency can be daily, weekly, monthly, quarterly, or at irregular intervals, depending on the change in the patient's condition or the progression of the disorder being treated. An exemplary frequency for intravenous administration is weekly to quarterly, depending on the cause of the treatment, although more or less frequent administration is possible. For subcutaneous administration, an exemplary frequency of administration is daily to monthly, although more or less frequent administration is possible.
[0476] The number of doses depends on whether the disorder is acute or chronic and the response of the disorder to treatment. For acute disorders or acute exacerbations of chronic disorders, often 1 to 10 doses. Sometimes, for acute disorders or acute exacerbations of chronic disorders, a single rapid dose, optionally in divided form, is sufficient. For recurrence of acute disorders or acute exacerbations, treatment may be repeated. For chronic disorders, the antibody may be administered at regular intervals, for example, weekly, biweekly, monthly, every 3 months, every 6 months, for at least 1, 5 or 10 years, or for the life of the patient.
[0477] A. Diagnostic and Monitoring Methods In vivo imaging, diagnostic methods, and optimized immunotherapy The present invention provides a method for in vivo imaging of tau protein deposits (e.g., neurofibrillary tangles and tau inclusions) in a patient. The method works by administering to the patient an agent, such as an antibody that binds to tau (e.g., murine, humanized, chimeric or veneered 5G8, 6A10, 8A4, or 7G6 antibody), and then detecting the agent bound to tau. Clearing responses of the administered antibody can be avoided or reduced by using antibody fragments that lack the full-length constant region, such as Fab. In some methods, the same antibody can function as both a treatment and a diagnostic reagent.
[0478] The diagnostic reagent can be administered by intravenous injection into the patient's body, or directly into the brain by intracranial injection or by drilling a hole in the skull. The dosage of the reagent should be in the same range as for the treatment method. Typically, the reagent is labeled, but in some methods, the primary reagent with affinity for tau is not labeled and a secondary labeling agent is used to bind to the primary reagent. The choice of label depends on the means of detection. For example, fluorescent labels are suitable for optical detection. The use of paramagnetic labels is suitable for tomographic detection without surgical intervention. Radioactive labels can also be detected using positron emission tomography (PET) or single photon emission computed tomography (SPECT).
[0479] The method of in vivo imaging of tau protein deposits is useful for diagnosing or confirming the diagnosis of tauopathies such as Alzheimer's disease, frontotemporal lobar degeneration, progressive supranuclear palsy and Pick's disease, or susceptibility to such diseases. For example, the method can be used in patients who show symptoms of dementia. If the patient has abnormal neurofibrillary tangles, the patient may have Alzheimer's disease. Alternatively, if the patient has abnormal tau inclusions, depending on the location of the inclusions, the patient may have frontotemporal lobar degeneration. The method can also be used in asymptomatic patients. The presence of abnormal tau protein deposits indicates a future susceptibility to symptomatic disease. The method is also useful for monitoring disease progression and / or response to treatment in patients previously diagnosed with a tau-related disease.
[0480] Diagnosis can be made by comparing the number, size, and / or intensity of the labeled loci with the corresponding baseline value. The baseline value can represent the average level in a population of non-disease individuals. The baseline value can also represent a previous level determined in the same patient. For example, the patient's baseline value can be measured before starting tau immunotherapy treatment, and the measured value can then be compared to the baseline value. A decrease in the value relative to the baseline signal indicates a positive response to the treatment.
[0481] In some patients, the diagnosis of a tauopathy may be aided by performing a PET scan, which may be performed, for example, using conventional PET imaging equipment and ancillary equipment. The scan typically includes one or more regions of the brain commonly known to be associated with tau protein deposits, and one or more regions where few, if any, deposits are typically present to serve as controls.
[0482] The signals detected in a PET scan can be represented as a multi-dimensional image. A multi-dimensional image can represent a cross-section of the brain in two dimensions, a three-dimensional brain in three dimensions, or a four-dimensional brain change over time. A color scale can be performed using different colors to indicate different amounts of label and putative tau protein deposits detected. The results of the scan can also be presented numerically in a number that correlates with the amount of label and, consequently, the amount of tau protein deposits detected. The label present in brain regions known to be associated with deposits of a particular tauopathy (e.g., Alzheimer's disease) can be compared to the label present in regions not known to be associated with deposits to provide a ratio that represents the extent of deposits in the former region. Such ratios for the same radiolabeled ligand provide a comparable measure of tau protein deposits and their changes between different patients.
[0483] In some methods, a PET scan is performed simultaneously with an MRI or CAT scan or at the same patient visit as an MRI or CAT scan. An MRI or CAT scan provides more anatomical detail of the brain than a PET scan. However, images from a PET scan can be overlaid onto the MRI or CAT scan images to more accurately show the location of the PET ligand and putative tau deposits relative to anatomical structures in the brain. Some devices can perform both a PET scan and an MRI or CAT scan of a patient without the patient changing position between scans, facilitating overlay of the images.
[0484] Suitable PET ligands include radiolabeled antibodies of the invention (e.g., murine, humanized, chimeric or veneered 5G8, 6A10, 8A4, or 7G6 antibodies). The radioisotopes used can be, for example, C 11 , N 13 , O 15 , F 18 , or I 123 The interval between administering the PET ligand and performing the scan may depend on the PET ligand, particularly its rate of uptake and clearance from the brain, and the half-life of its radiolabel.
[0485] PET scans can also be performed as a preventative measure in asymptomatic patients or in patients who have symptoms of mild cognitive impairment but have not been diagnosed with a tauopathy, yet are at high risk of developing a tauopathy. In asymptomatic patients, scans are particularly useful for individuals who are considered at high risk for tauopathy due to family history, genetic or biochemical risk factors, or advanced age. Preventative scans can begin in patients between the ages of 45 and 75, for example. In some patients, the first scan is performed at age 50.
[0486] Preventive scans may be performed, for example, at intervals of 6 months to 10 years, preferably 1 to 5 years. In some patients, preventive scans are performed annually. If a PET scan performed as a preventive measure shows abnormally high levels of tau protein deposits, immunotherapy may be initiated and then a PET scan may be initiated as in patients diagnosed with tauopathy. If a PET scan performed as a preventive measure shows levels of tau protein deposits within normal levels, further PET scans may be performed at intervals of 6 months to 10 years, preferably 1 to 5 years, as described above, or in response to the appearance of signs and symptoms of tauopathy or mild cognitive impairment. If above-normal levels of tau protein deposits are detected, by combining preventative scanning with administration of tau-targeted immunotherapy, the levels of tau protein deposits can be reduced to or closer to normal levels, or at least prevented from increasing further, and the patient can remain free of tauopathy for a longer period of time (e.g., at least 5, 10, 15 or 20 years, or for the remainder of the patient's life) than if the patient had not received preventative scanning and tau-targeted immunotherapy.
[0487] Normal levels of tau protein deposits may be determined by the amount of neurofibrillary tangles or tau inclusions in the brain of a representative sample of individuals from a population (e.g., a representative sample of disease-free individuals under the age of 50) who have not been diagnosed with a particular tauopathy (e.g., Alzheimer's disease) and are not considered at high risk for developing such a disease. Alternatively, normal levels may be recognized in an individual patient if the PET signal by the methods of the invention in brain regions where tau protein deposits are known to occur does not differ (within the precision of the measurement) from signals from brain regions where such deposits are known to normally occur. Elevated levels in an individual may be recognized by comparison with normal levels (e.g., levels outside the mean + standard deviation variance) or simply from elevated signals beyond experimental error in brain regions associated with tau protein deposits compared to regions not known to be associated with deposits. For purposes of comparing levels of tau protein deposits in individuals and populations, tau protein deposits should preferably be determined in the same region(s) of the brain, including at least one region known to form tau protein deposits associated with a particular tauopathy (e.g., Alzheimer's disease). Patients with elevated levels of tau protein deposits are candidates for initiating immunotherapy.
[0488] A reduction in the level of tau protein deposits after immunotherapy is initiated can initially be seen as an indication that the treatment is having the desired effect. The observed reduction can be, for example, within the range of 1-100%, 1-50%, or 1-25% of baseline values. Such effects can be measured in one or more areas of the brain known to form deposits, or can be measured from the average of such areas. The overall effect of the treatment can be estimated by adding the percentage reduction relative to baseline to the increase in tau protein deposits that would occur in the average untreated patient in the absence of treatment.
[0489] Maintenance of a near constant level of tau deposits or even a small increase in tau deposits may be indicative of a response to treatment, albeit a suboptimal response, which can be compared to the time course of tau deposit levels in untreated patients with a particular tauopathy (e.g., Alzheimer's disease) to determine whether immunotherapy is effective in inhibiting further increases in tau deposits.
[0490] Monitoring changes in tau protein deposits allows for adjustments of immunotherapy or other treatment regimes in response to the treatment. PET monitoring provides an indication of the nature and extent of the response to the treatment. It can then be determined whether or not treatment adjustments should be made, and if necessary, the treatment can be adjusted in response to the PET monitoring. Thus, PET monitoring allows for adjustments of tau-targeted immunotherapy or other treatment regimes before other biomarkers, MRI, or cognitive measures respond detectably. A significant change means that comparing the value of the parameter after treatment to the baseline provides evidence that the treatment has or has not produced a beneficial effect. In some cases, evidence that the treatment has or has not produced a beneficial effect is provided by changes in the value of the parameter in the patient himself. In other examples, the change in value in the patient is compared to the change in value, if any, in a representative control population of patients not receiving immunotherapy. The difference between the response of a particular patient and the normal response of control patients (e.g., the variance of the mean plus standard deviation) can also provide evidence that the immunotherapy regime has or has not achieved a beneficial effect in the patient.
[0491] In some patients, monitoring shows a detectable reduction in tau protein deposits, but levels of tau protein deposits remain above normal, and such patients can continue the treatment regimen at the same dosing frequency and / or dose in the absence of unacceptable side effects, or at an increased dosing frequency and / or dose if not at the maximum recommended dose.
[0492] If monitoring indicates that the levels of tau protein deposits in the patient have been reduced to normal or near normal, the immunotherapy regimen can be adjusted from an induction regimen (i.e., a regimen that reduces the levels of tau protein deposits) to a maintenance regimen (i.e., a regimen that maintains tau protein deposits at a near constant level). Such a regimen can be accomplished by reducing the dose and / or frequency of administration of the immunotherapy.
[0493] In other patients, monitoring may show that the immunotherapy has some beneficial effect, but suboptimally. Optimal effect may be defined as the percentage reduction in the level of tau protein deposits within the upper half or quartile of change in tau protein deposits (measured or calculated over the whole brain or representative area(s) where tau protein deposits are known to form) of a representative sample of tauopathy patients receiving immunotherapy at a given time point after the start of treatment. Patients whose tau protein deposits have a small decrease, or whose tau protein deposits remain constant, or whose tau protein deposits increase, but to a lesser extent than would be expected in the absence of immunotherapy (e.g., when extrapolated from a control group of patients not receiving immunotherapy) may be classified as patients experiencing a positive, but suboptimal, response. Such patients may be optionally treated with an adjustment of the regimen to increase the dose and / or frequency of administration of the drug.
[0494] In some patients, tau protein deposits may increase similarly to or exceed those in patients not receiving immunotherapy. If such an increase continues over a period of time, such as 18 months or 2 years, even after the frequency or dosage of the drug has been increased, immunotherapy may be discontinued in favor of other treatments, if necessary.
[0495] The foregoing discussion of diagnosing, monitoring, and adjusting treatment for tauopathies has focused primarily on the use of PET scanning, however, any other technique for visualizing and / or measuring tau protein deposits that is amenable to the use of the tau antibodies of the invention (e.g., murine, humanized, chimeric or veneered 5G8, 6A10, 8A4, or 7G6 antibodies) can be used in place of PET scanning to carry out such methods.
[0496] Also provided is a method for detecting immune responses against tau in patients suffering from or susceptible to tau-related diseases. This method can be used to monitor the course of therapeutic and prophylactic treatment with the agents provided herein. The antibody profile after passive immunization typically shows an immediate peak in antibody concentration followed by an exponential decay. Without further administration, the decay approaches pre-treatment levels within a period of several days to several months, depending on the half-life of the administered multipore body. For example, the half-life of some human antibodies is on the order of 20 days.
[0497] In some methods, a baseline measurement of the subject's antibody against tau is taken before administration, a second measurement is taken shortly thereafter to measure the peak level of the antibody, and one or more additional measurements are taken at intervals to monitor the decay of the antibody level. When the antibody level falls to a predetermined percentage (50%, 25% or 10%) of the baseline or baseline-subtracted peak, an additional dose of the antibody is administered. In some methods, the peak or background-subtracted subsequent measured levels are compared to a predetermined reference level to generate a beneficial prophylactic or therapeutic treatment regime for other subjects. If the measured antibody level is significantly lower than the reference level (e.g., less than the mean minus one standard deviation, preferably two standard deviations, of the reference value of the subject population that would benefit from treatment), an additional dose of the antibody is required.
[0498] Also provided is a method for detecting tau in a subject, for example by measuring tau in a sample from the subject or by in vivo imaging of tau in the subject. Such methods are useful for diagnosing or confirming a diagnosis of a tau-related disease or susceptibility thereto. The methods can also be used in asymptomatic subjects. The presence of tau indicates a future susceptibility to symptomatic disease. The methods are also useful for monitoring disease progression and / or response to treatment in subjects who have previously been diagnosed with Alzheimer's disease, Down's syndrome, mild cognitive impairment, primary age-related tauopathy, post-encephalitic parkinsonism, post-traumatic dementia or dementia pugilistica, Pick's disease, Niemann-Pick type C, supranuclear palsy, frontotemporal dementia, frontotemporal lobar degeneration, argyrophilic grain disease, globular glial cell tauopathy, amyotrophic lateral sclerosis / parkinsonism dementia complex of Guam, corticobasal degeneration (CBD), dementia with Lewy bodies, Lewy body variant of Alzheimer's disease (LBVAD), or progressive supranuclear palsy (PSP).
[0499] Biological samples obtained from subjects with, suspected of, or at risk of having Alzheimer's disease, Down's syndrome, mild cognitive impairment, primary age-related tauopathy, postencephalitic parkinsonism, posttraumatic dementia or dementia pugilistica, Pick's disease, Niemann-Pick type C, supranuclear palsy, frontotemporal dementia, frontotemporal lobar degeneration, argyrophilic grain disease, globular glial cell tauopathy, Guam amyotrophic lateral sclerosis / parkinsonism dementia complex, corticobasal degeneration (CBD), Lewy body dementia, Lewy body variant of Alzheimer's disease (LBVAD), or progressive supranuclear palsy (PSP) can be contacted with the antibody disclosed herein to assess the presence of tau. For example, the level of tau in such subjects can be compared to the level of tau present in healthy subjects. Alternatively, the tau levels of such subjects undergoing treatment for a disease can be compared with the tau levels of subjects who have not been treated for Alzheimer's disease, Down's syndrome, mild cognitive impairment, primary age-related tauopathy, postencephalitic parkinsonism, posttraumatic dementia or dementia pugilistica, Pick's disease, Niemann-Pick type C disease, supranuclear palsy, frontotemporal dementia, frontotemporal lobar degeneration, argyrophilic grain disease, globular glial cell tauopathy, Guam amyotrophic lateral sclerosis / parkinsonism dementia complex, corticobasal degeneration (CBD), Lewy body dementia, Lewy body variant of Alzheimer's disease (LBVAD), or progressive supranuclear palsy (PSP). Some such tests require tissue biopsies from such subjects. ELISA assays can also be a useful method for evaluating tau in, for example, fluid samples.
[0500] VII. Kits The invention further provides kits (e.g., containers), which contain the antibodies and related items disclosed herein, such as instructions for use (e.g., package inserts). The instructions can include, for example, instructions for administration of the antibody and, optionally, one or more additional agents. The containers of antibody can be unit doses, bulk packages (e.g., multi-dose packages), or sub-unit doses.
[0501] Package insert means instructions customarily included in commercial packages of therapeutic agents that contain information about the indications, uses, dosage, administration, contraindications and / or warnings concerning the use of such therapeutic agents.
[0502] The kit may also contain a second container containing a pharma- ceutically acceptable buffer, such as sterile water for injection (BWFI), phosphate-buffered saline, Ringer's solution, and dextrose solution. The kit may also include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.
[0503] VIII. Other Uses For clinical diagnosis or treatment or research, the antibodies can be used to detect tau or fragments thereof. For example, the antibodies can be used to detect the presence of tau in a biological sample as an indication that the biological sample contains tau deposits. The binding of the antibody to the biological sample can be compared to the binding of the antibody to a control sample. The control sample and the biological sample may contain cells of the same tissue origin. The control sample and the biological sample can be obtained from the same individual or different individuals, at the same time or at different times. If necessary, multiple biological samples and multiple control samples are evaluated at multiple times to protect against random variations unrelated to differences between samples. A direct comparison is then made between the biological sample(s) and the control sample(s) to determine whether the antibody binding (i.e., the presence of tau) to the biological sample(s) is increased, decreased, or the same as the antibody binding to the control sample(s). An increase in the binding of the antibody to the biological sample(s) compared to the binding to the control sample(s) indicates the presence of tau in the biological sample(s). In some cases, the increase in antibody binding is statistically significant. Optionally, antibody binding to the biological sample is at least 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, or 100-fold greater than antibody binding to a control sample.
[0504] Additionally, the antibodies can be used to detect the presence of tau in biological samples to monitor and evaluate the effectiveness of therapeutic agents being used to treat patients diagnosed with Alzheimer's disease, Down's syndrome, mild cognitive impairment, primary age-related tauopathy, post-encephalitic parkinsonism, post-traumatic dementia or dementia pugilistica, Pick's disease, Niemann-Pick type C, supranuclear palsy, frontotemporal dementia, frontotemporal lobar degeneration, argyrophilic grain disease, globular glial cell tauopathy, amyotrophic lateral sclerosis / parkinsonism dementia complex of Guam, corticobasal degeneration (CBD), dementia with Lewy bodies, Lewy body variant of Alzheimer's disease (LBVAD), or progressive supranuclear palsy (PSP). A biological sample from a patient diagnosed with Alzheimer's disease, Down's syndrome, mild cognitive impairment, primary age-related tauopathy, postencephalitic parkinsonism, posttraumatic dementia or dementia pugilistica, Pick's disease, Niemann-Pick type C, supranuclear palsy, frontotemporal dementia, frontotemporal lobar degeneration, argyrophilic grain disease, globular glial cell tauopathy, Guam amyotrophic lateral sclerosis / parkinsonism dementia complex, corticobasal degeneration (CBD), Lewy body dementia, Lewy body variant of Alzheimer's disease (LBVAD), or progressive supranuclear palsy (PSP) is evaluated to establish a baseline of antibody binding to the sample (i.e., a baseline for the presence of tau in the sample) before starting treatment with the therapeutic agent. In some cases, multiple biological samples from the patient are evaluated at multiple times to establish both a baseline and a criterion for random fluctuations unrelated to treatment. The therapeutic agent is then administered according to the regimen. The regimen may include multiple administrations of the agent over a period of time. Optionally, antibody binding (i.e., the presence of tau) is assessed in multiple biological samples at multiple time points to establish a baseline for random variation and indicate a trend toward response to immunotherapy. Multiple comparative assessments of antibody binding to the biological samples are then performed. If only two assessments are performed, a direct assessment is made between the two assessments to determine whether antibody binding (i.e., the presence of tau) increases, decreases, or remains the same between the two assessments. If three or more measurements are made, the measurements can be analyzed as a time course beginning before treatment with the therapeutic agent and as a time course progressing through the course of treatment.If antibody binding (i.e., the presence of tau) to the biological sample is reduced in the patient, it can be concluded that the therapeutic agent is effective in treating the patient's Alzheimer's disease, Down's syndrome, mild cognitive impairment, primary age-related tauopathy, postencephalitic parkinsonism, post-traumatic dementia or dementia pugilistica, Pick's disease, Niemann-Pick type C, supranuclear palsy, frontotemporal dementia, frontotemporal lobar degeneration, argyrophilic grain disease, globular glial cell tauopathy, amyotrophic lateral sclerosis / parkinsonism dementia complex of Guam, corticobasal degeneration (CBD), dementia with Lewy bodies, Lewy body variant of Alzheimer's disease (LBVAD), or progressive supranuclear palsy (PSP). The reduction in antibody binding is statistically significant. Optionally, binding is reduced by at least 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%. Assessment of counter-binding can be performed in conjunction with assessment of signs and symptoms of Alzheimer's disease, Down's syndrome, mild cognitive impairment, primary age-related tauopathy, post-encephalitic parkinsonism, post-traumatic dementia or dementia pugilistica, Pick's disease, Niemann-Pick type C, supranuclear palsy, frontotemporal dementia, frontotemporal lobar degeneration, argyrophilic grain disease, globular cell tauopathy, amyotrophic lateral sclerosis / parkinsonism dementia complex of Guam, corticobasal degeneration (CBD), dementia with Lewy bodies, Lewy body variant of Alzheimer's disease (LBVAD), or progressive supranuclear palsy (PSP).
[0505] Antibodies can also be used as research reagents for studies detecting tau or its fragments. For such applications, the antibodies can be labeled with fluorescent molecules, spin-labeled molecules, enzymes, radioisotopes, and provided in kit form with all the reagents necessary to perform the detection method. Antibodies can also be used to purify tau or binding partners of tau, for example, by affinity chromatography.
[0506] All patent applications, websites, other publications, accession numbers, etc. cited above or below are incorporated by reference in their entirety in this application to the same extent as if each individual item was specifically and individually indicated to be incorporated by reference. Where different versions of a sequence are associated with accession numbers at different times, it is meant the version associated with the accession number at the effective filing date of this application. The effective filing date means a date earlier than the actual filing date or, if applicable, the filing date of the priority application for the accession number. Similarly, where different versions of a publication, website, etc. were published at different times, it means the most recently published version at the effective filing date of the application, unless otherwise indicated. Any feature, step, element, embodiment, or aspect of the present invention can be used in combination with any other, unless otherwise indicated. Although the present invention has been described in some detail by way of illustration and example for purposes of clarity and understanding, it will be apparent that certain changes and modifications can be practiced within the scope of the appended claims. EXAMPLES
[0507] Example 1: Identification of tau monoclonal antibodies Monoclonal antibodies against tau were generated as follows: Immunization was performed with either recombinant 383 aa human tau (4R0N) with an N-terminal His tag and P301S mutation (Immunogen A) or recombinant 383 aa human tau (4R0N) with the P301S mutation lacking the N-terminal His tag (Immunogen B). Immunogens were emulsified in RIBI adjuvant.
[0508] Five-week-old female Balb / c mice were immunized intraperitoneally with 25 μg of immunogen A on day 0 and 10 μg of immunogen A on days 7, 14, 21, 27, 34, 48, 55, and 62, respectively. Mice were immunized with 10 μg of immunogen B on days 76 and 90. Mice were bled on days 43 and 98 and titers against immunogen A were measured. On day 101, animals with the highest titers were boosted with a final immunization of 50 μg of immunogen B (1 / 2 given intraperitoneally and 1 / 2 given intravenously). Fusion hybridomas were screened by ELISA against both immunogens.
[0509] Example 2: Mouse monoclonal antibodies bind to tau in ELISA assays
[0510] Method: Indirect ELISA 96-well polystyrene plates were coated with capture antibodies anti-6xHis (Figure 1A) or polyclonal anti-tau (Dako #A0024, Figure 1B) suspended in 1xPBS for 2 hours at room temperature or 16 hours at 4°C. The coating solution was removed and the plates were blocked with 1% BSA in 1xPBS for 1 hour and then incubated with human recombinant tau with (Figure 1A) or without (Figure 1B) a polyhistidine tag at the N-terminus of the protein. After washing, the plates were incubated with the indicated antibodies, washed and incubated with HRP-conjugated goat anti-mouse secondary antibody. The plates were developed with TMB and the A450 was measured on a plate reader.
[0511] Sandwich ELISA 96-well polystyrene plates were coated with anti-mouse antibodies in 1xPBS for 2 hours at room temperature or 16 hours at 4°C. The coating solution was removed and the plates were blocked with 1% BSA in 1xPBS for 1 hour. The plates were then incubated with the indicated antibodies at the same concentrations, diluted in 0.1% BSA in 1xPBS. The plates were treated sequentially with human tau, polyclonal rabbit anti-tau (Dako#A0024), and HRP-labeled goat anti-rabbit antibodies, all diluted in 0.1% BSA in PBS with washing between each step. Streptavidin-HRP was added, the plates were developed with TMB, and the A450 was measured on a plate reader. See Figure 1C.
[0512] result A panel of hybridoma-produced antibodies was assayed for binding to tau using several different ELISA formats. Detection of tau was confirmed using an indirect format, with tau protein immobilized by a polyhistidine tag fused to the N-terminus of tau (Figure 1A). Native, untagged protein was also confirmed (Figure 1B). To assess the solution affinity of the various antibodies, a sandwich ELISA format was used, with the hybridoma antibodies tested as capture reagents (Figure 1C).
[0513] Example 3: Affinity of mouse monoclonal antibodies to tau
[0514] method SPR analysis was performed using a Biacore T200 to measure the binding kinetics of murine antibodies to recombinant human tau. To prepare the sensor surface, anti-mouse antibodies (GE Life Sciences) were immobilized on a sensor chip CM5 via amine coupling and the antibody was captured at a level ensuring maximum binding of 50 RU. Various concentrations of recombinant tau ranging from 10 to 0.14 nM were passed over the captured ligand at a flow rate of 50 μL / min in running buffer (HBS + 0.05% P-20, 1 mg / ml BSA) for 180 s of binding and 900 s of dissociation. Data were double-referenced against both an unrelated sensor without antibody ligand and 0 nM analyte concentration to capture dissociation of the ligand from the captured molecule. Data were then analyzed using a global 1:1 fit.
[0515] result Several murine antibodies were selected based on their performance in a series of ELISA assays, and their binding affinities were assessed by SPR. Antibodies were tested in parallel sets, and their binding and dissociation rates were measured. The binding affinities are shown in Figure 2.
[0516] Example 4: Mouse monoclonal antibodies block binding of human tau to the surface of immortalized neuronal cells
[0517] method Inhibition of tau binding to B103 neuroblastoma cells by anti-tau monoclonal antibodies. 1. 5x10 B103 cells 5 Resuspend at 100 cells / mL. Seed 50 μL of cell suspension per well in MSD high binding plates. This will give 25K cells / well. Cover plates and allow cells to attach for 2 hours at 37° C., 5% CO2. 2. After cell attachment, remove PBS from wells by inverting the plate and gently tapping to remove excess buffer. Add 50 μl of 3% MSD Blocker A in PBS or other suitable blocking buffer to each well and incubate the plate for 1 hour at room temperature without shaking. 3. During the plate blocking step, tau and anti-tau antibodies are co-incubated as follows. a. Start with 2 mg / ml anti-tau antibody and perform 7 additional dilutions by serial 1:2 dilution in PBS. b. Tau is diluted to 20 nM in PBS, so that the tau concentration is constant in each well. c. Tau and anti-tau antibody are mixed 1:1 for a final tau concentration of 10 nM and a starting concentration of anti-tau of 1 mg / ml. d. The mixture is incubated at room temperature with shaking (600 rpm) for approximately 1 hour. 4. After blocking the plate in step 2, invert the plate to remove the blocking buffer from the wells, gently tap, then wash the plate twice with PBS using a multichannel pipette. Be sure to completely remove excess buffer. Chill the seeded cells to 4°C before adding tau (anti-tau complex). 5. Add 50 μL of chilled complex from step 3 to the plated cells and incubate on ice for 30 minutes. 6. Wash the plate twice with cold PBS as described above. 7. For detection of cell surface bound tau, add 50 μL of 16B5.SULFO-TAG per well. Incubate on ice for 30 minutes. 8. Wash the plates again twice with cold PBS as described above. 9. Add 150 μL of 1X detergent-free Read Buffer T (diluted in HO) per well and incubate in the MSD SECTOR TM Read immediately on the 600 counter. Avoid introducing air bubbles when adding the read buffer. 10. Report the MSD signal vs. Tau concentration.
[0518] Antibodies tested included the anti-tau antibodies 3D6, 16G7, 3H9, 4C5, and 5G8, as well as isotype controls.
[0519] result
[0520] A decrease in SulfoTag anti-tau signal with increasing test antibody indicates functional blocking of tau binding to the neuronal cell surface. No blocking was observed with isotype control, 16G7, or 3H9. Increased functional blocking activity was observed with 4C5, 5G8, and 3D6. See Figure 3.
[0521] Example 5: 3D6 and 5G8 immunocapture tau from human diseased tissue. method High-salt soluble protein fractions were prepared at 1 mg / ml. For each immunoprecipitation, 200 μg of sample was used. 10 μg of the indicated antibody (isotype control, anti-tau antibody 3D6, or 5G8) was added to the high-salt sample preparation and incubated for 2 h. Protein G magnetic beads were then added to the mixture and incubated for an additional 1 h to capture the antibody / antigen complex. Samples were washed thoroughly with 1xPBS, and the beads were boiled in reducing / denaturing sample buffer to release the captured proteins. The resulting samples were separated by SDS-PAGE and Western blotting was performed using a polyclonal anti-tau antibody (Dako, #A0024).
[0522] result As shown in Figure 4, the anti-tau antibodies 3D6 and 5G8 immunoprecipitated tau from Alzheimer's disease tissue. The high salt soluble fraction was immunoprecipitated with the indicated antibodies and detected with a polyclonal anti-tau antibody against a region of the tau molecule distinct from the binding sites of 3D6 and 5G8. Both 5G8 and 3D6 captured tau from this fraction. The input (high salt soluble sample) is shown on the right.
[0523] Example 6: Design of humanized 5G8
[0524] The murine antibody 5G8 was the starting point or donor antibody for humanization. The heavy chain variable amino acid sequence of mature m5G8 is SEQ ID NO: 9. The light chain variable amino acid sequence of mature m5G8 is SEQ ID NO: 10. The heavy chain Kabat / Chothia combined CDR1, CDR2, and CDR3 amino acid sequences are SEQ ID NOs: 11-13, respectively. The light chain Kabat CDR1, CDR2, and CDR3 amino acid sequences are SEQ ID NOs: 14-16, respectively. Kabat numbering is used throughout.
[0525] The CDRs of 5G8 VH and VL were identified using Martin's sequence-based CDR identification rules (Martin ACR. (2010). In: Kontermann R Dubel S (eds). Antibody Engineering. Heidelberg, Germany: Springer International Publishing AG.). The variable kappa (Vk) of the 5G8 antibody belongs to mouse Vk subgroup 2, which corresponds to human Vk subgroup 2, and the variable heavy chain (Vh) belongs to mouse VH subgroup 2c, which corresponds to human VH subgroup 1 [Kabat EA, et al., (1991), Sequences of Proteins of Immunological Interest, Fifth Edition. NIH Publication No. 91-3242]. The 16 residue Kabat CDR-L1 of Vk is similar to Chothia canonical class 4, the 7 residue Kabat CDR-L2 is of Chothia canonical class 1, and the 9 residue Kabat CDR-L3 is similar to Chothia canonical class 1 [Martin AC and Thornton JM (1996) J. Mol. Biol. 263:800-15.]. The 10 residue Kabat / Chothia combined CDR-H1 is similar to Chothia canonical class 1, and the 17 residue Kabat / Chothia combined CDR-H2 is similar to Chothia canonical class 2 [Martin & Thornton, 1996]. The Kabat / Chothia combined CDR-H3 has no canonical class.
[0526] The 5G8 VH and VL sequences were used to query the BioLuminate software (Schrodinger, LLC; Zhu K, et al., (2014) Proteins. 82(8):1646-1655) curated antibody database for proteins with similar amino acid sequences and known structures. The structure of the highly similar murine anti-prion antibody 3F4 (PDB ID: 1CR9; 1CR9_H; SEQ ID NO:27 and 1CR9_L; SEQ ID NO:30), discovered by Kascsak et al. ((1987) J Virol. 61(12):3688-93) and sequenced by Kanyo et al. ((1999). J Mol Biol. 293(4):855-63), at 2.9 Å resolution, was selected as a template to build a model of 5G8 in BioLuminate. Further interrogation of the BioLuminate database of human-derived antibodies revealed that the frameworks of 5G8 VH and VL share a high degree of sequence similarity with the corresponding regions of the VH and VL regions of the humanized anti-dabigatran Fab aDabi-Fab2b (VH accession no. 4YHM_H; VL accession no. 4YHM_L) designed by Schiele et al. ((2015) MAbs. 7(5):871-80). The variable domains of 5G8 and aDabi-Fab2b also have the same lengths of the CDR-H1, H2, L1, L2, and L3 loops. Therefore, the framework regions of aDabi-Fab2b VH (acc. no. 4YHM_H; SEQ ID NO: 28) and VL (acc. no. 4YHM_L; SEQ ID NO: 31) were selected as acceptor sequences for the CDRs of 5G8.
[0527] The heavy and light chain variant sequences resulting from the antibody humanization process were further aligned to human germline sequences and the humanness of the heavy and light chains was assessed using the IMGT Domain GapAlign tool as outlined in the WHO INN Committee guidelines (WHO-INN: International nonproprietary names (INN) for biological biotechnological substances (a review) (Internet) 2014., available at http: / / www.who.int / medicines / services / inn / BioRev2014.pdf). Where possible, residues were changed to match the corresponding human germline sequences to increase humanness. For the humanized VL_v5 and VL_v6 variants, mutations were introduced to make the sequence more similar to the human germline gene IGKV2-29 (acc. No. A2NJV5.2; SEQ ID NO: 32). For the humanized VH_v7 and VH_v8 variants, mutations were introduced to make the sequence more similar to the human germline gene IGHV1-46 (acc. No. P01743.2; SEQ ID NO: 29).
[0528] The amino acid sequences consisting of the aDabi-Fab2b framework and 5G8 CDRs are designated hu5G8-VH_v1 and hu5G8-VL_v1. Additional versions of hu5G8-VH and hu5G8-VL were designed to allow evaluation of various framework residues for their contribution to antigen binding and immunogenicity. Positions considered for mutation include the following: Define the canonical CDR structure (overview in Martin 2010). Within the Vernier zone (Foote J Winter G. (1992) Antibody framework residues affecting the conformation of the hypervariable loops. J Mol Biol. 224(2):487-99). - Localized at the VH / VL domain interface (reviewed in Leger OJP Saldanha J. (2000) Preparation of recombinant antibodies from immune rodent spleens the design of their humanization by CDR grafting. In: Shepherd P Dean C (eds). Monoclonal Antibodies: a Practical Approach. Oxford, UK: Oxford University Press). · Susceptible to post-translational modifications such as glycosylation and pyroglutamination. A model of the 5G8 CDRs grafted onto the aDabi-Fab2b framework positions residues predicted to clash with the CDRs. A rare residue is placed in the sequenced human antibody where the parental murine 5G8 residue or some other residue is much more prevalent.
[0529] Eight humanized heavy chain variable region variants and six humanized light chain variable region variants were constructed to contain different substitutions. Eight exemplary humanized mature heavy chain variable regions: hu5G8-VH_v1, hu5G8-VH_v2, hu5G8-VH_v3, hu5G8-VH_v4, hu5G8-VH_v5, hu5G8-VH_v6, hu5G8-VH_v7, and hu5G8-VH_v8 (SEQ ID NOs: 33-40, respectively), and hu5G8-VL_v1, hu5G8-VL_v2, hu5G8-VL_v3, hu5G8-VL_v4, hu5G8-VL_v5, and hu5G8-VL_v6 (SEQ ID NOs: 41-46, respectively) (Tables 4 and 3). Exemplary humanized Vk and Vh designs with back mutations and other mutations based on selected human frameworks are shown in Tables 6 and 7, respectively. Bolded regions in Tables 6 and 7 indicate the CDRs defined in the Kabat / Chothia combination. The "." in the columns of Table 6 for hu5G8-VL_v2, hu5G8-VL_v3, hu5G8-VL_v4, hu5G8-VL_v5, and hu5G8-VL_v6 indicates that the amino acid at the indicated position is the same as that in hu5G8-VL_v1. In the columns of Table 7, "." for hu5G8-VH_v2, hu5G8-VH_v3, hu5G8-VH_v4, hu5G8-VH_v5, hu5G8-VH_v6, hu5G8-VH_v7, and hu5G8-VH_v8 indicates that the amino acid at the indicated position is the same as that of hu5G8-VH_v1. In the columns of Tables 6 and 7, "-" indicates that there is no residue at the indicated position. In Table 8, SEQ ID NOs: 33-40 and 41-46 include back mutations and other mutations. The amino acid positions of hu5G8-VH_v1, hu5G8-VH_v2, hu5G8-VH_v3, hu5G8-VH_v4, hu5G8-VH_v5, hu5G8-VH_v6, hu5G8-VH_v7, and hu5G8-VH_v8 are shown in Table 9. The amino acid positions of hu5G8-VL_v1, hu5G8-VL_v2, hu5G8-VL_v3, hu5G8-VL_v4, hu5G8-VL_v5, and hu5G8-VL_v6 are shown in Table 10.The humanness ratios of the humanized VH chains hu5G8-VH_v1, hu5G8-VH_v2, hu5G8-VH_v3, hu5G8-VH_v4, hu5G8-VH_v5, hu5G8-VH_v6, hu5G8-VH_v7, and hu5G8-VH_v8 (SEQ ID NOs: 33-40, respectively) for the most similar human germline gene IGHV1-46, and the humanized VL chains hu5G8-VL_v1, hu5G8-VL_v2, hu5G8-VL_v3, hu5G8-VL_v4, hu5G8-VL_v5, and hu5G8-VL_v6 (SEQ ID NOs: 41-46, respectively) for the most similar human germline gene IGKV2-29 are shown in Table 11. [Table 6-1] [Table 6-2] [Table 6-3] [Table 6-4] [Table 6-5] [Table 6-6] [Table 6-7] [Table 7-1] [Table 7-2] [Table 7-3] [Table 7-4] [Table 7-5] [Table 7-6] [Table 7-7] [Table 7-8] [Table 8-1] [Table 8-2] [Table 9] [Table 10] [Table 11]
[0530] Chothia class canonical, Vernier, or interface / packing residue positions that differ between the mouse and human acceptor sequences are candidates for substitution. Examples of Chothia class canonical residues include Kabat residues L2, L27B, L27C, L34, L94, H29, H71, and H94 of Tables 3 and 4. Examples of Vernier residues include Kabat residues L2, L36, L46, H27, H28, H29, H30, H48, H71, H78, H93, and H94 of Tables 3 and 4. Examples of interface / packing (VH+VL) residues include Kabat residues L34, L36, L46, L89, L91, H93, and H95 of Tables 3 and 4.
[0531] The rationale for selecting the positions shown in Table 6 in the light chain variable region as candidates for substitution is as follows.
[0532] L2(I2V) is a backmutation of the canonical and vernier residues.
[0533] L7(T2S) is a mutation from a rare residue (T) to the most common residue (S) in humans at this position.
[0534] L17 (Q17E) is a mutation from a rare residue (Q) to the most common residue (E) in humans at this position.
[0535] L36 (Y36L) is a backmutation of a Vernier interface residue.
[0536] L45 (K45Q) is a mutation to the germline IGKV2-29 residue.
[0537] L46 (G46R) is a backmutation of a Vernier and interface residue.
[0538] L70 (G70D) is a reversion mutation to the germline IGKV2-29 residue, D, which is commonly seen in humans at this position.
[0539] The rationale for the humanized variants shown in Table 6 of the light chain variable region is as follows.
[0540] Hu5G8-VL_v1 consists of the CDR-L1, L2, and L3 loops of 5G8-VL grafted onto the aDabi-Fab2b-VL framework.
[0541] Hu5G8-VL_v2 reverts all framework substitutions at positions that are part of the keys for defining the Chothia canonical class, part of the Vernier zone, or located at the VH / VL domain interface. Kabat position 2 defines the Chothia canonical structure of CDR-L1. Kabat positions 2, 36, and 46 are part of the Vernier zone. Kabat positions 36 and 46 also localize to the VH / VL interface. hu5G8-VL_v2 incorporates the I2V, Y36L, and L46R back mutations, allowing the contribution of these positions to antigen binding affinity and immunogenicity to be evaluated.
[0542] Hu5G8-VL_v3 is identical to hu5G8-VL-v2, and additionally reverts all framework substitutions at positions where the parental murine 5G8-VL amino acids are more prevalent in sequenced human antibodies compared to the aDabi-Fab2b-VL residues. At Kabat position 70, the 5G8-VL residue is more prevalent in human antibodies than the aDabi-Fab2b-VL residue. Hu5G8-VL_v3 incorporates the back mutation G70D, which restores the parental 5G8-VL framework residue while simultaneously increasing the humanness of the sequence.
[0543] Hu5G8-VL_v4 is the same as hu5G8-VL-v3, but additionally incorporates substitutions at framework positions that are the most common residues in sequenced human antibodies that are absent in aDabi-Fab2b-VL and 5G8-VL. The most common residue at Kabat position 7 is S, which is absent in aDabi-Fab2b-VL (T) or 5G8-VL (T). Additionally, the most common residue at Kabat position 17 is E, which is absent in aDabi-Fab2b-VL (Q) or 5G8-VL (Q). Hu5G8-VL_v4 incorporates the T7S and Q17E mutations to increase the humanness of the sequence.
[0544] Hu5G8-VL_v5 consists of the CDR-L1, L2, and L3 loops of 5G8-VL grafted onto the aDabi-Fab2b-VL framework as hu5G8-VL_v1, and further incorporates framework mutations that provide a sequence more similar to certain human immunoglobulin kappa variable germline genes. The aDabi-Fab2b-VL framework, and thus that of hu5G8-VL_v1, shares a high degree of sequence similarity with the human germline gene IGKV2-29, with differences at Kabat positions 45 and 70. Hu5G8-VL_v5 includes the mutations K45Q and G70D as another strategy to increase the humanness of the sequence.
[0545] Hu5G8-VL_v6 contains the mutations of hu5G8-VL-v5 and further incorporates the mutations introduced in hu5G8-VL-v2, i.e., reverting all framework substitutions at positions located in the keys for defining the Chothia canonical class, in part of the Vernier zone, or at the VH / VL domain interface (back mutations I2V, Y36L, and L46R).
[0546] The rationale for selecting the positions shown in Table 7 in the heavy chain variable region as candidates for substitution is as follows.
[0547] H1(Q1E) is a reversion mutation, a stability-enhancing mutation that reduces the likelihood of pyroglutamate formation (Liu, 2011, supra).
[0548] H11(V11L) is a reversion mutation; L is commonly seen in humans at this position.
[0549] H12(K12V) is a reversion mutation. V is commonly seen in humans at this position.
[0550] H19(K19R) is a reversion mutation; R is common in humans at this position.
[0551] H20(V20L) is a reversion mutation; L is commonly seen in humans at this position.
[0552] H23 (K23A) is a mutation to the residue commonly found in humans at this position.
[0553] H46 (E46D) is a conservative mutation. E46 is predicted to clash with K62 in CDR-H2.
[0554] H48 (M48I) is a reversion mutation in the Vernier zone. I is common in humans at this position.
[0555] H66 (K66R) is a mutation to an IGHV1-46 germline residue. K is rare in humans at this position. R is the most common at this position.
[0556] H67 (A67V) is a mutation to an IGHV1-46 germline residue. A is rare in humans at this position. V is the most common at this position.
[0557] H71 (R71S) is a backmutation of the canonical and vernier residues.
[0558] H76 (S76N) is a reversion mutation; N is commonly seen in humans at this position.
[0559] H78 (A78V) is a mutation to an IGHV1-46 germline residue.
[0560] H80(M80L) is a reversion mutation; L is commonly seen in humans at this position.
[0561] H93 (T93S or T93A) T93S is a back mutation at the Vernier and interface residue. T93A is a mutation to an IGHV1-46 germline residue. T and S are rare at this position in humans. A is the most common at this position in humans.
[0562] H94 (I94P or I94R) I94P is a back mutation of the canonical and vernier residues. I94R is a mutation to the IGHV1-46 germline residue. I and P are rare in humans at this position. P is the most common at this position in humans.
[0563] The rationale for the humanized variants shown in Table 7 of the heavy chain variable region is as follows.
[0564] Hu5G8-VH_v1 consists of the CDR-H1, H2, and H3 loops of 5G8-VH grafted onto the aDabi-Fab2b-VH framework.
[0565] Hu5G8-VH_v2 reverts all framework substitutions at positions that are keys for defining the Chothia canonical class, part of the Vernier zone, or located at the VH / VL domain interface. Kabat positions 71 and 94 define the Chothia canonical structures of CDR-H2 and CDR-H1, respectively. Kabat positions 48, 71, 93, and 94 are part of the Vernier zone. Kabat position 93 also localizes to the VH / VL domain interface. Hu5G8-VH_v2 incorporates the following back mutations: M48I, R71S, T93S, and I94P, allowing the evaluation of the contribution of these positions to antigen binding affinity and immunogenicity.
[0566] Hu5G8-VH_v3 contains the back mutation of hu5G8-VH-v2 and, in addition, reverts the Kabat framework substitution at position 1. At the N-terminus of proteins, both E and Q are known to spontaneously cyclize to form pyroglutamate. However, the conversion from E occurs more slowly than that from Q (Liu YD, et al., (2011) J Biol Chem. 286(13):11211-7.; Schilling S, et al., (2008) Biol Chem. 389(8):983-91.). Hu5G8-VH-v3 incorporates the back mutation Q1E to reduce pyroglutamination.
[0567] Hu5G8-VH_v4 contains the back mutations of hu5G8-VH-v3 and additionally incorporates mutations in framework residues predicted by BioLuminate to clash with the CDRs. Based on van der Waals interactions, E at Kabat position 46 is predicted to clash with K at Kabat position 62 in CDR-H2. Hu5G8-VH_v4 incorporates the conservative mutation E46D.
[0568] Hu5G8-VH_v5 contains the mutations of hu5G8-VH-v4 and additionally reverts all framework substitutions at positions where the parental murine 5G8-VH amino acids are more prevalent in sequenced human antibodies compared to the aDabi-Fab2b-VH residues. At Kabat positions 11, 12, 19, 20, 76, and 80, the 5G8-VH residues are more prevalent in human antibodies than the aDabi-Fab2b-VH residues. Hu5G8-VH_v5 incorporates V11L, K12V, K19R, V20L, S76N, and M80L back mutations, restoring the parental 5G8-VH framework residues while enhancing the humanness of the sequence.
[0569] Hu5G8-VH_v6 contains the mutations of hu5G8-VH-v5 and further incorporates substitutions at framework positions that are the most common residues in sequenced human antibodies that are absent in aDabi-Fab2b-VH and 5G8-VH. The most common residue at Kabat position 23 is A, which is absent in aDabi-Fab2b-VH (K) or 5G8-VH (T). Hu5G8-VH_v6 incorporates the mutation K23A to increase the humanness of the sequence. In hu5G8-VH_v6, the following Kabat positions are not mutated to the most common residues because they are within or near the interface or Vernier zone: Position 66: R is the most common. aDabi-Fab2b-VH (K) and 5G8-VH (K), Position 67: V is the most common. aDabi-Fab2b-VH (A) and 5G8-VH (A), Position 93:A is the most common. aDabi-Fab2b-VH (T) and 5G8-VH (S), and Position 94: R is most common. aDabi-Fab2b-VH (I) and 5G8-VH (P).
[0570] Hu5G8-VH_v7 is composed of the CDR-H1, H2, and H3 loops of 5G8-VH grafted onto the aDabi-Fab2b-VH framework as hu5G8-VH_v1, and further incorporates framework mutations that provide a sequence more similar to certain human immunoglobulin variable heavy chain germline genes. The aDabi-Fab2b-VH framework, and thus that of hu5G8-VH_v1, shares a high degree of sequence similarity with the human germline gene IGHV1-46, with differences at Kabat positions 66, 67, 78, 93, and 94. Hu5G8-VH_v7 includes the mutations K66R, A67V, A78V, T93A, and I94R as another strategy to increase the humanness of the sequence.
[0571] Hu5G8-VH_v8 contains the mutations of hu5G8-VH-v7 and further incorporates the mutations introduced in hu5G8-VH-v2, 3, and 4. reverting all framework substitutions in the key for defining the Chothia canonical class, in parts of the Vernier zone, or at positions located at the VH / VL domain interface (reversion mutations M48I, R71S, A93S, and R94P), Reversing the Kabat framework substitution at position 1 to reduce pyroglutamination (reversion mutation Q1E), and -Incorporates a mutation in a framework residue predicted by BioLuminate to clash with the CDRs (conservative mutation E46D).
[0572] Humanized sequences are generated using the QuikChange site-directed mutagenesis method (Wang, W. Malcolm, BA (1999) BioTechniques 26:680-682), using a two-step PCR protocol that allows for the introduction of multiple mutations, deletions, and insertions.
[0573] Heavy chain variable region > 5G8-VH (SEQ ID NO: 7) EVQLQQSGAELVRSGASVRLSCTASGFNIKDYYMHWVRQRPEQGLEWIGWIDPENGDTVYAPKFQGKATMTSDTSSNTAYLHLSSLTSEDTAVYYCSPLDFWGQGTTLTVSS
[0574] >3F4-VH Accession No. 1CR9_H (SEQ ID NO: 27) KVKLQQSGAELVRSGASVKLSCTASGFNIKDYYIQWVKQRPEQGLEWIGWIDPENGNSEYAPRFQGKATMTADTLSNTAYLQLSSLTSEDTAVYYCNADLHDYWGQGTTLTVSS
[0575] >aDabi-Fab2b-VH Accession No. 4YHM_H (SEQ ID NO: 28) QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYMHWVRQAPGQGLEWMGETNPRNGGTTYNEKFKGKATMTRDTSTSTAYMELSSLRSEDTAVYYCTIGTSGYDYFDYWGQGTLVTVSS
[0576] >IGHV1-46 Accession No. P01743.2 (SEQ ID NO:29) QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCAR
[0577] > hu5G8-VH_v1 (SEQ ID NO: 33) QVQLVQSGAEVKKPGASVKVSCKASGFNIKDYYMHWVRQAPGQGLEWMGWIDPENGDTVYAPKFQGKATMTRDTSTSTAYMELSSLRSEDTAVYYCTILDFWGQGTLVTVSS
[0578] > hu5G8-VH_v2 (SEQ ID NO: 34) QVQLVQSGAEVKKPGASVKVSCKASGFNIKDYYMHWVRQAPGQGLEWIGWIDPENGDTVYAPKFQGKATMTSDTSTSTAYMELSSLRSEDTAVYYCSPLDFWGQGTLVTVSS
[0579] > hu5G8-VH_v3 (SEQ ID NO: 35) EVQLVQSGAEVKKPGASVKVSCKASGFNIKDYYMHWVRQAPGQGLEWIGWIDPENGDTVYAPKFQGKATMTSDTSTSTAYMELSSLRSEDTAVYYCSPLDFWGQGTLVTVSS
[0580] > hu5G8-VH_v4 (SEQ ID NO: 36) EVQLVQSGAEVKKPGASVKVSCKASGFNIKDYYMHWVRQAPGQGLDWIGWIDPENGDTVYAPKFQGKATMTSDTSTSTAYMELSSLRSEDTAVYYCSPLDFWGQGTLVTVSS
[0581] > hu5G8-VH_v5 (SEQ ID NO: 37) EVQLVQSGAELVKPGASVRLSCKASGFNIKDYYMHWVRQAPGQGLDWIGWIDPENGDTVYAPKFQGKATMTSDTSTNTAYLELSSLRSEDTAVYYCSPLDFWGQGTLVTVSS
[0582] > hu5G8-VH_v6 (SEQ ID NO: 38) EVQLVQSGAELVKPGASVRLSCAASGFNIKDYYMHWVRQAPGQGLDWIGWIDPENGDTVYAPKFQGKATMTSDTSTNTAYLELSSLRSEDTAVYYCSPLDFWGQGTLVTVSS
[0583] > hu5G8-VH_v7 (SEQ ID NO:39 QVQLVQSGAEVKKPGASVKVSCKASGFNIKDYYMHWVRQAPGQGLEWMGWIDPENGDTVYAPKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARLDFWGQGTLVTVSS
[0584] > hu5G8-VH_v8 (SEQ ID NO: 40) EVQLVQSGAEVKKPGASVKVSCKASGFNIKDYYMHWVRQAPGQGLDWIGWIDPENGDTVYAPKFQGRVTMTSDTSTSTVYMELSSLRSEDTAVYYCSPLDFWGQGTLVTVSS
[0585] Kappa light chain variable region >5G8-VL (SEQ ID NO: 8) DVVMTQTPLTLSVTIGQPASISCKSSQSLLDSDGKTYLNWLLQRPGQSPKRLIYLVSKLDSGVPDRFTGSGSGTDFTLKIRRVEAEDLGVYYCWQGTLFPYTFGGGTKLEIK
[0586] >3F4-VL Accession No. 1CR9_L (SEQ ID NO: 30) DVVMTQTPLSLSVTIGQPASISCKSSQSLLDSDGKTYLIWVFQRPGQSPKRLIFLVSKRDSGVPDRFTGSGSGTDFTLKISRVEAEDVGVYYCWQGTHFPHTVGGGTKLEIA
[0587] >aDabi-Fab2b-VL Accession No. 4YHM_L (SEQ ID NO: 31) DIVMTQTPLSLSVTPGQPASISCRSSQSIVHSDGNIYLEWYLQKPGQSPKLLIYKVSYRFSGVPDRFSGSGSGTGFTLKISRVEAEEDVGVYYCFQASHVPYTFGGGTKLEIK
[0588] >IGKV2-29 Accession No. A2NJV5.2 (SEQ ID NO:32) DIVMTQTPLSLSVTPGQPASISCKSSQSLLHSDGKTYLYWYLQKPGQSPQLLIYEVSSRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGIHLP
[0589] > hu5G8-VL_v1 (SEQ ID NO: 41) DIVMTQTPLSLSVTPGQPASISCKSSQSLLDSDGKTYLNWYLQKPGQSPKLLIYLVSKLDSGVPDRFSGSGSGTGFTLKISRVEAEDVGVYYCWQGTLFPYTFGGGTKLEIK
[0590] > hu5G8-VL_v2 (SEQ ID NO: 42) DVVMTQTPLSLSVTPGQPASISCKSSQSLLDSDGKTYLNWLLQKPGQSPKRLIYLVSKLDSGVPDRFSGSGSGTGFTLKISRVEAEDVGVYYCWQGTLFPYTFGGGTKLEIK
[0591] > hu5G8-VL_v3 (SEQ ID NO: 43) DVVMTQTPLSLSVTPGQPASISCKSSQSLLDSDGKTYLNWLLQKPGQSPKRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTLFPYTFGGGTKLEIK
[0592] > hu5G8-VL_v4 (SEQ ID NO: 44) DVVMTQSPLSLSVTPGEPASISCKSSQSLLDSDGKTYLNWLLQKPGQSPKRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTLFPYTFGGGTKLEIK
[0593] > hu5G8-VL_v5 (SEQ ID NO: 45) DIVMTQTPLSLSVTPGQPASISCKSSQSLLDSDGKTYLNWYLQKPGQSPQLLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTLFPYTFGGGTKLEIK
[0594] > hu5G8-VL_v6 (SEQ ID NO: 46) DVVMTQTPLSLSVTPGQPASISCKSSQSLLDSDGKTYLNWLLQKPGQSPQRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTLFPYTFGGGTKLEIK
[0595] <Example 7> Design of humanized 6A10 antibody
[0596] The murine antibody 6A10 was the starting point for humanization of monoclonal antibody 6A10. The heavy chain variable amino acid sequence of mature 6A10 is SEQ ID NO: 63. The light chain variable amino acid sequence of mature 6A10 is SEQ ID NO: 64. The heavy chain Kabat / Chothia combined CDR1, CDR2, and CDR3 amino acid sequences are SEQ ID NOs: 65-67, respectively. The light chain Kabat CDR1, CDR2, and CDR3 amino acid sequences are SEQ ID NOs: 68-70, respectively. Kabat numbering is used throughout.
[0597] The variable kappa (Vk) of the 6A10 antibody belongs to mouse Kabat subgroup 2, which corresponds to human Kabat subgroup 3, and the variable heavy chain (Vh) belongs to mouse Kabat subgroup 2c, which corresponds to human Kabat subgroup 1 [Kabat EA, et al, (1991) Sequences of Proteins of Immunological Interest, Fifth Edition. NIH Publication No. 91-3242.]. The 16-residue CDR-L1 of Vk belongs to canonical class 4, the 7-residue CDR-L2 belongs to class 1, and the 9-residue CDR-L3 belongs to class 1 [Martin AC, and Thornton JM (1996) J. Mol. Biol. 263:800-815.]. The 10 residue CDR-H1 belongs to class 1, and the 17 residue CDR-H2 belongs to class 1 [Martin & Thornton, 1996]. CDR-H3 has no canonical class.
[0598] Residues at the interface between the Vk and Vh domains are commonly found, except for 93T in the heavy chain, which is usually an alanine; therefore, this residue is analyzed as a target for backmutation. Similarly, 36L in Vk is usually Y or F, and 46R is usually L; therefore, these residues are also analyzed for backmutation.
[0599] A protein sequence search was performed in the PDB database [Deshpe N. et al., (2005) Nucleic Acids Res. 33: D233-D237.] to find structures that provide a rough structural model of 6A10. The crystal structure of the antibody fab [pdb code 1CR9; SEQ ID NO: 30] [Kanyo ZF et al., (1999) J. Mol. Biol. 293:855-863.] was used for the Vk structure because it has good resolution (2.0 Å) and overall sequence similarity to 6A10 Vk, and retains the same canonical structure of the loops. The same structure [pdb code 1CR9; SEQ ID NO: 27] was used for the Vh structure because it has good overall sequence similarity and a fairly high resolution (2.0 Å). Furthermore, CDR-H1 and H2 have the same canonical structure as 6A10 Vh. The rough structure of 6A10 was modeled using Bioluminate software, which was licensed from Schrodinger Inc.
[0600] A search of the non-redundant protein sequence database from NCBI allowed the selection of suitable human frameworks into which the murine CDRs were grafted. For Vk, the human kappa light chain variable region with accession number ABC66863 [SEQ ID NO: 83, Shriner, AK, et al., (2016) 24:7159-7166] was selected. It has the same canonical class of CDR-L1 and L2. It is a member of Kabat human kappa subgroup 3. For Vh, the human heavy chain variable region with accession number ACR16112 [SEQ ID NO: 81, Williams, JV et al., (2009) Mol. Immunol. 47:407-414] was selected. It has the same canonical class. It is a member of Kabat human heavy chain subgroup 1.
[0601] Three humanized heavy chain variable region variants and three humanized light chain variable region variants were constructed to contain different substitutions: hu6A10-VH_v1, hu6A10-VH_v2, and hu6A10-VH_v3 (SEQ ID NOs: 85-87, respectively), and hu6A10-VL_v1, hu6A10-VL_v2, and hu6A10-VL_v3 (SEQ ID NOs: 88-90). (Tables 12 and 13). Exemplary humanized VL and VH designs with back mutations and other mutations based on selected human frameworks are shown in Tables 12 and 13, respectively. Bolded regions in Tables 12 and 13 indicate CDRs as defined by the Kabat / Chothia combination. "-" in columns of Tables 12 and 13 indicates no residue at the indicated position. In Table 14, SEQ ID NOs: 85-87 and SEQ ID NOs: 88-90 contain back mutations and other mutations. The amino acid positions of hu6A10-VH_v1, hu6A10-VH_v2, and hu6A10-VH_v3 are shown in Table 15. The amino acid positions of hu6A10-VL_v1, hu6A10-VL_v2, and hu6A10-VL_v3 are shown in Table 16. The humanness ratios of the humanized VH chains hu6A10-VH_v1, hu6A10-VH_v2, and hu6A10-VH_v3 (SEQ ID NO: 85 to 87, respectively) for the most similar human germline gene IGHV1-2*02 (SEQ ID NO: 82), and the humanized VL chains hu6A10-VL_v1, hu6A10-VL_v2, and hu6A10-VL_v3 (SEQ ID NO: 88 to 90, respectively) for the most similar human germline gene IGKV2-30*02 (SEQ ID NO: 84) are shown in Table 17. [Table 12-1] [Table 12-2] [Table 12-3] [Table 12-4] [Table 12-5]
Table 13-1
Table 13-2
Table 13-3
Table 13-4
Table 13-5
Table 13-6
Table 14-1
Table 14-2
Table 15
Table 16
Table 17
[0602] Chothia class canonical, Vernier, or interface / packing residue positions that differ between the mouse and human acceptor sequences are candidates for substitution. Examples of Chothia class canonical residues include Kabat residues H48 and H93 in Tables 12 and 13. Examples of Vernier residues include Kabat residues in Tables 12 and 13. Examples of interface / packing (VH+VL) residues include Kabat residues H35, H37, H39, H45, H47, H91, H93, H95, H103, L34, L36, L38, L44, L46, L87, L89, L91, L96, and L98 in Tables 12 and 13.
[0603] The rationale for selecting the positions shown in Table 12 in the light chain variable region as candidates for substitution is as follows. R46L: an interface residue, usually L. P12S:P is rare in the human framework at this position, while S is common. Q17E: Q is rare in the human framework at this position, E is common.
[0604] Light chain variable region:
[0605] Mature region of m6A10VL amino acid sequence (SEQ ID NO:64) DVVMTQTPLTLSVTIGQPASISCKSSQSLLDSDGKTYLNWLLQRPGQSPKRLIYLVSKLDSGVPDRFTGSGSGTDFTLKISRVEAEDLGVYYCWQGTHFPYTFGGGTKLEIK
[0606] 6A10 VL acceptor accession number ABC66863 (SEQ ID NO:83) DIVMTQSPLSLPVTLGQPASISCRSSQSLVYSDGNTYLNWFQQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHRPLTFGGGTKVEIK
[0607] >3F4-VL Accession No. 1CR9_L (SEQ ID NO: 30) DVVMTQTPLSLSVTIGQPASISCKSSQSLLDSDGKTYLIWVFQRPGQSPKRLIFLVSKRDSGVPDRFTGSGSGTDFTLKISRVEAEDVGVYYCWQGTHFPHTVGGGTKLEIA
[0608] >IGKV2-30*02 (SEQ ID NO:84) DVVMTQSPLSLPVTLGQPASISCRSSQSLVHSDGNTYLNWFQQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPLTFGGGTKVEIK
[0609] >hu6A10-VL_v1 (SEQ ID NO:88) DIVMTQSPLSLPVTLGQPASISCKSSQSLLDSDGKTYLNWFQQRPGQSPRRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEEDVGVYYCFGGGTKVEIK
[0610] >hu6A10-VL_v2 (SEQ ID NO:89) DIVMTQSPLSLPVTLGQPASISCKSSQSLLDSDGKTYLNWFQQRPGQSPRLLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFGGGTKVEIK
[0611] >hu6A10-VL_v3 (SEQ ID NO:90) DIVMTQSPLSLSVTLGEPASISCKSSQSLLDSDGKTYLNWFQQRPGQSPRLLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEEDVGVYYCFGGGTKVEIK
[0612] The rationale for selecting the positions shown in Table 13 in the heavy chain variable region as candidates for substitution is as follows. M48I: a canonical / CDR interacting residue that was backmutated to maintain CDR interactions. A16G:Ala is rare in human frameworks at this position, whereas Gly is common. T69I:Thr is rare in this position, while Ile is common. M80L:Met is common, but Leu is the most common at this position.
[0613] Heavy chain variable region:
[0614] Mature region of m6A10VH amino acid sequence (SEQ ID NO:63) EVQLQQSGAELVRSGASVKLSCTASGLNIKDYYIHWVKQRPEQGLEWIGWIDPENDDTEYAPKFQGRATLTTDTSSNTAYLQLSSLTSEDTAVYYCTPLDYWGQGTSVTVSS
[0615] 6A10 VH acceptor accession number ACR16112 (SEQ ID NO:84) QVQLQESGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGDTNYAQKFQGRVTTTRDTSISTAYMELSRLRSDDTAVYYCARLAARPLDYWGQGTLVTVSS
[0616] >3F4-VH Accession No. 1CR9_H (SEQ ID NO: 27) KVKLQQSGAELVRSGASVKLSCTASGFNIKDYYIQWVKQRPEQGLEWIGWIDPENGNSEYAPRFQGKATMTADTLSNTAYLQLSSLTSEDTAVYYCNADLHDYWGQGTTLTVSS
[0617] > IGHV1-2*02 (SEQ ID NO:82) QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARSRRGYYDFWSGSPEDYWGQGTLVTVSS
[0618] >hu6A10-VH_v1 (SEQ ID NO:85) QVQLQESGAEVKKPGASVKVSCKASGLNIKDYYIHWVRQAPGQGLEWMGWIDPENDDTEYAPKFQGRVTTTRDTSISTAYMELSRLRSDDTAVYYCARLDYWGQGTLVTVSS
[0619] >hu6A10-VH_v2 (SEQ ID NO:86) QVQLQESGAEVKKPGASVKVSCKASGLNIKDYYIHWVRQAPGQGLEWIGWIDPENDDTEYAPKFQGRVTTTRDTSISTAYMELSRLRSDDTAVYYCARLDYWGQGTLVTVSS
[0620] >hu6A10-VH_v3 (SEQ ID NO:87) QVQLQESGAEVKKPGGSVKVSCKASGLNIKDYYIHWVRQAPGQGLEWIGWIDPENDDTEYAPKFQGRVTITRDTSISTAYLELSRLRSDDTAVYYCARLDYWGQGTLVTVSS
[0621] <Example 8> Design of humanized 8A4 antibody
[0622] The murine antibody 8A4 was the starting point for humanization of monoclonal antibody 8A4. The heavy chain variable amino acid sequence of mature 8A4 is SEQ ID NO: 91. The light chain variable amino acid sequence of mature 8A4 is SEQ ID NO: 92. The heavy chain Kabat / Chothia combined CDR1, CDR2, and CDR3 amino acid sequences are SEQ ID NOs: 93-95, respectively. The light chain Kabat CDR1, CDR2, and CDR3 amino acid sequences are SEQ ID NOs: 96-98, respectively. Kabat numbering is used throughout.
[0623] The variable region sequence of 8A4 and the results of Kabat et al. (Kabat EA, Wu TT, Foeller C, Perry HM, Gottesman KS. (1991) Sequences of Proteins of Immunological Interest (5 th Alignment with the consensus sequence of antibody variable regions from the National Institutes of Health (International Edition); Bethesda, MD: National Institutes of Health) indicates that the heavy chain variable region (VH) of 8A4 belongs to mouse VH subgroup 2c, which corresponds to human VH subgroup 1. The kappa light chain variable region (VL) of 8A4 belongs to mouse Vk subgroup 2, which corresponds to human Vk subgroup 2.
[0624] The CDRs of 8A4 VH and VL were identified using Martin's sequence-based CDR identification rules (Martin ACR. (2010) Protein sequence structure analysis of antibody variable domains. In: Kontermann R Dubel S (eds). Antibody Engineering. Heidelberg, Germany: Springer International Publishing AG.). The CDRs were then assigned to Cothia canonical classes using the summary of key residues shown in Martin's Table 3.5. CDR-H1 consists of 10 amino acids and is similar to Cothia canonical class 1. CDR-H2 consists of 17 amino acids and is similar to Cothia canonical class 2. CDR-H3 consists of three amino acids. There are no classes of CDR-H3. CDR-L1 consists of 16 amino acids and is similar to Cothia canonical class 4. CDR-L2 consists of 7 amino acids and is Cothia canonical class 1. CDR-L3 consists of 9 amino acids and is similar to Cothia canonical class 1.
[0625] Residues at the interface between the Vk and Vh domains are commonly found, except for 93S in the heavy chain, which is usually an alanine; therefore, this residue is analyzed as a target for backmutation. Similarly, 36L in Vk is usually Y or F; therefore, these residues are also analyzed for backmutation. In addition, the light chain CRD3 has an unpaired cysteine residue.
[0626] A protein sequence search was performed in the PDB database [Deshpe N. et al., (2005) Nucleic Acids Res. 33: D233-D237.] to find structures that provide a rough structural model for 8A4. The crystal structure of the antibody fab (pdb code 3JAU; SEQ ID NO: 111) [Ye X, et al., (2016) PLoS Pathog.] was used for the Vk structure because it has good resolution (4.8A) and overall sequence similarity to 8A4 Vk, and retains the same canonical structure of the loops. The same structure [pdb code 3JAU; SEQ ID NO: 109] was also used for the Vh structure because it has good overall sequence similarity and fairly high resolution (4.8A). Furthermore, CDR-H1 and H2 have the same canonical structure as 8A4 Vh. The rough structure of 8A4 was modeled using Bioluminate software. This software is licensed from Schrodinger Inc.
[0627] A search of the non-redundant protein sequence database from NCBI allowed the selection of suitable human frameworks into which the murine CDRs were grafted. For Vk, the human kappa light chain variable region with accession number ABA26100 [SEQ ID NO: 112, Rabquer, .BJ, et al, 2016; Differential variable gene usage between pneumococcal polysaccharide specific B cells isolated 5-10 days 4-6 weeks post-vaccination. Unpublished] was selected. It has the same canonical class of CDR-L1 and L2 as murine 8A4 VL. It is a member of Kabat human kappa subgroup 2. For Vh, the human heavy chain variable region with accession number ADU57742 [SEQ ID NO: 110, Lantto, J., et al, 2011 J. Virol. 85: 1820-1833] was selected. It has the same canonical class as murine 8A4 VH. It is a member of Kabat human heavy chain subgroup 1.
[0628] Three humanized heavy chain variable region variants and three humanized light chain variable region variants were constructed to contain different substitutions: hu8A4-VH_v1, hu8A4-VH_v2, and hu8A4-VH_v3 (SEQ ID NOs: 113-115, respectively), and hu8A4-VL_v1, hu8A4-VL_v2, and hu8A4-VL_v3 (SEQ ID NOs: 116-118). (Tables 18 and 19). Exemplary humanized VL and VH designs with back mutations and other mutations based on selected human frameworks are shown in Tables 18 and 19, respectively. Bolded regions in Tables 18 and 19 indicate CDRs as defined by the Kabat / Chothia combination. "-" in columns of Tables 18 and 19 indicates no residue at the indicated position. In Table 20, SEQ ID NOs: 113-115 and SEQ ID NOs: 116-118 contain back mutations and other mutations. The amino acid positions of hu8A4-VH_v1, hu8A4-VH_v2, and hu8A4-VH_v3 are shown in Table 21. The amino acid positions of hu8A4-VL_v1, hu8A4-VL_v2, and hu8A4-VL_v3 are shown in Table 22. The humanness ratios of the humanized VH chains hu8A4-VH_v1, hu8A4-VH_v2, and hu8A4-VH_v3 (SEQ ID NO: 113 to 115, respectively) for the most similar human germline gene IGHV1-2*02 (SEQ ID NO: 82), and the humanized VL chains hu8A4-VL_v1, hu8A4-VL_v2, and hu8A4-VL_v3 (SEQ ID NO: 116 to 118, respectively) for the most similar human germline gene IGKV2-30*02 (SEQ ID NO: 84) are shown in Table 23. [Table 18-1] [Table 18-2] [Table 18-3] [Table 18-4] [Table 18-5]
Table 18-6
Table 19-1
Table 19-2
Table 19-3
Table 19-4
Table 19-5
Table 19-6
Table 20
Table 21
Table 22
Table 23
[0629] Chothia class canonical, Vernier, or interface / packing residue positions that differ between the mouse and human acceptor sequences are candidates for substitution. Examples of Chothia class canonical residues include Kabat residues H24, H26, H29, H34, H54, H55, H71, H94, L2, L25, L27B, L27C, L29, L33, L34, L71, L90, L94, L95, and L97 in Tables 18 and 19 and y. Examples of Vernier residues include Kabat residues H2, H27, H28, H29, H30, H47, H48, H49, H67, H69, H71, H73, H78, H93, H94, H103, L2, L4, L35, L36, L46, L47, L48, L49, L64, L66, L68, L69, L71, and L98 of Tables 18 and 19. Examples of interface / packing (VH+VL) residues include Kabat residues H35, H37, H39, H45, H47, H91, H93, H95, H103, L34, L36, L38, L44, L46, L87, L89, L91, L96, and L98 of Tables 18 and 19.
[0630] The rationale for selecting the positions shown in Table 18 in the light chain variable region as candidates for substitution is as follows. I2V is a backmutation of the canonical and Vernier residues. Q17E is a frequency-based mutation because Q is rare in the human framework at this position and E is the most common. F36L is a back mutation in the interface and Vernier residues.
[0631] Light chain variable region:
[0632] Mature region of murine 8A4VL (SEQ ID NO:92) DVVMTQTPLTLSVTIGQPASISCKSSQSLLDSDGKTYLNWLLQRPGQSPKRLIYLVSKLDSGVPDRFTGSGSGTDFTLKISRVEAEDLGVYYCWQGTHFPCTFGGGTKLEIK
[0633] 3JAUVL (SEQ ID NO:111) DVLMTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEADDVGVYYCYQGSHVPYTFGGGTKLEIK
[0634] ABA26100 (SEQ ID NO:112) DVMTSSSVTGASSCRSSSVYSDGSTWNWRGSRRYDVSTRDSGVDRSGSGSGTDTKSRVADVGVYYCMDWHTGGTKK
[0635] IGKV2-30*02 (SEQ ID NO:84) DIVMTQSPLSLSVTLGQPASISCKSSQSLLDSDGKTYLNWFQQRPGQSPRRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTHFPCTFGQGTKLEIK
[0636] hu8A4-VL_v1 (SEQ ID NO:116) DIVMTQSPLSLSVTLGQPASISCKSSQSLLDSDGKTYLNWFQQRPGQSPRRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTHFPCTFGQGTKLEIK
[0637] hu8A4-VL_v2 (SEQ ID NO:117) DIVMTQSPLSLSVTLGEPASISCKSSQSLLDSDGKTYLNWFQQRPGQSPRRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTHFPCTFGQGTKLEIK
[0638] hu8A4-VL_v3 (SEQ ID NO:118) DVVMTQSPLSLSVTLGEPASISCKSSQSLLDSDGKTYLNWLQQRPGQSPRRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTHFPCTFGQGTKLEIK
[0639] The rationale for selecting the positions shown in Table 19 in the light chain variable region as candidates for substitution is as follows. K12V is a backmutation and a frequency-based mutation because V is commonly found at this position in human frameworks. S16G is a frequency-based mutation because G is the most common at this position. V20L is a reversion and a frequency-based mutation because L is the most common mutation at this position. M48I is a backmutation of the Vernier residue. I67A is a backmutation of the Vernier residue. N68T is a frequency-based mutation because T is the most common at this position. D85E is a frequency-based mutation because E is the most common position in the human framework. A93S is a backmutation of hu8A4-VHv1 and hu8A4VH-v2 at the Vernier and interface residues to maintain CDR packing. In hu8A4VH-v3, the Kabat position is A, since A is the most common at this position and S is rare. 【064...
Claims
1. A humanized antibody or antigen-binding antibody fragment that binds to human tau, (i) three heavy chain CDRs as set forth in SEQ ID NO: 7 and three light chain CDRs as set forth in SEQ ID NO: 8, or three heavy chain CDRs as set forth in SEQ ID NO: 55 and three light chain CDRs as set forth in SEQ ID NO: 59; (ii) a humanized mature heavy chain variable region comprising an amino acid sequence having at least 90% identity to any one of SEQ ID NOs: 33-40, and a humanized mature light chain variable region comprising an amino acid sequence having at least 90% identity to any one of SEQ ID NOs: 41-46; wherein the antibody or antigen-binding antibody fragment does not comprise a humanized mature heavy chain variable region comprising the amino acid sequence of any one of SEQ ID NOs: 33-40 and a humanized mature light chain variable region comprising the amino acid sequence of any one of SEQ ID NOs: 41-46.
2. At least one of the following positions is filled with an amino acid as specified below:
2. The humanized antibody or antigen-binding antibody fragment of claim 1, wherein H48 is substituted with I, H71 is substituted with S, H93 is substituted with S, and H94 is substituted with P.
3. 3. The humanized antibody or antigen-binding antibody fragment of claim 2, wherein positions H48, H71, H93 and H94 are substituted with I, S, S and P, respectively.
4. At least one of the following positions is filled with an amino acid as specified below:
2. The humanized antibody or antigen-binding antibody fragment of claim 1, wherein H1 is substituted with E, H48 is substituted with I, H71 is substituted with S, H93 is substituted with S, and H94 is substituted with P.
5. 5. The humanized antibody or antigen-binding antibody fragment of claim 4, wherein positions H1, H48, H71, H93 and H94 are configured with E, I, S, S and P, respectively.
6. At least one of the following positions is filled with an amino acid as specified below:
2. The humanized antibody or antigen-binding antibody fragment of claim 1, wherein H1 is substituted with E, H46 is substituted with D, H48 is substituted with I, H71 is substituted with S, H93 is substituted with S, and H94 is substituted with P.
7. 7. The humanized antibody or antigen-binding antibody fragment of claim 6, wherein positions H1, H46, H48, H71, H93 and H94 are filled with E, D, I, S, S and P, respectively.
8. At least one of the following positions is filled with an amino acid as specified below:
2. The humanized antibody or antigen-binding antibody fragment of claim 1, wherein H1 is assigned to E, H11 is assigned to L, H12 is assigned to V, H19 is assigned to R, H20 is assigned to L, H46 is assigned to D, H48 is assigned to I, H71 is assigned to S, H76 is assigned to N, H80 is assigned to L, H93 is assigned to S, and H94 is assigned to P.
9. 9. The humanized antibody or antigen-binding antibody fragment of claim 8, wherein positions H1, H11, H12, H19, H20, H46, H48, L71, H76, H80, H93 and H94 are configured as E, L, V, R, L, D, I, S, N, L, S and P, respectively.
10. At least one of the following positions is filled with an amino acid as specified below:
2. The humanized antibody or antigen-binding antibody fragment of claim 1, wherein H66 is substituted with R, H67 is substituted with V, and H78 is substituted with V.
11. 11. The humanized antibody or antigen-binding antibody fragment of claim 10, wherein positions H66, H67 and H78 are filled with R, V and V, respectively.
12. At least one of the following positions is filled with an amino acid as specified below:
2. The humanized antibody or antigen-binding antibody fragment of claim 1, wherein H1 is arranged to have Q or E, H11 is arranged to have V or L, H12 is arranged to have K or V, H19 is arranged to have K or R, H20 is arranged to have V or L, H23 is arranged to have K or A, H46 is arranged to have E or D, H48 is arranged to have M or I, H66 is arranged to have K or R, H67 is arranged to have A or V, H71 is arranged to have R or S, H76 is arranged to have S or N, H78 is arranged to have A or V, H80 is arranged to have M or L, H93 is arranged to have T, S, or A, and H94 is arranged to have I, P, or R.
13. Positions H48, H71, H93, and H94 are respectively arranged with I, S, S, and P; Positions H1, H48, H71, H93, and H94 are respectively filled with E, I, S, S, and P; Positions H1, H46, H48, H71, H93, and H94 are respectively filled with E, D, I, S, S, and P; Positions H1, H11, H12, H19, H20, H46, H48, H71, H76, H80, H93, and H94 are respectively arranged with E, L, V, R, L, D, I, S, N, L, S, and P; Positions H1, H11, H12, H19, H20, H23, H46, H48, H71, H76, H80, H93, and H94 are respectively arranged with E, L, V, R, L, A, D, I, S, N, L, S, and P; Positions H66, H67, H78, H93, and H94 are populated with R, V, V, A, and R, respectively; or 13. The humanized antibody or antigen-binding antibody fragment of claim 12, wherein positions H1, H46, H48, H66, H67, H71, H78, H93, and H94 are configured as E, D, I, R, V, S, V, S, and P, respectively.
14. At least one of the following positions is filled with an amino acid as specified below:
2. The humanized antibody or antigen-binding antibody fragment of claim 1, wherein L2 is assigned to V, L7 is assigned to S, L17 is assigned to E, L36 is assigned to L, L45 is assigned to Q, L46 is assigned to R, and L70 is assigned to D.
15. At least one of the following positions is filled with an amino acid as specified below:
15. The humanized antibody or antigen-binding antibody fragment of claim 14, wherein L2 is positioned to V, L36 is positioned to L, and L46 is positioned to R.
16. 16. The humanized antibody or antigen-binding antibody fragment of claim 15, wherein positions L2, L36, and L46 are configured with V, L, and R, respectively.
17. At least one of the following positions is filled with an amino acid as specified below:
15. The humanized antibody or antigen-binding antibody fragment of claim 14, wherein L2 is positioned at V, L36 is positioned at L, L46 is positioned at R, and L70 is positioned at D.
18. 18. The humanized antibody or antigen-binding antibody fragment of claim 17, wherein positions L2, L36, L46, and L70 are configured with V, L, R, and D, respectively.
19. At least one of the following positions is filled with an amino acid as specified below:
15. The humanized antibody or antigen-binding antibody fragment of claim 14, wherein L45 is configured to Q and L70 is configured to D.
20. The humanized antibody or antigen-binding antibody fragment of claim 19, wherein the L45 and L70 positions of the VL region are Q and D, respectively.
21. At least one of the following positions is filled with an amino acid as specified below:
15. The humanized antibody or antigen-binding antibody fragment of claim 14, wherein L2 is arranged to be I or V, L7 is arranged to be T or S, L17 is arranged to be Q or E, L36 is arranged to be Y or L, L45 is arranged to be K or Q, L46 is arranged to be L or R, and L70 is arranged to be G or D.
22. At positions L2, L36, and L46, V, L, and R are arranged, respectively. At positions L2, L36, L46, and L70, V, L, R, and D are arranged, respectively. At positions L2, L7, L17, L36, L46, and L70, V, S, E, L, R, and D are arranged, respectively. Positions L45 and L70 are respectively configured with Q and D; or 22. The humanized antibody or antigen-binding antibody fragment of claim 21, wherein positions L2, L36, L45, L46, and L70 are filled with V, L, Q, R, and D, respectively.
23. 23. The humanized antibody or antigen-binding antibody fragment of any one of claims 1 to 22, which is a humanized antibody.
24. 23. The humanized antibody or antigen-binding antibody fragment of any one of claims 1 to 22, which is a humanized antigen-binding antibody fragment.
25. 24. The humanized antibody or antigen-binding antibody fragment of claim 23, wherein the humanized antibody has an isotype of human IgG1.
26. 23. The humanized antibody or antigen-binding antibody fragment of any one of claims 1 to 22, wherein the humanized mature light chain variable region is fused to a light chain constant region and the humanized mature heavy chain variable region is fused to a heavy chain constant region.
27. 27. The humanized antibody or antigen-binding antibody fragment of claim 26, wherein the heavy chain constant region is a mutated version of a native human heavy chain constant region that has reduced binding to Fcγ receptors compared to a native human heavy chain constant region.
28. 28. The humanized antibody or antigen-binding antibody fragment of claim 26 or 27, wherein the heavy chain constant region is of the IgG1 isotype.
29. 24. The humanized antibody or antigen-binding antibody fragment of any one of claims 1 to 23, wherein the humanized antibody has at least one mutation in the heavy chain constant region.
30. 30. The humanized antibody or antigen-binding antibody fragment of claim 29, wherein at least one of the mutations in the heavy chain constant region reduces complement fixation or activation by the constant region.
31. 31. The humanized antibody or antigen-binding antibody fragment of claim 30, wherein at least one of the mutations in the heavy chain constant region is at one or more of positions 241, 264, 265, 270, 296, 297, 318, 320, 322, 329, and 331 according to the EU numbering system.
32. 32. The humanized antibody or antigen-binding antibody fragment of claim 31 , wherein the humanized antibody has alanines at positions 318, 320 and 322.
33. 24. The humanized antibody or antigen-binding antibody fragment of claim 23, wherein the humanized antibody is of a human IgG2 or IgG4 isotype.
34. 34. The humanized antibody or antigen-binding antibody fragment of any one of claims 1 to 33, wherein the humanized antibody or antigen-binding antibody fragment is conjugated to a therapeutic agent, a cytotoxic agent, a cytostatic agent, a neurotrophic agent, or a neuroprotective agent.
35. 35. A pharmaceutical composition comprising the humanized antibody or antigen-binding antibody fragment of any one of claims 1 to 34 and a pharma- ceutically acceptable carrier.
36. A nucleic acid encoding the heavy and light chains of a humanized antibody according to any one of claims 1 to 23 and 25 to 33.
37. A vector comprising the nucleic acid of claim 36.
38. A host cell comprising the nucleic acid of claim 36 or the vector of claim 37.
39. 35. A pharmaceutical composition comprising the humanized antibody or antigen-binding antibody fragment of any one of claims 1 to 34 for treating or preventing a tau-related disease.
40. 35. A pharmaceutical composition for inhibiting or reducing tau aggregation in a subject having a tau-related disease, comprising the humanized antibody or antigen-binding antibody fragment of any one of claims 1 to 34.
41. 35. A pharmaceutical composition for reducing the abnormal propagation of tau in a subject having a tau-associated disease, comprising the humanized antibody or antigen-binding antibody fragment of any one of claims 1 to 34.
42. A pharmaceutical composition for inducing phagocytosis of tau in a subject having a tau-associated disease, comprising a humanized antibody or antigen-binding antibody fragment of any one of claims 1 to 34.
43. A pharmaceutical composition for inhibiting the formation of tau tangles in a subject having a tau-related disease, comprising a humanized antibody or antigen-binding antibody fragment of any one of claims 1 to 34.
44. 44. The pharmaceutical composition of any one of claims 39 to 43, wherein the tau-related disease is Alzheimer's disease, Down's syndrome, mild cognitive impairment, primary age-related tauopathy, postencephalitic parkinsonism, post-traumatic dementia or dementia pugilistica, Pick's disease, Niemann-Pick type C disease, supranuclear palsy, frontotemporal dementia, frontotemporal lobar degeneration, argyrophilic grain disease, globular glial cell tauopathy, amyotrophic lateral sclerosis / parkinsonism dementia complex of Guam, corticobasal degeneration (CBD), dementia with Lewy bodies, Lewy body variant of Alzheimer's disease (LBVAD), or progressive supranuclear palsy (PSP).
45. 35. An in vitro method for detecting tau protein deposits in a sample from a subject having or at risk of having a tau-related disease, comprising contacting the sample with a humanized antibody or antigen-binding antibody fragment of any one of claims 1 to 34, and detecting the humanized antibody or antigen-binding antibody fragment bound to tau in the sample.
46. 46. The method of claim 45, wherein the tau-related disease is Alzheimer's disease, Down's syndrome, mild cognitive impairment, primary age-related tauopathy, postencephalitic parkinsonism, post-traumatic dementia or dementia pugilistica, Pick's disease, Niemann-Pick type C, supranuclear palsy, frontotemporal dementia, frontotemporal lobar degeneration, argyrophilic grain disease, globular glial cell tauopathy, amyotrophic lateral sclerosis / parkinsonism dementia complex of Guam, corticobasal degeneration (CBD), dementia with Lewy bodies, Lewy body variant of Alzheimer's disease (LBVAD), or progressive supranuclear palsy (PSP).
Citation Information
Patent Citations
Humanized anti-Tau antibody
JP2017521097A
Antibodies against tau and their use
JP2018508210A
JPP7442790B
Anti-TAU antibodies
WO2016137950A1
